



National
Comprehensive
Cancer
Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Myeloproliferative Neoplasms

Version 2.2019 — October 29, 2018

NCCN.org

Continue



NCCN Guidelines Version 2.2019

Myeloproliferative Neoplasms

***Aaron T. Gerds, MD, MS/Chair ‡ †**
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer
Center and Cleveland Clinic Taussig Cancer
Institute

***Jason Gotlib, MD, MS/Vice-Chair ‡**
Stanford Cancer Institute

Prithviraj Bose, MD ‡
The University of Texas
MD Anderson Cancer Center

Michael W. Deininger, MD, PhD ‡
Huntsman Cancer Institute
at the University of Utah

Ivana Gojo, MD ‡
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins

Krishna Gundabolu, MBBS ‡
Fred & Pamela Buffett Cancer Center

Gabriela Hobbs, MD ‡
Massachusetts General Hospital
Cancer Center

Catriona Jamieson, MD, PhD ‡
UC San Diego Moores Cancer Center

Brandon McMahon, MD ‡
University of Colorado Cancer Center

Sanjay R. Mohan, MD ‡
Vanderbilt-Ingram Cancer Center

Vivian Oehler, MD ‡
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Stephen Oh, MD, PhD ‡
Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University School
of Medicine

Eric Padron, MD †
Moffitt Cancer Center

Philip Pancari, MD ‡ †
Fox Chase Cancer Center

Nikolaos Papadantonakis, MD, PhD ‡ †
University of Alabama at Birmingham
Comprehensive Cancer Center

Animesh Pardhanani, MBBS, PhD ‡
Mayo Clinic Cancer Center

Nikolai Podoltsev, MD, PhD ‡
Yale Cancer Center/Smilow Cancer Hospital

Raajit Rampal, MD, PhD ‡ † †
Memorial Sloan Kettering Cancer Center

Erik Ranheim, MD, PhD ≠
University of Wisconsin Carbone Cancer
Center

Lindsay Rein, MD ‡
Duke Cancer Institute

David S. Snyder, MD ‡ ξ
City of Hope National Medical Center

Brady L. Stein, MD, MHS ‡ †
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Moshe Talpaz, MD †
University of Michigan Rogel Cancer Center

Swapna Thota, MD ‡
Roswell Park Comprehensive Cancer Center

Martha Wadleigh, MD ‡ †
Dana-Farber/Brigham and Women's Cancer
Center

Katherine Walsh, MD †
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital and
Solove Research Institute

NCCN
Mary Anne Bergman
Hema Sundar, PhD



NCCN Guidelines Version 2.2019

Myeloproliferative Neoplasms

[NCCN Myeloproliferative Neoplasms Panel Members](#) [Summary of the Guidelines Updates](#)

Myeloproliferative Neoplasms:

- [Workup \(MPN-1\)](#)
- [Diagnosis and Risk Stratification \(MPN-2\)](#)

Myelofibrosis:

- [Treatment for Low-Risk Myelofibrosis \(MF-1\)](#)
- [Treatment for Intermediate-Risk 1 \(INT-1\) Myelofibrosis \(MF-2\)](#)
- [Treatment for Intermediate-Risk 2 \(INT-2\) or High-Risk Myelofibrosis \(MF-3\)](#)
- [Management of MF-Associated Anemia \(MF-4\)](#)
- [Disease Progression to Advanced-Phase/AML \(MF-5\)](#)
- [Risk Stratification for Patients with Myelofibrosis \(MF-A\)](#)
- [Supportive Care \(MF-B\)](#)
- [2013 IWG-MRT AND ELN Response Criteria for MF \(MF-C\)](#)

Polycythemia Vera:

- [Treatment for Low-Risk Polycythemia Vera \(PV-1\)](#)
- [Treatment for High-Risk Polycythemia Vera \(PV-2\)](#)
- [2013 IWG-MRT AND ELN Response Criteria for PV \(PV-A\)](#)

Essential Thrombocythemia:

- [Treatment for Very Low-Risk or Low-Risk ET \(ET-1\)](#)
- [Treatment for Intermediate-Risk Essential Thrombocythemia \(ET-2\)](#)
- [Treatment for High-Risk Essential Thrombocythemia \(ET-3\)](#)
- [2013 IWG-MRT AND ELN Response Criteria for ET \(ET-A\)](#)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical_trials/clinicians.aspx](#).

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

[2017 WHO Diagnostic Criteria for Primary Myelofibrosis \(MPN-A\)](#)
[2017 WHO Diagnostic Criteria for PV and ET \(MPN-B\)](#)
[Assessment of Symptom Burden \(MPN-C 1 of 2\)](#)
[Myeloproliferative Neoplasm Symptom Assessment Form: Total Symptom Score \(MPN-SAF TSS; MPN-10\) \(MPN-C 2 of 2\)](#)
[Prognostic Significance of Mutations in MPN \(MPN-D\)](#)
[IWG-MRT Diagnostic Criteria for Post PV/Post ET MF \(MPN-E\)](#)
[Special Considerations for the Use of Ruxolitinib \(MPN-F\)](#)
[Special Considerations in the Treatment of PV and ET \(MPN-G\)](#)
[Definition of Resistance/Intolerance to Hydroxyurea \(MPN-H\)](#)

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2018.



NCCN Guidelines Version 2.2019

Myeloproliferative Neoplasms

Updates in Version 2.2019 of the NCCN Guidelines for Myeloproliferative Neoplasms from Version 1.2019 include:

MS-1

- The Discussion section has been updated to reflect the changes in the algorithm.

Updates in Version 1.2019 of the NCCN Guidelines for Myeloproliferative Neoplasms from Version 2.2018 include:

MPN-1

Workup:

- 4th bullet modified: "FISH or *multiplex* RT-PCR..."
- 8th bullet modified: "Molecular testing (blood) for *JAK2* V617F mutation; if negative, test for *CALR* and *MPL* mutations (for patients with ET and MF) and *JAK2* exon 12 mutations (for patients with PV) or molecular testing using multi-gene NGS panel that includes *JAK2*, *CALR*, and *MPL*."
- 9th bullet modified: "Assessment of symptom burden using MPN Symptom Assessment form Total Symptom Score (MPN-SAF TSS; MPN-10)"

Footnotes:

- "c": 1st sentence modified as follows, "Prognostic models incorporating other mutations have been proposed to identify patients with myelofibrosis (MF) who may be at risk of leukemic transformation."
- "d": ~~"Assessment of symptoms (in provider's office) at baseline using MPN Symptom Assessment form (MPN-SAF) is recommended for all patients. See Assessment of Symptom Burden (MPN-C 1 of 2)."~~
- "e": ~~"See MF-2 and MF-3. Evaluation for allogeneic HCT is recommended for all patients with intermediate-2-risk (INT-2) and high-risk myelofibrosis and for patients with intermediate-1-risk (INT-1) myelofibrosis with low platelet counts and complex cytogenetics. Identification of "higher-risk" mutations may be helpful in the decision-making regarding allogeneic HCT for patients with primary myelofibrosis (PMF). See Prognostic Significance of Mutations in MPN (MPN-D)."~~

MPN-2

- "At diagnosis, IPSS/During treatment, DIPSS-Plus (preferred)/DIPSS (if karyotyping is not available)" is a new pathway off Primary myelofibrosis, Post-PV, Post-ET MF
- IPSET-Thrombosis (revised) is a new pathway off Essential thrombocythemia

Footnotes:

- "j": "Other prognostic models incorporating relevant clinical, cytogenetic, and mutation data (eg, Mutation-Enhanced International Prognostic Scoring System [MIPSS]) have been developed to further refine the risk stratification of patients with PMF. See MF-A" is a new footnote corresponding to Primary myelofibrosis. (Also for MF-1, MF-2, MF-3)
- "i": "IPSS, DIPSS, and DIPSS-Plus have been studied and validated only in

patients with PMF but clinically have been used for the risk stratification of patients with Post-PV or Post-ET MF. Novel prognostic models are being developed for the risk stratification of post-PV and post-ET MF. See MF-A (4 of 4)." (Also for MF-1, MF-2, MF-3)

MF-1

- First pathway has been modified to include "and/or" after each prognostic scoring system. (Also for MF-2, MF-3)

Footnote:

- "h": "Additional molecular testing using multi-gene NGS panel should be considered to evaluate for higher-risk mutations associated with disease progression in patients with primary PMF. See Prognostic Significance of Mutations in MPN (MPN-D)." (Also for MF-2, MF-3)

MF-4

- Bullets 1–6 have been deleted: H&P, CBC with differential, Examination of blood smear, Bone marrow aspirate and biopsy with trichrome and reticulin stain, Bone marrow cytogenetics (blood, if bone marrow is inaspirable) (karyotype ± FISH), Serum EPO level.
- 4th column, upper pathway, modified by replacing "and" with "or" between "darbepoetin alfa" and "Epoetin alfa."
- Lower pathway: "Alternative androgen" has been deleted as well as pomalidomide (category 3) ± prednisone

Footnotes:

- "m": Deleted: "See 2016 WHO Diagnostic Criteria for Primary Myelofibrosis (PMF). See (MPN-A)."
- "n": Deleted: "See 2016 WHO Diagnostic Criteria for PV and ET. See (MPN-B)"

MF-5

- 3rd column, lower pathway: added "≥" in front of 20%.
- 5th column, upper pathway: "Clinical trial" is new

Footnotes:

"r": "AML-type induction chemotherapy regimens are generally used for the management of disease progression of MPN. However, these regimens typically result in poor responses" is new to the page corresponding to Hypomethylating agents (azacitidine or decitabine) or low-intensity induction chemotherapy.

**Continued
UPDATES**



NCCN Guidelines Version 2.2019

Myeloproliferative Neoplasms

Updates in Version 1.2019 of the NCCN Guidelines for Myeloproliferative Neoplasms from Version 2.2018 include:

[MF-A \(3 of 4\)](#)

- New page in the guideline: "Mutation-enhanced IPSS (*MIPSS70*) for Patients with PMF Age ≤70 Years and *MIPSS70-Plus*."

[MF-A \(4 of 4\)](#)

- New page in the guideline: "Myelofibrosis Secondary to PV and ET- Prognostic Model (*MYSEC-PM*)."

[PV-1](#)

- 2nd column, 3rd bullet modified: "Aspirin for vascular symptoms (81–100 mg/d)" with a corresponding reference: *Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.* (Also for PV-2).
- 5th column deleted the following: "Symptomatic or progressive splenomegaly, Symptomatic thrombocytosis, Progressive leukocytosis, Progressive disease-related symptoms (eg, pruritus, night sweats, fatigue)." (Also for PV-2, ET-1, ET-2, ET-3).

Footnotes:

- "f": the following has been updated, "*Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018;32:1057-1069.*" (Also for PV-2, ET-1, ET-2, ET-3).

[PV-2](#)

Footnotes:

- "k": "While normalization of blood counts after initiation of treatment is usually done in clinical practice, it is not associated with long-term clinical benefit and there is no evidence-based data to recommend a target WBC or platelet count for patients receiving cytoreductive therapy. In selected patients with a severe thrombotic event, normalization of blood counts might be an essential goal of treatment," is new to the page corresponding to the 3rd column monitoring signs and symptoms of disease progression. (Also for ET-3)

[ET-3](#)

- 2nd column, 3rd bullet: "Aspirin (81–100 mg/d) for vascular symptoms."

[MPN-B](#)

- Major Criteria (ET): 3rd sub-bullet modified with the *deletion of BCR-ABL1+*

[MPN-C \(1 of 2\)](#)

- 2nd bullet modified: "Myeloproliferative Neoplasm Symptom Assessment Form *Total Symptom Score* (MPN-SAF TSS; *MPN-10*) is recommended for the assessment of symptom burden at baseline and monitoring symptom status during the course of treatment (See [MPN-C, 2 of 2](#))."
- 3rd bullet deleted: "The 2013 IWG-MRT and ELN Response Criteria for MF recommend the use of MPN-SAF Total Symptom Score (MPN-SAF TSS; MPN-10) for monitoring symptom status during the course of treatment (See [MPN-C 3 of 3](#))."

[MPN-C \(2 of 3\)](#)

- Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) has been removed from the guidelines.

[MPN-C \(2 of 2\)](#)

- "Numbness/Tingling (in my hands and feet)" removed from the form as it is not included in the original MPN-SAF TSS 10 questions form.

[MPN-D \(1 of 4\)](#)

- *U2AF1* Q157: "Inferior overall survival compared to patients with *U2AF1* S34 mutated or *U2AF1* unmutated PMF. The effect was most evident in younger patients" is new to the page with the following reference: "*Tefferi A, Finke CM, Lasho TL, et al. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia 2018;32:2274-2278.*"

[MPN-F \(1 of 2\)](#)

- Lymphoma Risk with JAK Inhibitors in patients with MPN
 - ▶ New paragraph added: "Both low- and high-grade neoplasms may be diagnosed concurrently with MPNs or may develop during the natural history of PV, ET, or MF. Although one report indicated an increased risk of lymphomas with JAK inhibitor therapy, additional studies are required to validate these observations." Corresponding reference: Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. *Blood 2018;132(7):694-706.*

[MPN-F \(2 of 2\)](#)

- *PML and Hepes Zoster*: last sentence modified as follows: "Consider the use of non-live, subunit herpes zoster vaccine is not recommended for patients receiving ruxolitinib."



NCCN Guidelines Version 2.2019

Myeloproliferative Neoplasms

WORKUP

Suspicion of
myeloproliferative
neoplasms (MPN)

- H&P, including spleen size by palpation, evaluation of thrombotic/hemorrhagic events and cardiovascular risk factors
- CBC with differential
- Comprehensive metabolic panel with uric acid, lactate dehydrogenase (LDH), and liver function tests (LFTs)
- FISH or multiplex RT-PCR for *BCR-ABL1* to exclude the diagnosis of CML; if *BCR-ABL1*-positive, [See NCCN Guidelines for Chronic Myeloid Leukemia](#)
- Examination of blood smear
- Bone marrow aspirate and biopsy with trichrome and reticulin stain^{a,b}
- Bone marrow cytogenetics (blood, if bone marrow is inaspirable) (karyotype ± FISH)^{a,b}
- Molecular testing (blood) for *JAK2 V617F* mutation; if negative, test for *CALR* and *MPL* mutations (for patients with ET and MF) and *JAK2* exon 12 mutations (for patients with PV) or molecular testing using multi-gene NGS panel that includes *JAK2*, *CALR*, and *MPL*^c
- Assessment of symptom burden using MPN Symptom Assessment Form Total Symptom Score (MPN-SAF TSS; MPN-10)^d
- Documentation of transfusion/medication history
- Human leukocyte antigen (HLA) testing, if considering allogeneic hematopoietic cell transplant (HCT)^e
- Serum erythropoietin (EPO) level
- Serum iron studies
- Coagulation tests to evaluate for acquired von Willebrand disease (VWD) and/or other coagulopathies in selected patients^f
 - ▶ Prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen
 - ▶ Plasma von Willebrand Factor Antigen (VWFA) measurement
 - ▶ Von Willebrand Ristocetin Cofactor (VWF:RCo) activity^g

Diagnosis
and
Risk stratification

[See MPN-2](#)

^aSee 2017 WHO Diagnostic Criteria for Primary Myelofibrosis (PMF). [See \(MPN-A\)](#).

^bSee 2017 WHO Diagnostic Criteria for PV and ET. [See \(MPN-B\)](#).

^cPrognostic models incorporating other mutations have been proposed to identify patients with myelofibrosis (MF) who may be at risk of leukemic transformation. Next-generation sequencing (NGS) may be useful to establish clonality in selected circumstances (eg, triple negative non-mutated *JAK2*, *MPL*, and *CALR*). [See MPN-D](#) for a list of somatic mutations with prognostic significance in patients with MPN.

^d[See Assessment of Symptom Burden \(MPN-C 1 of 2\)](#).

^eSee [MF-2](#) and [MF-3](#).

^fPatients undergoing high-risk surgical procedures and those with elevated platelet count and/or splenomegaly or unexplained bleeding.

^gAn expanded panel including von Willebrand factor (VWF) antigen, Factor VIII activity, and VWF multimers may be useful under certain circumstances.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




NCCN Guidelines Version 2.2019

Myeloproliferative Neoplasms

DIAGNOSIS^{h,i}

RISK STRATIFICATION



^aSee 2017 WHO Diagnostic Criteria for Primary Myelofibrosis. [See \(MPN-A\)](#).

^bSee 2017 WHO Diagnostic Criteria for PV and ET. [See \(MPN-B\)](#).

^hThe diagnosis of MPN is based on the 2016 WHO Criteria and requires a combination of clinical, laboratory, cytogenetic, and molecular testings.

ⁱReferral to specialized centers with expertise in the management of MPN is strongly recommended for all patients diagnosed with MF, PV, or ET.

^jOther prognostic models incorporating relevant clinical, cytogenetic, and mutation data (eg, Mutation-Enhanced International Prognostic Scoring System [MIPSS]) have been developed to further refine the risk stratification of patients with PMF. [See MF-A \(3 of 4\)](#).

^kDiagnostic criteria for post-ET or post-PV MF. [See \(MPN-E\)](#).


^lIPSS, DIPSS, and DIPSS-Plus have been studied and validated only in patients with PMF, but clinically have been used for the risk stratification of patients with post-PV or post-ET MF. Novel prognostic models have been developed for the risk stratification of post-PV and post-ET MF. [See MF-A \(4 of 4\)](#).

^mThe revised International Prognostic Score of Thrombosis for ET (IPSET-thrombosis) is preferred for the risk stratification of ET (Haider M, Gangat N, Lasho T, et al. *Am J Hematol* 2016;91:390-394. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. *Blood Cancer J* 2015;5:e369).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

TREATMENT FOR LOW-RISK MYELOFIBROSIS



^aIPSS, DIPSS, and DIPSS-Plus have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with post-PV or post-ET MF. Novel prognostic models have been developed for the risk stratification of post-PV and post-ET MF. [See MF-A 4 of 4.](#)

^bOther prognostic models incorporating relevant clinical, cytogenetic, and mutation data (eg, Mutation-Enhanced International Prognostic Scoring System [MIPSS]) have been developed to further refine the risk stratification of patients with PMF. [See MF-A \(3 of 4\).](#)

^c[See Assessment of Symptom Burden \(MPN-C 2 of 2\).](#)

^d[See Supportive Care \(MF-B\).](#)

^e[See Special Considerations for the Use of Ruxolitinib \(MPN-F\).](#)

^fBone marrow aspirate and biopsy should be performed at diagnosis and as clinically indicated (if supported by increased symptoms and signs of progression).

^g[See 2013 IWG-MRT and ELN Response Criteria for MF \(MF-C\).](#) These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.


^hAdditional molecular testing using multi-gene NGS panel should be considered to evaluate for higher-risk mutations associated with disease progression in patients with primary PMF. [See Prognostic Significance of Mutations in MPN \(MPN-D\).](#)

ⁱClinical benefit may not reach the threshold of the 2013 IWG Response Criteria and continuation of ruxolitinib is recommended based on the discretion of the clinician. [See 2013 IWG-MRT and ELN Response Criteria for MF \(MF-C\).](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

TREATMENT FOR INTERMEDIATE-RISK 1 (INT-1) MYELOFIBROSIS



^aIPSS, DIPSS, and DIPSS-Plus have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with post-PV or post-ET MF. Novel prognostic models have been developed for the risk stratification of post-PV and post-ET MF. [See MF-A \(4 of 4\)](#).

^bOther prognostic models incorporating relevant clinical, cytogenetic, and mutation data (eg, Mutation-Enhanced International Prognostic Scoring System [MIPSS]) have been developed to further refine the risk stratification of patients with PMF. [See MF-A \(3 of 4\)](#).

^cSee [Assessment of Symptom Burden \(MPN-C 2 of 2\)](#).

^dSee [Supportive Care \(MF-B\)](#).

^eSee [Special Considerations for the Use of Ruxolitinib \(MPN-F\)](#).

^fBone marrow aspirate and biopsy should be performed at diagnosis and as clinically indicated (if supported by increased symptoms and signs of progression).

^gSee [2013 IWG-MRT and ELN Response Criteria for MF \(MF-C\)](#). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

^hAdditional molecular testing using multi-gene NGS panel should be considered to evaluate for higher-risk mutations associated with disease progression in patients with primary PMF. [See Prognostic Significance of Mutations in MPN \(MPN-D\)](#).

ⁱClinical benefit may not reach the threshold of the IWG Response Criteria and continuation of ruxolitinib is recommended based on the discretion of the clinician. [See 2013 IWG-MRT and ELN Response Criteria for MF \(MF-C\)](#).

^jEvaluation for allogeneic HCT is recommended for all patients with intermediate-2 risk (INT-2) and high-risk disease and for patients with intermediate-1 (INT-1) disease with low platelet counts or complex cytogenetics. Identification of “higher-risk” mutations may be helpful in the decision-making regarding allogeneic HCT for patients with PMF. [See Prognostic Significance of Mutations in MPN \(MPN-D\)](#).

^kThe selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of caregiver. Patients may be taken immediately to transplant or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2019

Myelofibrosis

TREATMENT FOR INTERMEDIATE-RISK 2 (INT-2) OR HIGH-RISK MYELOFIBROSIS



^aIPSS, DIPSS, and DIPSS-Plus have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with post-PV or post-ET MF. Novel prognostic models have been developed for the risk stratification of post-PV and post-ET MF. [See MF-A \(4 of 4\)](#).

^bOther prognostic models incorporating relevant clinical, cytogenetic, and mutation data (eg, Mutation-Enhanced International Prognostic Scoring System [MIPSS]) have been developed to further refine the risk stratification of patients with PMF. [See MF-A \(3 of 4\)](#).

^c[See Assessment of Symptom Burden \(MPN-C 2 of 2\)](#).

^d[See Supportive Care \(MF-B\)](#).

^e[See Special Considerations for the Use of Ruxolitinib \(MPN-F\)](#).

^fBone marrow aspirate and biopsy should be performed at diagnosis and as clinically indicated (if supported by increased symptoms and signs of progression).

^g[See 2013 IWG-MRT and ELN Response Criteria for MF \(MF-C\)](#). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

^hAdditional molecular testing using multi-gene NGS panel should be considered to evaluate for higher-risk mutations associated with disease progression in patients with primary PMF. [See Prognostic Significance of Mutations in MPN \(MPN-D\)](#).

ⁱClinical benefit may not reach the threshold of the IWG Response Criteria and continuation of ruxolitinib is recommended based on the discretion of the clinician. [See 2013 IWG-MRT and ELN Response Criteria for MF \(MF-C\)](#).

^jEvaluation for allogeneic HCT is recommended for all patients with intermediate-2 risk (INT-2) and high-risk disease and for patients with intermediate-1 (INT-1) disease with low platelet counts and complex cytogenetics. Identification of “higher-risk” mutations may be helpful in the decision-making regarding allogeneic HCT for patients with PMF. [See Prognostic Significance of Mutations in MPN \(MPN-D\)](#).


^kThe selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of caregiver. Patients may be taken immediately to transplant or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant.

^lIf a clinical trial is not available, other options should be considered. [See Discussion](#) for further details.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

MANAGEMENT OF MF-ASSOCIATED ANEMIA



^dSee Supportive Care (MF-B).

^gSee 2013 IWG-MRT and ELN Response Criteria for MF (MF-C). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

^mProstate cancer screening for men and monitoring of liver function tests are recommended.


ⁿPresence of del(5q) is associated with better response rates with lenalidomide.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2019

Myelofibrosis



^kThe selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of caregiver. Patients may be taken immediately to transplant or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant.

^oThe WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].

^pRuxolitinib may be continued for the improvement of splenomegaly and other disease-related symptoms.

^qConsider prophylaxis for tumor lysis syndrome (TLS). [See Supportive Care \(MF-B\)](#).

^rAML-type induction chemotherapy regimens are generally used for the management of disease progression of MPN. However, these regimens typically result in poor responses.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

RISK STRATIFICATION FOR PATIENTS WITH MYELOFIBROSIS
INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)^{1,2}

Prognostic Variable	Points	
	0	1
Age, y	≤65	>65
White blood cell count, x10 ⁹ /L	≤25	>25
Hemoglobin, g/dL	≥10	<10
Peripheral blood blast, %	<1	≥1
Constitutional symptoms, Y/N	N	Y

Risk Group	Points
Low	0
Intermediate-1 (INT-1)	1
Intermediate-2 (INT-2)	2
High	≥3

¹These risk stratification systems have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with post-PV or post-ET MF. Novel prognostic models have been developed for the risk stratification of post-PV and post-ET MF. See [MF-A \(4 of 4\)](#).

²Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

NCCN Guidelines Version 2.2019
Myelofibrosis**RISK STRATIFICATION FOR PATIENTS WITH MYELOFIBROSIS¹****DYNAMIC INTERNATIONAL PROGNOSTIC SCORING SYSTEM (DIPSS)³**

Prognostic Variable	Points		
	0	1	2
Age, y	≤65	>65	
White blood cell count, x10 ⁹ /L	≤25	>25	
Hemoglobin, g/dL	≥10		<10
Peripheral blood blast, %	<1	≥1	
Constitutional symptoms, Y/N	N	Y	

Risk Group	Points
Low	0
Intermediate-1 (INT-1)	1 or 2
Intermediate-2 (INT-2)	3 or 4
High	5 or 6

DIPSS-PLUS⁴

Prognostic Variable	Points
DIPSS low-risk	0
DIPSS intermediate-risk 1 (INT-1)	1
DIPSS intermediate-risk 2 (INT-2)	2
DIPSS high-risk	3
Platelets <100 x 10 ⁹ /L	1
Transfusion need	1
Unfavorable karyotype*	1

*Unfavorable karyotype: complex karyotype or sole or two abnormalities that include trisomy 8, 7/7q-, i(17q), 5/5q-, 12p-, inv(3), or 11q23 rearrangement.

Risk Group	Points
Low	0
Intermediate-1 (INT-1)	1
Intermediate-2 (INT-2)	2 or 3
High	4 to 6

¹These risk stratification systems have been studied and validated only in patients with PMF but clinically have been used for the risk stratification of patients with post-PV or post-ET MF. Novel prognostic models have been developed for the risk stratification of post-PV and post-ET MF. See [MF-A \(4 of 4\)](#).

³Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood* 2010;115:1703-1708. [Available at: http://www.ncbi.nlm.nih.gov/pubmed/20008785](http://www.ncbi.nlm.nih.gov/pubmed/20008785).

⁴Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol* 2011;29:392-397. [Available at: http://www.ncbi.nlm.nih.gov/pubmed/21149668](http://www.ncbi.nlm.nih.gov/pubmed/21149668). www.qxmd.com/calculate/dipss-plus-score-for-prognosis-in-myelofibrosis.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



NCCN Guidelines Version 2.2019

Myelofibrosis

RISK STRATIFICATION FOR PATIENTS WITH MYELOFIBROSIS

MUTATION-ENHANCED IPSS (MIPSS70) FOR PATIENTS WITH PMF AGE ≤70 YEARS⁵

Prognostic Variable	Points
Hemoglobin <100 g/L	1
Leukocytes >25 x 10 ⁹ /L	2
Platelets <100 x 10 ⁹ /L	2
Circulating blasts >2%	1
Bone marrow fibrosis grade ≥2	1
Constitutional symptoms	1
<i>CALR</i> type-1 unmutated genotype	1
High-molecular risk (HMR) mutations	1
≥2 HMR mutations	2

Risk Group	Points
Low	0–1
Intermediate	2–4
High	≥5

MIPSS70-Plus⁵

Prognostic Variable	Points
Hemoglobin <100 g/L	1
Circulating blasts >2 %	1
Constitutional symptoms	1
<i>CALR</i> type-1 unmutated genotype	2
HMR mutations	1
≥2 HMR mutations	2
Unfavorable karyotype*	3

*Unfavorable karyotype: any abnormal karyotype other than normal karyotype or sole abnormalities of 20q-,13q-, +9, chromosome 1 translocation/duplication, -Y, or sex chromosome abnormality other than -Y.

Risk Group	Points
Low	0–2
Intermediate	3
High	4–6
Very high	≥7

⁵Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients with Primary Myelofibrosis. *J Clin Oncol* 2018;36:310-318.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



RISK STRATIFICATION FOR PATIENTS WITH POST-PV AND POST-ET MYELOFIBROSIS
MYELOFIBROSIS SECONDARY TO PV AND ET-PROGNOSTIC MODEL (MYSEC-PM)⁶

Prognostic Variable	Points
Age at diagnosis	0.15 per patient's year of age
Hemoglobin <11 g/dL	2
Circulating blasts ≥3%	2
<i>CALR</i>-unmutated genotype	2
Platelets <150 x 10⁹/L	1
Constitutional symptoms	1

Risk Group	Points
Low	<11
Intermediate-1 (INT-1)	≥11
Intermediate-2 (INT-2)	≥14 and <16
High	≥16

⁶Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. *Leukemia* 2017;31:2726-2731.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**SUPPORTIVE CARE**

- **Transfusion support**
 - ▶ RBC transfusions for symptomatic anemia; platelet transfusions for thrombocytopenic bleeding or a platelet count <10,000 m³. In transplant candidates, use leukocyte-reduced blood products to prevent HLA alloimmunization and reduce the risk of cytomegalovirus (CMV) transmission.
- Consider antifibrinolytic agents for bleeding that is refractory to transfusions.
- Iron chelation could be considered for patients who have received >20 transfusions and/or ferritin >2500 ng/mL in low/INT-1-risk patients. However, the role of iron chelation remains unclear.
- Antibiotic prophylaxis for recurrent infections is recommended. [See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections](#). In splenectomized patients, antibiotic prophylaxis should be given per [IDSA Guidelines](#).
- Vaccinations: [See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections](#).
- Hematopoietic growth factor therapy
 - ▶ ESA: [See “Management of MF-Associated Anemia” \(MF-4\)](#). Not effective for patients with transfusion-dependent anemia.
 - ▶ Consider G-CSF or GM-CSF for recurrent infections in patients with neutropenia. However, these should be used with caution in patients with an enlarged spleen since the use of G-CSF or GM-CSF has been associated with splenic rupture. [See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections](#).
- Consider cytoreductive therapy (eg, hydroxyurea) for hyperproliferative manifestations of PMF (thrombocytosis or leukocytosis).
- Consider prophylaxis for tumor lysis syndrome (TLS) for patients undergoing induction therapy for advanced-stage MF or disease progression to AML.
 - ▶ Hydration and/or diuresis
 - ▶ Consider management of hyperuricemia with allopurinol or rasburicase.
 - ▶ Rasburicase should be considered as initial treatment in patients with rapidly increasing blast counts, high uric acid, and evidence of impaired renal function.
- Counseling at baseline and throughout disease course for assessment for, identification of, and decreasing cardiovascular risk factors (eg, smoking, diet, exercise, thrombotic and hemorrhagic risk factors).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

2013 IWG-MRT AND ELN RESPONSE CRITERIA FOR MYELOFIBROSIS (MF)^{1,2}

Resonse Categories	Required Criteria (for all response categories, benefit must last for ≥12 wk to qualify as response)	
CR	<p>Bone marrow:^a Age-adjusted normocellularity; <5% blasts; ≤grade 1 MF^b</p> <p>AND</p> <p>Peripheral blood: Hemoglobin ≥10 g/dL and <upper normal limit (UNL); Neutrophil count ≥1 x 10⁹/L and <UNL; Platelet count ≥100 x 10⁹/L and <UNL; <2% immature myeloid cells^c</p>	<p>Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis (EMH)</p>
PR	<p>Peripheral blood: Hemoglobin ≥10 g/dL and <UNL; Neutrophil count ≥1 x 10⁹/L and <UNL; Platelet count ≥100 x 10⁹/L and <UNL; <2% immature myeloid cells^c</p> <p>OR</p> <p>Bone marrow:^a Age-adjusted normocellularity; <5% blasts; ≤grade 1 MF^b</p> <p>AND</p> <p>Peripheral blood: Hemoglobin ≥85, but <10 g/dL and <UNL; Neutrophil count ≥1 x 10⁹/L and <UNL; Platelet count ≥50, but <100 x 10⁹/L and <UNL; <2% immature myeloid cells^c</p>	<p>Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of EMH</p> <p style="text-align: right;">See Footnotes on MF-C (4 of 4)</p>

¹Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013;122(8):1395-1398.

²These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

2013 IWG-MRT AND ELN RESPONSE CRITERIA FOR MYELOFIBROSIS (MF)^{1,2}

Response Categories	Required Criteria (for all response categories, benefit must last for ≥12 wk to qualify as a response)
Progressive disease ^j	Appearance of a new splenomegaly that is palpable at least 5 cm below the left costal margin (LCM) or A ≥100% increase in palpable distance, below LCM, for baseline splenomegaly of 5–10 cm or A 50% increase in palpable distance, below LCM, for baseline splenomegaly of >10 cm or Leukemic transformation confirmed by a bone marrow blast count of ≥20% or A peripheral blood blast content of ≥20% associated with an absolute blast count of ≥1 x 10 ⁹ /L that lasts for at least 2 weeks
Stable disease	Belonging to none of the above listed response categories
Relapse	No longer meeting criteria for at least clinical improvement (CI) after achieving complete response (CR), partial response (PR), or CI or Loss of anemia response persisting for at least 1 month or Loss of spleen response persisting for at least 1 month
Clinical improvement (CI)	The achievement of anemia, spleen, or symptoms response without progressive disease or increase in severity of anemia, thrombocytopenia, or neutropenia ^d
Anemia response	Transfusion-independent patients: a ≥2.0 g/dL increase in hemoglobin level ^e Transfusion-dependent patients: becoming transfusion-independent ^f
Spleen response ^g	A baseline splenomegaly that is palpable at 5–10 cm, below the LCM, becomes not palpable ^h or A baseline splenomegaly that is palpable at >10 cm below the LCM, decreases by ≥50% ^h A baseline splenomegaly that is palpable at <5 cm below the LCM, not eligible for spleen response A spleen response requires confirmation by MRI or CT showing ≥35% spleen volume reduction
Symptoms response	A ≥50% reduction in the MPN-SAF TSS ⁱ

[See Footnotes on MF-C \(4 of 4\)](#)

¹Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood* 2013;122(8):1395-1398.

²These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



NCCN Guidelines Version 2.2019

Myelofibrosis

2013 IWG-MRT AND ELN RESPONSE CRITERIA FOR MYELOFIBROSIS (MF)^{1,2}

RECOMMENDATIONS FOR ASSESSING TREATMENT-INDUCED CYTOGENETIC AND MOLECULAR CHANGES

Cytogenetic remission	At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6-month window CR: Eradication of a pre-existing abnormality PR: ≥50% reduction in abnormal metaphases (partial response applies only to patients with at least 10 abnormal metaphases at baseline)
Molecular remission	Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6-month window CR: Eradication of a pre-existing abnormality PR: ≥50% decrease in allele burden (partial response applies only to patients with at least 20% mutant allele burden at baseline)
Cytogenetic/molecular relapse	Re-emergence of a pre-existing cytogenetic or molecular abnormality that is confirmed by repeat testing

¹Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood* 2013;122(8):1395-1398.

²These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES**


- ^aBaseline and posttreatment bone marrow slides are to be interpreted at one sitting by a central review process. Cytogenetic and molecular responses are not required for CR assignment.
- ^bGrading of MF is according to the European classification. (Thiele et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. *Haematologica* 2005;90:1128.) It is underscored that the consensus definition of a CR bone marrow is to be used only in those patients in which all other criteria are met, including resolution of leukoerythroblastosis. It should also be noted that it was a particularly difficult task for the working group to reach a consensus regarding what represents a complete histologic remission.
- ^cImmature myeloid cells constitute blasts + promyelocytes + myelocytes + metamyelocytes + nucleated red blood cells. In splenectomized patients, <5% immature myeloid cells is allowed.
- ^dSee definitions of anemia response, spleen response, and progressive disease. Increase in severity of anemia constitutes the occurrence of new transfusion dependency or a ≥ 20 g/dL decrease in hemoglobin level from pretreatment baseline that lasts for at least 12 weeks. Increase in severity of thrombocytopenia or neutropenia is defined as a 2-grade decline, from pretreatment baseline, in platelet count or absolute neutrophil count, according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. In addition, assignment to CI requires a minimum platelet count of $\geq 25,000 \times 10^9/L$ and absolute neutrophil count of $\geq 0.5 \times 10^9/L$.
- ^eApplicable only to patients with baseline hemoglobin of <10 g/dL. In patients not meeting the strict criteria for transfusion dependency at the time of study enrollment (see as follows), but in those who have received transfusions within the previous month, the pretransfusion hemoglobin level should be used as the baseline.
- ^fTransfusion dependency before study enrollment is defined as transfusions of at least 6 units of packed red blood cells (PRBCs), in the 12 weeks prior to study enrollment, for a hemoglobin level of <85 g/dL, in the absence of bleeding or treatment-induced anemia. In addition, the most recent transfusion episode must have occurred in the 28 days prior to study enrollment. Response in transfusion-dependent patients requires absence of any PRBC transfusions during any consecutive “rolling” 12-week interval during the treatment phase, capped by a hemoglobin level of ≥ 85 g/dL.
- ^gIn splenectomized patients, palpable hepatomegaly is substituted with the same measurement strategy.
- ^hSpleen or liver responses must be confirmed by imaging studies where a $\geq 35\%$ reduction in spleen volume, as assessed by MRI or CT, is required. Furthermore, a $\geq 35\%$ volume reduction in the spleen or liver, by MRI or CT, constitutes a response regardless of what is reported with physical examination.
- ⁱSymptoms are evaluated by the MPN-SAF TSS. The MPN-SAF TSS is assessed by the patients themselves and this includes fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Scoring is from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) for each item. The MPN-SAF TSS is the summation of all the individual scores (0–100 scale). Symptoms response requires $\geq 50\%$ reduction in the MPN-SAF TSS.
- ^jProgressive disease assignment for splenomegaly requires confirmation by MRI or CT showing a $\geq 25\%$ increase in spleen volume from baseline. Baseline values for both physical examination and imaging studies refer to pretreatment baseline and not to posttreatment measurements.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



TREATMENT FOR LOW-RISK POLYCYTHEMIA VERA



^aCytoreductive therapy is not recommended as initial treatment.

^bLandolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med* 2004;350:114-124.

^cHematocrit <45% is based on the data from the CYTO-PV Study (Marchioli R et al. *N Engl J Med* 2013;368(1):22-33). There may be situations in which a lower hematocrit cutoff may be appropriate and it should be individualized (eg, 42% for female patients and/or progressive symptoms).

^dSee [Assessment of Symptom Burden \(MPN-C 2 of 2\)](#).

^eBone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.

^fBarbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia* 2018;32:1057-1069.

^gDiagnostic criteria for post-ET or post-PV MF. See [\(MPN-E\)](#).


^hThe WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



TREATMENT FOR HIGH-RISK POLYCYTHEMIA VERA



^bLandolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med* 2004;350:114-124.

^cHematocrit <45% is based on the data from the CYTO-PV Study (Marchioli R et al. *N Engl J Med*. 2013;368(1):22-33). There may be situations in which a lower hematocrit cutoff may be appropriate and it should be individualized (eg, 42% for female patients and/or progressive symptoms).

^dSee [Assessment of Symptom Burden \(MPN-C 2 of 2\)](#).

^eBone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.

^fBarbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia* 2018;32:1057-1069.

^gDiagnostic criteria for post-ET or post-PV MF. See [\(MPN-E\)](#).

^hThe WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].t(15;17), t(8;21), t(16;16), inv(16)].

ⁱInterferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b could be considered for younger patients or in pregnant patients in need of cytoreductive therapy or in those in need of cytoreductive therapy that defer hydroxyurea.

^jSee [2013 IWG-MRT and ELN Response Criteria for PV \(PV-A\)](#). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

^kWhile normalization of blood counts after initiation of treatment is usually done in clinical practice, it is not associated with long-term clinical benefit and there are no evidence-based data to recommend a target WBC or platelet count for patients receiving cytoreductive therapy. In selected patients with a severe thrombotic event, normalization of blood counts might be an essential goal of treatment.

^lDefinition of intolerance/resistance to hydroxyurea [\(MPN-H\)](#).

^mSee [Special Considerations for the Use of Ruxolitinib \(MPN-F\)](#).

ⁿRuxolitinib is FDA approved for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2019

Polycythemia Vera

2013 IWG-MRT AND ELN RESPONSE CRITERIA FOR POLYCYTHEMIA VERA (PV)^{1,2}


Complete remission	
A	Durable* resolution of disease-related signs including palpable hepatosplenomegaly, large symptoms improvement, [†] AND
B	Durable* peripheral blood count remission, defined as: hematocrit lower than 45% without phlebotomies; platelet count $\leq 400 \times 10^9/L$, WBC count $< 10 \times 10^9/L$, AND
C	Without progressive disease, and absence of any hemorrhagic or thrombotic event, AND
D	Bone marrow histologic remission defined as the presence of age-adjusted normocellularity and disappearance of trilineage hyperplasia, and absence of $>$ grade 1 reticulin fibrosis.
Partial remission	
A	Durable* resolution of disease-related signs including palpable hepatosplenomegaly, large symptoms improvement, [†] AND
B	Durable* peripheral blood count remission, defined as: hematocrit lower than 45% without phlebotomies; platelet count $\leq 400 \times 10^9/L$, WBC count $< 10 \times 10^9/L$, AND
C	Without progressive disease, and absence of any hemorrhagic or thrombotic event, AND
D	Without bone marrow histologic remission defined as persistence of trilineage hyperplasia.
No response	Any response that does not satisfy partial remission.
Progressive disease	Transformation into post-PV myelofibrosis, myelodysplastic syndrome, or acute leukemia.

WBC: White blood cell count

*Lasting at least 12 weeks

[†]Large symptom improvement (≥ 10 -point decrease) in MPN-SAF TSS.¹Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. *Blood* 2013;121(23):4778-4781.²These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.**Note: All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

TREATMENT FOR VERY LOW-RISK OR LOW-RISK ESSENTIAL THROMBOCYTHEMIA^a



^aThe revised International Prognostic Score of Thrombosis for ET (IPSET-thrombosis) is preferred for the risk stratification of ET (Haider M, Gangat N, Lasho T, et al. *Am J Hematol* 2016;91:390-394. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. *Blood Cancer J* 2015;5:e369).

^bCytoreductive therapy is not recommended as initial treatment. Harrison CN, Campbell PJ, Buck G, et al. *Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia*. *N Engl J Med* 2005;353:33-45.

^cAspirin should be used with caution in patients with acquired VWD. Higher-dose aspirin may be appropriate in selected patients as clinically indicated. The risk and benefits of higher-dose aspirin must be weighed based on the presence of vasomotor symptoms versus the risk of bleeding.

^dReport from a recent retrospective analysis (Alvarez-Larran et al. *Haematologica* 2016;101(8):926-31) suggests that the use of low-dose aspirin may not be

beneficial in patients with low-risk CALR-mutated ET. However, at the present time, there is not enough evidence to recommend withholding aspirin for this group of patients.

^eSee [Assessment of Symptom Burden \(MPN-C 2 of 2\)](#).

^fBone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.

^gBarbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia* 2018;32:1057-1069.

^hDiagnostic criteria for post-ET or post-PV MF. See [\(MPN-E\)](#).

ⁱThe WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2019

Essential Thrombocythemia

TREATMENT FOR INTERMEDIATE-RISK ESSENTIAL THROMBOCYTHEMIA^a



^aThe revised International Prognostic Score of Thrombosis for ET (IPSET-thrombosis) is preferred for the risk stratification of ET (Haider M, Gangat N, Lasho T, et al. *Am J Hematol* 2016;91:390-394. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. *Blood Cancer J* 2015;5:e369).

^cAspirin should be used with caution in patients with acquired VWD. Higher-dose aspirin may be appropriate in selected patients as clinically indicated. The risk and benefits of higher-dose aspirin must be weighed based on the presence of vasomotor symptoms versus the risk of bleeding.

^eSee [Assessment of Symptom Burden \(MPN-C 2 of 2\)](#).

^fBone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.

^gBarbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia* 2018;32:1057-1069.

^hDiagnostic criteria for post-ET or post-PV MF. See [\(MPN-E\)](#).

ⁱThe WHO classification defines acute leukemia as ≥20% blasts in the marrow or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)].

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2019

Essential Thrombocythemia

TREATMENT FOR HIGH-RISK ESSENTIAL THROMBOCYTHEMIA^a



^aThe revised International Prognostic Score of Thrombosis for ET (IPSET-thrombosis) is preferred for the risk stratification of ET (Haider M, Gangat N, Lasho T, et al. *Am J Hematol* 2016;91:390-394. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. *Blood Cancer J* 2015;5:e369).

^cAspirin should be used with caution in patients with acquired VWD. Higher-dose aspirin may be appropriate in selected patients as clinically indicated. The risk and benefits of higher-dose aspirin must be weighed based on the presence of vasomotor symptoms versus the risk of bleeding.

^eSee [Assessment of Symptom Burden \(MPN-C 2 of 2\)](#).

^fBone marrow aspirate and biopsy should be performed to rule out disease progression to myelofibrosis prior to the initiation of cytoreductive therapy.

^gBarbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia* 2018;32:1057-1069.

^hDiagnostic criteria for post-ET or post-PV MF See [\(MPN-E\)](#).

ⁱThe WHO classification defines acute leukemia as ≥20% blasts in the marrow

or blood. A diagnosis of AML may be made with less than 20% in patients with recurrent cytogenetic abnormalities [eg, t(15;17), t(8;21), t(16;16), inv(16)]

^jInterferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b could be considered for younger patients or in pregnant patients in need of cytoreductive therapy or in those in need of cytoreductive therapy that defer hydroxyurea.

^kSee [2013 IWG-MRT and ELN Response Criteria for ET \(ET-A\)](#). These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

^lWhile normalization of blood counts after initiation of treatment is usually done in clinical practice, it is not associated with long-term clinical benefit and there is no evidence-based data to recommend a target WBC or platelet count for patients receiving cytoreductive therapy. In selected patients with a severe thrombotic event, normalization of blood counts might be an essential goal of treatment.

^mDefinition of intolerance/resistance to hydroxyurea [\(MPN-H\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2019

Essential Thrombocythemia

2013 IWG-MRT AND ELN RESPONSE CRITERIA FOR ESSENTIAL THROMBOCYTHEMIA (ET)^{1,2}

Complete remission	
A	Durable* resolution of disease-related signs including palpable hepatosplenomegaly, large symptoms improvement, [†] AND
B	Durable* peripheral blood count remission, defined as: platelet count $\leq 400 \times 10^9/L$, WBC count $< 10 \times 10^9/L$, absence of leukoerythroblastosis, AND
C	Without signs of progressive disease, and absence of any hemorrhagic or thrombotic events, AND
D	Bone marrow histologic remission defined as disappearance of megakaryocyte hyperplasia and absence of >grade 1 reticulin fibrosis.
Partial remission	
A	Durable* resolution of disease-related signs including palpable hepatosplenomegaly, and large symptoms improvement, AND
B	Durable* peripheral blood count remission, defined as: platelet count $\leq 400 \times 10^9/L$, WBC count $< 10 \times 10^9/L$, absence of leukoerythroblastosis, AND
C	Without signs of progressive disease, and absence of any hemorrhagic or thrombotic events, AND
D	Without bone marrow histologic remission, defined as the persistence of megakaryocyte hyperplasia
No response	Any response that does not satisfy partial remission
Progressive disease	Transformation into PV, post-ET myelofibrosis, myelodysplastic syndrome or acute leukemia

WBC White blood count

*Lasting at least 12 weeks

†Large symptom improvement (≥ 10 -point decrease) in MPN-SAF TSS.

¹Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. *Blood* 2013;121(23):4778-4781.

²These response criteria were developed mainly for use in clinical trials. Clinical benefit may not reach the threshold of the IWG-MRT Response Criteria. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**2017 WHO DIAGNOSTIC CRITERIA FOR PRIMARY MYELOFIBROSIS¹****WHO prePMF Criteria****(Diagnosis of prePMF requires meeting all 3 major criteria, and at least 1 minor criterion)****• Major criteria**

- ▶ Megakaryocytic proliferation and atypia, without reticulin fibrosis >grade 1,² accompanied by increased age-adjusted BM cellularity, granulocytic proliferation, and often decreased erythropoiesis
- ▶ Not meeting WHO criteria for *BCR-ABL1*+ CML, PV, ET, myelodysplastic syndromes, or other myeloid neoplasms
- ▶ Presence of *JAK2*, *CALR*, or *MPL* mutation or in the absence of these mutations, presence of another clonal marker,³ or absence of minor reactive BM reticulin fibrosis⁴

• Minor criteria

- ▶ Presence of at least one of the following, confirmed in 2 consecutive determinations:
 - ◇ Anemia not attributed to a comorbid condition
 - ◇ Leukocytosis $\geq 11 \times 10^9/L$
 - ◇ Palpable splenomegaly
 - ◇ LDH increased to above upper normal limit of institutional reference range

WHO Overt PMF Criteria**(Diagnosis of overt PMF requires meeting all 3 major criteria, and at least 1 minor criterion)****• Major criteria**

- ▶ Presence of megakaryocytic proliferation and atypia, accompanied by either reticulin and/or collagen fibrosis grades 2 or 3²
- ▶ Not meeting WHO criteria for ET, PV, *BCR-ABL1*+ CML, myelodysplastic syndromes, or other myeloid neoplasms
- ▶ Presence of *JAK2*, *CALR*, or *MPL* mutation or in the absence of these mutations, presence of another clonal marker,³ or absence of reactive myelofibrosis⁵

• Minor criteria

- ▶ Presence of at least one of the following, confirmed in 2 consecutive determinations:
 - ◇ Anemia not attributed to a comorbid condition
 - ◇ Leukocytosis $\geq 11 \times 10^9/L$
 - ◇ Palpable splenomegaly
 - ◇ LDH increased to above upper normal limit of institutional reference range
 - ◇ Leukoerythroblastosis

¹Adapted with permission Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. IARC, Lyon, 2017.

²See Grading of Myelofibrosis ([MPN-A 2 of 2](#)).

³In the absence of any of the 3 major clonal mutations, the search for the most frequent accompanying mutations (eg, *ASXL1*, *EZH2*, *TET2*, *IDH1/IDH2*, *SRSF2*, *SF3B1*) are of help in determining the clonal nature of the disease.

⁴Minor (grade 1) reticulin fibrosis secondary to infection, autoimmune disorder or other chronic inflammatory conditions, hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy, or toxic (chronic) myelopathies.

⁵BM fibrosis secondary to infection, autoimmune disorder or other chronic inflammatory conditions, hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy, or toxic (chronic) myelopathies.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)**MPN-A**
1 OF 2



GRADING OF MYELOFIBROSIS¹

Myelofibrosis Grading

- **MF-0**
 - ▶ Scattered linear reticulin with no intersections (crossovers) corresponding to normal BM
- **MF-1**
 - ▶ Loose network of reticulin with many intersections, especially in perivascular areas
- **MF-2**
 - ▶ Diffuse and dense increase in reticulin with extensive intersections, occasionally with focal bundles of thick fibers mostly consistent with collagen, and/or focal osteosclerosis*
- **MF-3**
 - ▶ Diffuse and dense increase in reticulin with extensive intersections and course bundles of thick fibers consistent with collagen, usually associated with osteosclerosis*

¹Reproduced with permission ©2018 Ferrata Storti Foundation. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. *Haematologica* 2005;90(8):1128-1132.

*In grades MF-2 or MF-3 an additional trichrome stain is recommended.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



2017 WHO DIAGNOSTIC CRITERIA FOR POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA¹

Polycythemia Vera (PV)

(Diagnosis requires meeting either all 3 major criteria, or the first 2 major criteria and the minor criterion²)

• Major criteria

▶ Hemoglobin >16.5 g/dL in men, >16.0 g/dL in women

OR

Hematocrit >49% in men, >48% in women

OR

Increased red cell mass (RCM)³

▶ Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) including prominent erythroid, granulocytic, and megakaryocytic proliferation with pleomorphic, mature megakaryocytes (differences in size)

▶ Presence of *JAK2* V617F or *JAK2* exon 12 mutation

• Minor criteria

▶ Subnormal serum EPO level

Essential Thrombocythemia (ET)

(Diagnosis requires meeting all 4 major criteria or the first 3 major criteria and the minor criterion)

• Major criteria

▶ Platelet count $\geq 450 \times 10^9/L$

▶ Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage with increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant increase or left shift in neutrophil granulopoiesis or erythropoiesis and very rarely minor (grade 1) increase in reticulin fibers

▶ Not meeting WHO criteria for CML, PV, PMF, myelodysplastic syndromes, or other myeloid neoplasms

▶ Presence of *JAK2*, *CALR*, or *MPL* mutation

• Minor criterion

▶ Presence of a clonal marker or absence of evidence for reactive thrombocytosis

¹Adapted with permission Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. IARC, Lyon, 2017.

²Criterion number 2 (BM biopsy) may not be required in cases with sustained absolute erythrocytosis; hemoglobin levels >18.5 g/dL in men (hematocrit, 55.5%) or >16.5 g/dL in women (hematocrit, 49.5%) if major criterion 3 and the minor criterion are present. However, initial myelofibrosis (present in up to 20% of patients) can only be detected by performing a BM biopsy; this finding may predict a more rapid progression to overt myelofibrosis (post-PV MF).

³More than 25% above mean normal predicted value.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

ASSESSMENT OF SYMPTOM BURDEN

- **Assessment of symptoms (in provider's office) at baseline and monitoring symptom status (stable, improved, or worsening) during the course of treatment is recommended for all patients.**
- **Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS; MPN-10) is recommended for the assessment of symptom burden at baseline and monitoring symptom status during the course of treatment ([See MPN-C, 2 of 2](#)).**
- **MPN-SAF TSS is assessed by the patients themselves. Scoring is from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) for each item. The MPN-SAF TSS is the summation of all the individual scores (0–100 scale).**
- **Symptom response requires $\geq 50\%$ reduction in the MPN-SAF TSS. A symptom response $< 50\%$ may be clinically meaningful and justify continued use of ruxolitinib.**
- **Changes in symptom status could be a sign of disease progression. Therefore, change in symptom status should prompt evaluation of treatment efficacy and/or disease status.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2019

Myeloproliferative Neoplasms

MYELOPROLIFERATIVE NEOPLASM SYMPTOM ASSESSMENT FORM TOTAL SYMPTOM SCORE (MPN-SAF TSS; MPN-10)¹

(Recommended for monitoring symptoms during the course of treatment)

Symptom	1 to 10 (0 if absent) ranking 1 is most favorable and 10 least favorable
Please rate your fatigue (weariness, tiredness) by circling the one number that best describes your WORST level of fatigue during past 24 hours	(No Fatigue) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)

Circle the one number that describes, during the past week, how much difficulty you have had with each of the following symptoms

Filling up quickly when you eat (early satiety)	(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)
Abdominal discomfort	(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)
Inactivity	(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)
Problems with concentration-compared to prior to my MPD	(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)
Night sweats	(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)
Itching (pruritus)	(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)
Bone pain (diffuse not joint pain or arthritis)	(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)
Fever (>100 F)	(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Daily)
Unintentional weight loss last 6 months	(Absent) 0 1 2 3 4 5 6 7 8 9 10 (Worst Imaginable)

¹Reproduced with permission from Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012;30:4098-4103.

**Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



PROGNOSTIC SIGNIFICANCE OF MUTATIONS IN MPN

Mutated Gene	Primary Myelofibrosis (PMF)
JAK2 V617F	Intermediate prognosis and higher risk of thrombosis compared to patients with <i>CALR</i> mutation ¹
MPL W515L/K	Intermediate prognosis and higher risk of thrombosis compared to patients with <i>CALR</i> mutation ¹
CALR	Improved survival compared to <i>JAK2</i> mutation and "triple-negative" PMF ¹⁻⁴ Lower risk of thrombosis compared to <i>JAK2</i> mutation ¹
CALR Type 1/Type 1-like	Improved overall survival compared to <i>CALR</i> type 2/type 2-like and <i>JAK2</i> V617F mutation ⁵⁻⁸
"Triple Negative" (non-mutated <i>JAK2</i> , <i>MPL</i> , and <i>CALR</i>)	Inferior leukemia-free survival compared to patients with <i>JAK2</i> - and/or <i>CALR</i> -mutated PMF ¹⁻³ Inferior overall survival compared to patients with <i>CALR</i> -mutated PMF ²
ASXL1	Independently associated with inferior overall survival* and leukemia-free survival ⁹
EZH2	Independently associated with inferior overall survival ⁹
IDH1/2	Independently associated with inferior leukemia-free survival ⁹
SRSF2	Independently associated with inferior overall survival and leukemia-free survival ⁹
Combined <i>CALR</i> and <i>ASXL1</i> status	Survival longest for <i>CALR</i> (+) <i>ASXL1</i> (-) patients (median 10.4 years) and shortest in <i>CALR</i> (-) <i>ASXL1</i> (+) patients (median 2.3 years) ^{**10} Intermediate survival (median 5.8 years) for <i>CALR</i> (+) <i>ASXL1</i> (+) or <i>CALR</i> (-) <i>ASXL1</i> (-) patients ¹⁰
TP53	Associated with leukemic transformation ¹¹
U2AF1 Q157	Inferior overall survival compared to patients with <i>U2AF1</i> S34 mutated or <i>U2AF1</i> unmutated PMF. The effect was most evident in younger patients ¹²

**ASXL1* mutation retains prognostic significance for inferior overall survival independent of IPSS or DIPSS-Plus risk score.

**The *CALR/ASXL1* mutation status was DIPSS-Plus independent ($P < .0001$) and effective in identifying low-/intermediate-1-risk patients with shorter (median, 4 years) or longer (median 20 years) survival and high-/intermediate-2-risk patients with shorter (median, 2.3 years) survival.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)
[References](#)

MPN-D
1 OF 4



REFERENCES

- ¹Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. *Blood* 2014;124:1062-1069.
- ²Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. *Leukemia* 2014;28:1472-1477.
- ³Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood* 2014; 124:2507-2513.
- ⁴Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med* 2013;369:2379-2390.
- ⁵Guglielmelli P, Rotunno G, Fanelli T, et al. Validation of the differential prognostic impact of type 1/type-1 like versus type 2/type 2-like CALR mutations in myelofibrosis. *Blood Cancer J* 2015;5:e360.
- ⁶Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. *Blood* 2014;124:2465-2466.
- ⁷Tefferi A, Lasho TL, Finke CM, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. *Leukemia* 2014;28:1568-1570.
- ⁸Li B, Xu J, Wang J, et al. Calreticulin mutations in Chinese with primary myelofibrosis. *Haematologica* 2014;99:1697-1700.
- ⁹Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. *Leukemia* 2013;27:1861-1869.
- ¹⁰Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. *Leukemia* 2014;28:1494-1500.
- ¹¹Rampal et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. *Proc Natl Acad Sci USA* 2014;111:E5401-5410.
- ¹²Tefferi A, Finke CM, Lasho TL, et al. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. *Leukemia* 2018;32:2274-2278.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

NCCN Guidelines Version 2.2019
Myeloproliferative Neoplasms**PROGNOSTIC SIGNIFICANCE OF MUTATIONS IN MPN**

Mutated Gene	Polycythemia Vera (PV)
<i>ASXL1/ SRSF2/ IDH1/21</i>	The presence of at least 1 of these "adverse variants/mutations" is associated with inferior overall survival (compared to other sequence variants/mutations, or none) independent of age, IWG prognostic model for PV, and karyotype. ² Adverse variants/mutations also affected myelofibrosis-free survival.
<i>JAK2</i> exon 12 mutation	Patients with <i>JAK2</i> exon 12-mutated PV exhibit younger age, increased mean hemoglobin/hematocrit, and lower mean white blood cell and platelet counts at diagnosis compared to those with <i>JAK2</i> <i>V617F</i> -mutated PV. However, both <i>JAK2</i> mutations are associated with similar rates of thrombosis, evolution to myelofibrosis or leukemia, and death. ^{3,4}

¹Next-generation sequencing (NGS) remains a research tool in many situations. However, it may be useful to establish clonality in selected circumstances (eg, "triple negative" non-mutated *JAK2*, *MPL*, and *CALR*).

²Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Advances* 2016;1(1):21-30.

³Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with *JAK2* exon 12 mutations. *Blood* 2011;117:2813-2816.

⁴Scott L. The *JAK2* exon 12 mutations: a comprehensive review. *Am J Hematol* 2011;86:668-676.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

MPN-D
3 OF 4

PROGNOSTIC SIGNIFICANCE OF MUTATIONS IN MPN

Mutated Gene	Essential Thrombocythemia (ET)
<i>CALR</i>	<p>Lower-risk of thrombosis compared to <i>JAK2</i>-mutated ET¹⁻³</p> <p>No difference in overall survival or myelofibrotic or leukemic transformation compared to <i>JAK2</i>-mutated ET¹⁻³</p> <p><i>CALR</i> mutation does not modify the IPSET score for predicting thrombosis in patients with ET⁴</p>
<i>TP53</i>	Associated with inferior leukemia-free survival in multivariate analysis ⁵
<i>SH2B3/IDH2/U2AF1/SF3B1/EZH2/TP53</i>⁶	<p>The presence of at least 1 of these "adverse variants/mutations" is associated with inferior overall survival (compared to other sequence variants/ mutations, or none) independent of age and karyotype⁷</p> <p>Adverse variants/mutations also affect myelofibrosis-free survival⁷</p>

¹Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med* 2013 Dec 19;369(25):2379-90.

²Rumi E, Pietra D, Ferretti V, et al. *JAK2* or *CALR* mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. *Blood* 2014 Mar 6;123(10):1544-51.

³Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. *Blood* 2014 Mar 6;123(10):1552-5.

⁴Finazzi G, Carobbio A, Guglielmelli P, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. *Blood* 124(16):2611-2.

⁵Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. *Proc Natl Acad Sci U S A* 2014;111:E5401-5410.

⁶Next-generation sequencing (NGS) remains a research tool in many situations. However, it may be useful to establish clonality in selected circumstances (eg, "Triple Negative" non-mutated *JAK2*, *MPL*, and *CALR*).

⁷Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Advances* 2016;1(1):21-30.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



IWG-MRT DIAGNOSTIC CRITERIA FOR POST-POLYCYTHEMIA VERA (PV) AND POST-ESSENTIAL (ET) MYELOFIBROSIS¹

Criteria for post-PV myelofibrosis

Required criteria:

- Documentation of a previous diagnosis of PV as defined by the WHO criteria²
- Bone marrow fibrosis grade 2–3 (on 0–3 scale)³ or grade 3–4 (on 0–4 scale)^{4,5}

Additional criteria (two are required):

- Anemia⁶ or sustained loss of requirement of either phlebotomy (in the absence of cytoreductive therapy) or cytoreductive treatment for erythrocytosis
- A leukoerythroblastic peripheral blood picture
- Increasing splenomegaly defined as either an increase in palpable splenomegaly of ≥5 cm (distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly
- Development of ≥1 of three constitutional symptoms: >10% weight loss in 6 months, night sweats, unexplained fever (>37.5°C)

Criteria for post-ET myelofibrosis

Required criteria:

- Documentation of a previous diagnosis of ET as defined by the WHO criteria²
- Bone marrow fibrosis grade 2–3 (on 0–3 scale)³ or grade 3–4 (on 0–4 scale)^{4,5}

Additional criteria (two are required):

- Anemia⁶ and ≥2 g/dL decrease from baseline hemoglobin level
- A leukoerythroblastic peripheral blood picture
- Increasing splenomegaly defined as either an increase in palpable splenomegaly of ≥5 cm (distance of the tip of the spleen from the left costal margin) or the appearance of a newly palpable splenomegaly
- Increased LDH (above reference level)
- Development of ≥1 of 3 constitutional symptoms: >10% weight loss in 6 months, night sweats, unexplained fever (>37.5°C)

¹Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. *Leukemia* 2008;22:437-438.

²Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. *Blood* 2007;110:1092-1097.

³Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. *Haematologica* 2005;90:1128-1132.

⁴Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. *Br J Haematol* 1979;43:185-190.

⁵Grade 2–3 according to the European classification: diffuse, often coarse fiber network with no evidence of collagenization (negative trichrome stain) or diffuse, coarse fiber network with areas of collagenization (positive trichrome stain). Grade 3–4 according to the standard classification: diffuse and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen and/or focal osteosclerosis or diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis.

⁶Below the reference range for appropriate age, sex, gender, and altitude considerations.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

SPECIAL CONSIDERATIONS FOR THE USE OF RUXOLITINIB¹

- CBC with differential and comprehensive metabolic panel with uric acid and LDH must be performed before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.
- A baseline MPN-SAF TSS (MPN-10) (prior to initiation of therapy) is recommended to monitor symptoms during the course of therapy.
- Symptoms may return to pretreatment levels over a period of approximately one week following discontinuation or interruption of ruxolitinib. Consider tapering the dose of ruxolitinib gradually, when discontinuing or interrupting therapy with ruxolitinib for reasons other than thrombocytopenia or neutropenia.
- Monitor spleen size either by palpation or imaging.

Myelofibrosis (MF)

Dosing and administration:

The recommended initial dosing of ruxolitinib (as described in the full prescribing information) is dependent on the patient's baseline platelet counts. However, certain clinical situations may support initiation of ruxolitinib at a lower dose with subsequent dose adjustments.

- 50 X 10⁹/L to less than 100 X 10⁹/L: 5 mg twice daily
- 100 X 10⁹/L - 200 X 10⁹/L: 15 mg twice daily
- >200 X 10⁹/L: 20 mg twice daily

Dose modifications based on insufficient response:

- Increase dose as tolerated, at 4-week intervals, in 5 mg twice daily increments to a maximum of 10 mg twice daily (if <100 x 10⁹/L)/ 25 mg twice daily (if >100 x 10⁹/L).
- Doses should not be increased during the first 4 weeks of therapy and not more frequently than every 2 weeks.
- Consider dose increases in patients who meet all of the following conditions. Discontinue if no response or improvement of symptoms after 6 months.
 - ▶ Failure to achieve a 50% reduction in palpable splenomegaly or symptom improvement or a 35% reduction in spleen volume as measured by CT or MRI. Inadequate reduction in splenomegaly is determined by the treating clinician. Less than 50% reduction in palpable splenomegaly may be clinically meaningful and justify continued use of ruxolitinib.
 - ▶ Platelet count >125 X 10⁹/L at 4 weeks and platelet count never <100 X 10⁹/L; ANC levels greater than 0.75 X 10⁹/L.

Polycythemia Vera (PV)

Dosing and administration:

The recommended initial dosing of ruxolitinib (as described in the full prescribing information) is 10 mg twice daily. Doses may be titrated based on safety and efficacy.

Dose modifications based on insufficient response:

- Dose modification should be based on the efficacy of ruxolitinib (eg, improving phlebotomy burden, symptom burden, and splenomegaly) versus toxicity.
- Doses may be increased as tolerated in 5 mg twice-daily increments to a maximum of 25 mg twice daily.
- Doses should not be increased during the first 4 weeks of therapy and not more frequently than every two weeks.

Lymphoma risk with JAK Inhibitors in patients with MPN:

Both low- and high-grade neoplasms may be diagnosed concurrently with MPNs or may develop during the natural history of PV, ET, or MF. Although one report indicated an increased risk of lymphomas with JAK inhibitor therapy, additional studies are required to validate these observations.²

See [MPN-F \(2 of 2\)](#) for Hematologic Toxicities

¹Please refer to package insert for full prescribing information available at www.fda.gov.

²Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 2018;132(7):694-706.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**SPECIAL CONSIDERATIONS FOR THE USE OF RUXOLITINIB¹****Dose Modifications for Hematologic and Non-Hematologic Toxicities:****Hematologic Toxicities**

Thrombocytopenia should be managed by dose reduction or dose interruption (at the discretion of treating clinician based on clinical parameters). Platelet transfusions may be necessary. Management of anemia may require blood transfusions and/or dose modifications. Severe neutropenia (ANC less than $0.5 \times 10^9/L$) was generally reversible by withholding ruxolitinib. Ruxolitinib may be restarted at prior dose or with subsequent modifications if necessary after recovery of the hematologic parameter(s) to acceptable levels. Monitor CBCs every 2 to 4 weeks until doses are stabilized, and then as clinically indicated. See prescribing information for dose modifications for hematologic toxicities.

Non-Hematologic Toxicities***Lipid Elevations***

Ruxolitinib has been associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Assess lipid parameters approximately 8–12 weeks following initiation of ruxolitinib. Monitor and treat according to clinical guidelines for the management of hyperlipidemia.

Renal Impairment

Dose reduction is recommended for patients with moderate (CrCl 30–59 mL/min) or severe renal impairment (CrCl 15–29 mL/min) with a platelet count between $50 \times 10^9/L$ and $150 \times 10^9/L$. See prescribing information for dose adjustments related to renal impairment.

Hepatic Impairment

Dose reduction is recommended for patients with any degree of hepatic impairment and platelet count between $50 \times 10^9/L$ and $150 \times 10^9/L$. See prescribing information for dose adjustments related to hepatic impairment.

Infections

Ruxolitinib is associated with a potentially increased risk of opportunistic infections. Patients should be assessed for the risk of developing serious bacterial, mycobacterial, fungal, and viral infections. Patients receiving ruxolitinib should be carefully observed for signs and symptoms of infections. Appropriate treatment should be initiated promptly to resolve active serious infections before initiating ruxolitinib therapy.

Tuberculosis

Tuberculosis infection has been reported in patients receiving ruxolitinib. Patients should be evaluated for tuberculosis risk factors, and those at higher risk should be tested for latent infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended prior to initiating ruxolitinib for patients with evidence of active or latent tuberculosis.

Hepatitis B

Increases in Hepatitis B viral load (HBV-DNA titer) with or without associated elevations in alanine aminotransferase and aspartate aminotransferase have been reported in patients with chronic HBV infections treated with ruxolitinib. Patients with chronic HBV infection should be treated and monitored according to clinical guidelines.

PML and Herpes Zoster

Progressive multifocal leukoencephalopathy (PML) and herpes zoster virus (HZV) infection have been reported in patients treated with ruxolitinib. If PML is suspected, ruxolitinib should be discontinued. Patients with suspected HZV infection should be treated and monitored according to clinical guidelines. Consider the use of non-live, subunit herpes zoster vaccine for patients receiving ruxolitinib.

Non-Melanoma Skin Cancer

Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred in patients treated with ruxolitinib. Perform periodic skin examinations.

¹Please refer to package insert for full prescribing information available at www.fda.gov.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**SPECIAL CONSIDERATIONS IN THE TREATMENT OF POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)****Management of Vascular Events****• Thrombosis**

- ▶ The use of clinically appropriate anticoagulant therapy (eg, low-molecular-weight heparin [LMWH], direct oral anticoagulant, warfarin) is recommended for patients with active thrombosis. The initial use of anticoagulant therapy for the prevention and treatment of thrombosis should be based on the current American College of Chest Physicians (ACCP) Guidelines.¹
- ▶ There are no data to guide the selection or appropriate duration of anticoagulation with or without antiplatelet therapy in patients with PV or ET. The duration of anticoagulant therapy is dependent on the severity of the thrombotic event (eg, abdominal vein thrombosis vs. deep vein thrombosis), degree of disease control, and assessment of likelihood of recurrence after cessation of anticoagulant therapy.
- ▶ Assess the need for cytoreductive therapy (if not done before) and initiate cytoreductive therapy (to maintain hematocrit <45% in patients with PV) if necessary. In the presence of inadequate response, consider intensification of therapy or switch to an alternate agent. The value of cytoreduction in reducing future vascular events has not been studied in a prospective, randomized, controlled trial.
- ▶ Plateletpheresis may be indicated in patients with ET presenting with acute life-threatening thrombosis or severe bleeding.

• Bleeding

- ▶ Rule out other potential causes and treat coexisting causes as necessary.
- ▶ Aspirin should be withheld until bleeding is under control. Consider the use of appropriate cytoreductive therapy to normalize platelet counts.
- ▶ Coagulation tests to evaluate for acquired VWD and/or other coagulopathies are recommended for patients undergoing high-risk surgical procedures and those with elevated platelet count and/or splenomegaly or unexplained bleeding (see [MPN-1](#)).
- ▶ In unanticipated gastrointestinal (GI) bleeding, particularly in the setting of splenomegaly, portal hypertension, and gastric varices, special consultation (for endoscopic evaluation) with a hepatologist or a GI specialist is recommended.

Surgery

- Multi-disciplinary management with surgical and perioperative medical teams (eg, review of bleeding and thrombosis history; medication list) is recommended.
- Emergency surgery should be performed as necessary with close postoperative surveillance for the symptoms of arterial or venous thrombosis and bleeding.
- Patients with PV and ET are at higher risk for bleeding despite optimal management. The thrombotic and bleeding risk of the surgical procedure (eg, orthopedic and cardiovascular surgery) should be strongly considered prior to elective surgery.
- Thrombosis and bleeding risk should be well controlled (normalization or near-normalization CBC without causing prohibitive cytopenias) prior to performing elective surgery (particularly for orthopedic surgeries or any surgical procedures associated with prolonged immobilization) with the use of appropriate anticoagulant prophylaxis and cytoreductive therapy. If surgery is associated with a high risk for venous thromboembolism (eg, cancer surgery, splenectomy, orthopedic and cardiovascular surgery), extended prophylaxis with LMWH should be considered. Prophylaxis with aspirin may be considered following vascular surgery.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)
[References](#)

MPN-G
1 OF 2

**SPECIAL CONSIDERATIONS IN THE TREATMENT OF POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOCYTHEMIA (ET)****Surgery (continued)**

- In patients with PV, hematocrit should be controlled for 3 months before elective surgery (normalization or near-normalization of CBC). Additional phlebotomy may also be necessary to maintain hematocrit <45% prior to performing elective surgery.
- Aspirin should be discontinued one week prior to surgical procedure and restarted 24 hours after surgery or when considered acceptable depending on the bleeding risk.
- Anticoagulant therapy should be withheld (based on the half-life/type of agent) prior to surgery and restarted after surgery when considered acceptable depending on the bleeding risk.
- Cytoreductive therapy could be continued throughout the perioperative period, unless there are unique contraindications expressed by the surgical team.

Pregnancy^{2,3}

- Pre-conception meeting and evaluation by high-risk obstetrician should be considered.
- Low-risk pregnancy: Low-dose aspirin (50–100 mg/d) is recommended throughout pregnancy (to maintain hematocrit <45% in patients with PV) and for six weeks postpartum. Aspirin could be stopped and LMWH could be considered about two weeks before labor is expected.
- High-risk pregnancy:^{3,4} Consider the use of prophylactic LMWH (subcutaneously) with low-dose aspirin throughout pregnancy (to maintain hematocrit <45% in patients with PV) and for six weeks postpartum.
- Consider stopping low-dose aspirin 1 to 2 weeks prior to delivery. LMWH should be stopped 12 hours to 24 hours before labor is expected. In patients taking LMWH, consultation with high-risk obstetrician and obstetric anesthesiologist is recommended regarding the optimal timing of discontinuation in preparation for an epidural prior to delivery.
- In patients without prior bleeding or thrombotic complications, consider the use of LMWH instead of aspirin in the last two weeks of pregnancy (to maintain hematocrit <45% in patients with PV) and continued until six weeks post partum. The duration of LMWH post partum could be extended in high-risk pregnancy or in women who have undergone C-section.
- If cytoreductive therapy is needed, interferons (interferon alfa-2b, peginterferon alfa-2a, and peginterferon alfa-2b) should be considered. Patients on hydroxyurea prior to pregnancy should be switched to interferons.
- Hydroxyurea is excreted in breastmilk and should be avoided in women who are breastfeeding.

¹Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012;141(2 Suppl):7S-47S.

Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest* 2016;149:315-352.

²Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia*. 2018;32:1057-1069.

³Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. *Blood Rev* 2008;22:235-245.

⁴If any of the following factors are present then the pregnancy should be considered at high risk:

- Previous microcirculatory disturbances or presence of two or more hereditary thrombophilic factors.
- Severe complications in a previous pregnancy (≥3 first trimester losses or ≥1 second or third trimester pregnancy loss, birth weight <5th percentile for gestation, intrauterine death or stillbirth, stillbirth and preeclampsia necessitating preterm delivery <37 weeks, or development of any such complication in the index pregnancy).
- Age >35 years.
- Platelet count >1000 x 10⁹/l.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

DEFINITION OF RESISTANCE/INTOLERANCE TO HYDROXYUREA¹

Myeloproliferative Neoplasm	Definition of Resistance/Intolerance to Hydroxyurea
Polycythemia vera	<ol style="list-style-type: none"> 1. Need for phlebotomy to keep hematocrit <45% after 3 months of at least 2 g/d of hydroxyurea, OR 2. Uncontrolled myeloproliferation (ie, platelet count >400 x 10⁹/L AND WBC count >10 x 10⁹/L) after 3 months of at least 2 g/d of hydroxyurea, OR 3. Failure to reduce massive* splenomegaly by >50% as measured by palpation OR failure to completely relieve symptoms related to splenomegaly after 3 months of at least 2 g/d of hydroxyurea, OR 4. Absolute neutrophil count <1.0 x 10⁹/L OR platelet count <100 x 10⁹/L OR hemoglobin <10 g/dL at the lowest dose of hydroxyurea required to achieve a complete or partial clinicohematologic response,† OR 5. Presence of leg ulcers or other unacceptable hydroxyurea-related nonhematologic toxicities, such as mucocutaneous manifestations, GI symptoms, pneumonitis, or fever at any dose of hydroxyurea
Essential thrombocythemia	<ol style="list-style-type: none"> 1. Platelet count >600 x 10⁹/L after 3 months of at least 2 g/d of hydroxyurea (2.5 g/d in patients with a body weight >80 kg), OR 2. Platelet count >400 x 10⁹/L and WBC count <2.5 x 10⁹/L at any dose of hydroxyurea, OR 3. Platelet count >400 x 10⁹/L and hemoglobin <10 g/dL at any dose of hydroxyurea, OR 4. Presence of leg ulcers or other unacceptable mucocutaneous manifestations at any dose of hydroxyurea, OR 5. Hydroxyurea-related fever

*Organ extending by >10 cm from the costal margin.

†Complete response is defined as hematocrit less than 45% without phlebotomy, platelet count ≤400 x 10⁹/L, WBC count ≤10 x 10⁹/L, and no disease-related symptoms. Partial response is defined as hematocrit less than 45% without phlebotomy or response in three or more of other criteria.

¹Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-770.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 2.2019 Myeloproliferative Neoplasms

Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

Overview	MS-1
Literature Search Criteria and Guidelines Update Methodology	MS-1
Molecular Abnormalities in MPN	MS-2
Diagnostic Classification	MS-4
Workup of Suspected MPN	MS-5
Assessment of Symptom Burden	MS-6
Management of Myelofibrosis	MS-7
Management of Polycythemia Vera and Essential Thrombocythemia	MS-22
Summary	MS-30
References	MS-31



Overview

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPN). The prevalence of MF, ET, and PV in the United States is estimated to be approximately 13,000, 134,000, and 148,000, respectively.¹ In a more recent survey that assessed the incidence rates (IRs) of different subtypes of MPN in the United States (2001–2012), the IRs were highest for PV (IR = 11) and ET (IR = 10).²

MPN are characterized by a complicated symptom profile; the symptom profile varies within and between each MPN subtype, but often includes constitutional symptoms, fatigue, pruritus, weight loss, symptoms from splenomegaly, and variable lab abnormalities, including erythrocytosis, thrombocytosis, and leukocytosis.³⁻⁶ A SEER-Medicare database analysis showed that patients with MPN have substantially inferior survival compared to matched controls, and the survival for patients with MF is worse than that of patients with ET or PV and significantly worse than matched controls.⁷ In addition, MPN also have the propensity for disease transformation into blast phase (MPN-BP) and acute myeloid leukemia (AML), both of which are associated with poor prognosis.^{8,9}

The diagnosis and the management of patients with MPN has evolved since the identification of “driver” mutations (*JAK2*, *CALR*, and *MPL* mutations), and the development of targeted therapies has resulted in significant improvements in disease-related symptoms and quality of life.¹⁰ However, certain aspects of clinical management regarding the diagnosis, assessment of symptom burden, and selection of appropriate

symptom-directed therapies continue to present challenges for hematologists and oncologists.¹¹

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the aim to provide recommendations for the management of MPN in adults. The NCCN Guidelines® for Myeloproliferative Neoplasms include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of MF, PV, and ET.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Myeloproliferative Neoplasms an electronic search of the PubMed database was performed to obtain key literature in Myeloproliferative Neoplasms published since the previous Guidelines update using the following search terms: myeloproliferative neoplasms, myelofibrosis, polycythemia vera, and essential thrombocythemia. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.¹²

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 146 citations and their potential relevance was examined. The data from key PubMed articles selected by the panel for review during the Guidelines update as well as articles from additional sources deemed as relevant to these Guidelines and

discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available at www.NCCN.org.

Molecular Abnormalities in MPN

JAK2 V617F mutations account for the majority of patients with PV (more than 90%) and 60% of patients with ET or MF.¹³⁻¹⁵ The V617F mutation occurs in exon 14; however, rare insertions and deletions have been found in exon 12. *JAK2* exon12 mutations have been described in 2% to 3% of patients with PV.^{16,17}

Activating mutations in the thrombopoietin receptor gene (*MPL* W515L/K) are reported in approximately 5% to 8% of all patients with MF and 1% to 4% of all patients with ET.¹⁸⁻²⁰

Mutations in exon 9 of the calreticulin gene (*CALR*) are reported in approximately 20% to 35% of all patients with ET and MF (accounting for about 60%–80% of patients with *JAK2/MPL*-negative ET and MF).^{21,22} *Type 1* (52 base pair deletions) and *Type 2* (5 base pair insertions) mutations are the most frequent variants. *CALR*-Type 1 mutations are more frequent in patients with MF and *CALR*-Type 2 mutations are preferentially associated with ET.²³⁻²⁵

Mutations in several other genes that are involved in signal transduction (*CBL*, *LNK/SH2B3*), chromatin modification (*TET2*, *EZH2*, *IDH1/2*, *ASXL1*, *DNM3TA*), RNA splicing (*SF3B1*, *SRSF2*, *U2AF1*), and tumor

suppressor function (*TP53*) have also been reported in patients with MPN.^{26,27}

Myelofibrosis

CALR mutation is associated with better overall survival (OS) than *JAK2* V617F or *MPL* W515 mutation and the survival advantage is significant in patients with type 1/type 1-like mutation.^{9,24,28,29} In a study of 617 patients with primary MF (PMF), the median OS was 18 years for those with *CALR* mutations versus 9 years for those with *JAK2* V617F mutation or *MPL* mutation and 3 years for patients with triple-negative MF.²⁸ *CALR* mutations retained their prognostic significance for better OS compared to *JAK2* V617F mutation ($P = .19$) or triple-negative status ($P < .001$) in a multivariate analysis corrected for age. The 10-year cumulative incidence of leukemic transformation was also lower (9%) for patients with *CALR* mutation compared to 19% for those with *JAK2* V617F mutation, 17% for those with *MPL* mutation, and 34% for those who were triple negative. In the study that evaluated the prognostic impact of the two different types of *CALR* mutations in 396 patients with PMF, the median survival was significantly higher for patients with type 1/type 1-like mutation (26 years; $P < .0001$) versus 7 years for those with type 2/type 2-like mutation or *JAK2* V617F mutation. The rate of leukemic transformation was also higher among patients with type 2/type 2-like mutation than for those with type 1/type 1-like and *JAK2* V617F mutation.²⁹

MPL mutations are associated with lower hemoglobin levels at diagnosis and increased risk of transfusion dependence in patients with MF.³⁰ The “triple-negative” mutation status (lack of all 3 “driver” mutations — *JAK2*, *CALR*, or *MPL*), which occurs in approximately in 10% of patients, is associated with a worse prognosis in patients with MF.^{31,32}

ASXL1, *EZH2*, *SRSF2*, *TP53*, *IDH1*, or *IDH2* mutations are considered as "high-molecular-risk" (HMR) mutations, associated with significantly shorter OS and leukemia-free survival (LFS) in patients with PMF.³³⁻³⁶ *ASXL1*, *EZH2*, and *SRSF2* mutations are predictive of OS, while *ASXL1*, *SRSF2*, and *IDH1* or *IDH2* are predictive of leukemic transformation in patients with PMF.³³⁻³⁶ *TET2* or *TP53* mutations have also been associated with a worsened overall prognosis and an increased rate of leukemic transformation.^{27,37} *U2AF1* mutations have also been associated with inferior survival in patients with PMF.³⁸ OS was significantly shorter for patients with *U2AF1* Q157 mutations, compared to those with *U2AF1* S34 mutations or unmutated *U2AF1* and the survival effect was most evident in younger patients.

In a study that evaluated the prognostic significance of somatic mutations in 879 patients with PMF, the median survival was significantly shorter (81 vs. 148 months; $P < .0001$) in patients with at least one mutation in the prognostically significant genes (*ASXL1*, *EZH2*, *SRSF2*, *IDH1*, or *IDH2*) compared with those with no mutation in any of these genes.³⁵ However, only *ASXL1* mutations retained prognostic significance after accounting for known prognostic factors. The results of a subsequent analysis that evaluated the additional prognostic value of the "number" of mutated genes in 797 patients with PMF confirmed that patients harboring ≥ 2 HMR mutations had significantly reduced OS and LFS compared not only in patients with no mutations but also in those presenting with only one HMR mutation.³⁶ The median OS was 3 years for patients with ≥ 2 HMR mutations compared to 7 years and 12 years, respectively, for those with one HMR mutation and no mutations. The corresponding LFS was 7 years, 11 years, and 27 years, respectively.

An analysis that assessed the impact of both *CALR* and *ASXL1* mutations on OS in 570 patients with PMF identified *CALR*(-)/*ASXL1*(+)

mutational status as the most significant risk factor for survival.³⁹ *CALR*(+)/*ASXL1*(-) was associated with the longest median OS (10 years) and *CALR*(-)/*ASXL1*(+) was associated with shortest median OS, and this prognostic significance was independent of the dynamic international prognostic scoring system (DIPSS-plus) risk score.

The prognostic significance of these HMR mutations, perhaps with the exception of *SRSF2* mutations, has not yet been established in patients with post-PV or post-ET MF.⁴⁰

Polycythemia Vera and Essential Thrombocythemia

JAK2 exon 12-mutated PV is characterized by significantly higher hemoglobin level and lower platelet and leukocyte counts at diagnosis compared to *JAK2*-mutated PV.⁴¹ However, both *JAK2* V617F and *JAK2* exon 12 mutations are associated with similar rates of thrombosis, transformation to MF or leukemia, and death.

CALR-mutated ET is characterized by younger age, male sex, higher platelet count, lower hemoglobin, lower leukocyte count, and lower risk of thrombosis than *JAK2*- or *MPL*-mutated ET, whereas the presence of *MPL* mutations might be associated with a higher risk of fibrotic transformation.⁴²⁻⁴⁴ However, *CALR* mutations have no impact on OS or myelofibrotic or leukemic transformation.^{44,45} *CALR* mutation status also did not have a significant impact on the International Prognostic Score for ET (IPSET)-thrombosis prognostic score for predicting the risk of thrombosis.⁴⁶

Next-generation sequencing (NGS) has identified adverse variants/mutations in several other genes and may be useful to identify a minority of patients with PV and ET with increased risk of leukemic transformation.^{32,47,48} In one report, the presence of at least one of the 3 non-driver mutations (*ASXL1*, *SRSF2*, and *IDH2*) was associated with

inferior OS and MF-free survival but it did not significantly affect the LFS in patients with PV.⁴⁷ In the multivariable analysis, *ASXL1* and *SRSF2* retained the prognostic significance for OS and *ASXL1* was prognostic of MF-free survival. *SH2B3*, *IDH2*, *U2AF1*, *SF3B1*, *EZH2*, and *TP53* mutations were identified as significant risk factors for inferior OS, for MF-free survival, and in patients with ET. Multivariable analysis confirmed the individual prognostic significance of *U2AF1* mutation for OS and MF-free survival and *TP53* mutation for LFS. In a more recent report, myelofibrotic transformation was more frequent in patients with *SF3B1* and *IDH1/2* mutation, although a persistently high or a progressive increase of the *JAK2* V617F allele burden while receiving cytoreductive therapy was the strongest predictor of myelofibrotic transformation.⁴⁸

Diagnostic Classification

The WHO classification of myeloid neoplasm was first published in 2001 and was updated in 2008 to refine the diagnostic criteria for previously described neoplasms based on the new scientific and clinical information and to introduce newly recognized disease entities.^{49,50} It was revised again in 2017 to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the publication of the 2008 WHO classification.^{51,52}

The 2017 WHO diagnostic criteria include molecular testing for *JAK2*, *CALR*, and *MPL* mutations for PMF and ET and molecular testing for *JAK2* V617F or *JAK2* exon 12 mutations for PV.⁵² In the absence of *JAK2*, *CALR*, and *MPL* mutations, the presence of another clonal marker is included as one of the major diagnostic criteria for PMF. Additional mutations in *ASXL1*, *EZH2*, *TET2*, *IDH1*, *IDH2*, *SRSF2*, and *SF3B1* genes are noted to be of use in determining the clonal nature of the disease.^{35,36}

MF can either present as a de novo disorder (PMF) or it can develop from the transformation of PV and ET (post-PV MF or post-ET MF).⁵³ Prefibrotic/early-stage PMF is characterized by an increase in atypical megakaryocytes, reduced erythropoiesis, and increased age-matched bone marrow cellularity. However, overt bone marrow fibrosis might be absent in early-stage/prefibrotic PMF, leading to a diagnosis of ET.⁵⁴ The revised 2017 WHO diagnostic criteria also include separate criteria for prefibrotic/early-stage PMF and overt fibrotic-stage PMF in order to differentiate true ET from prefibrotic/early PMF by the morphologic findings of the bone marrow biopsy, including the lack of reticulin fibrosis at onset.⁵² The revised diagnostic criteria for prefibrotic/early-stage PMF and overt fibrotic-stage PMF have also been validated in a large series of patients with pre-PMF and overt PMF.^{55,56}

In the International Working Group for MPN Research and Treatment (IWG-MRT) study that reevaluated 1104 patients with a diagnosis of ET, central pathology review revealed a diagnosis (as defined by the WHO criteria) of ET in 891 patients (81%) and early/prefibrotic PMF in 180 patients (16%). The remaining 33 patients (3%) were unevaluable.⁵⁴ The frequency of grade 1 bone marrow fibrosis was greater in patients with early/prefibrotic PMF. In addition, leukocyte count, platelet count, serum lactate dehydrogenase (LDH) level, and the incidence of palpable splenomegaly were greater in patients with early/prefibrotic PMF, whereas hemoglobin level was greater in patients with ET. The long-term clinical outcomes were significantly worse for patients with early-stage/prefibrotic PMF. The 15-year rates of OS, leukemic transformation, and fibrotic progression were 59%, 12%, and 17%, respectively, for patients with early-stage/prefibrotic PMF. The corresponding rates were 80%, 2%, and 9%, respectively, for patients with ET. In a multivariate analysis, bone marrow histopathology remained prognostically significant for survival ($P = .03$), leukemic

transformation ($P = .007$), and overt fibrotic progression ($P = .019$). Therefore, accurate evaluation of bone marrow morphology is essential to distinguish early-stage/prefibrotic PMF from ET, especially since the long-term clinical outcomes are significantly better for patients with ET than for those with prefibrotic MF.

The diagnostic criteria for PV have also been refined to differentiate masked PV from ET (recognizing the utility of bone marrow biopsy in patients with hemoglobin levels <18.5 g/dL in men and <16.5 g/dL in women).⁵² In an international study of 397 patients with *JAK2* V617F or a *JAK2* exon12 mutation and WHO-defined PV morphology, 257 patients were diagnosed with overt PV that met the full 2008 WHO diagnostic criteria for PV. The remaining 140 patients were classified as having masked PV with hemoglobin levels at diagnosis of <18.5 g/dL in men (range 16.0–18.4 g/dL) and <16.5 g/dL in women (range 15.0–16.4 g/dL) and frequent presence of subnormal erythropoietin (EPO) levels.⁵⁷ In a multivariate analysis, the diagnosis of masked PV was an independent predictor of poor survival in patients aged >65 years with a leukocyte count $>10 \times 10^9/L$. In the absence of these risk factors, the outcome of patients with masked PV was similar to that of patients with overt PV, suggesting that a fraction of patients with lower hemoglobin levels should still be considered as overt PV. The results of a more recent study also showed that the OS, rates of thrombosis and major bleeding, and probability of transformation were similar among patients with masked and overt PV.⁵⁸ Thus, the major diagnostic criteria for PV have been refined to include hemoglobin levels (>16.5 g/dL in men and >16.0 g/dL in women) or hematocrit $>49\%$ in men and $>48\%$ in women and a bone marrow biopsy to confirm the age-matched hypercellularity.⁵² However, bone marrow biopsy may not be required in patients with sustained absolute erythrocytosis (hemoglobin levels >18.5 g/dL in men [hematocrit, 55.5%] or >16.5 g/dL in women

[hematocrit, 49.5%]) and *JAK2* V617F or *JAK2* exon 12 mutations and subnormal EPO levels.

The diagnosis of MPN should be based on the 2017 WHO diagnostic criteria and requires a combination of clinical, laboratory, cytogenetic, and molecular testing.⁵² The diagnosis of PMF requires meeting all 3 major criteria and at least one minor criterion as outlined in the revised 2017 WHO criteria.⁵² The diagnosis of PV requires meeting either all 3 major criteria or the first 2 major criteria and the minor criterion, whereas the diagnosis of ET requires meeting all 4 major criteria or the first 3 major criteria and the minor criterion as outlined in the revised 2017 WHO criteria.⁵² See *2017 WHO Diagnostic Criteria for PMF, PV, and ET* in the algorithm for a list of major and minor criteria. The diagnosis of post-PV MF or post-ET MF is based on the 2008 IWG-MRT diagnostic criteria, requiring the documentation of a previous diagnosis of PV or ET as defined by the WHO criteria and the development of bone marrow fibrosis of grade 2–3 (or 3–4, depending on the scale) and at least 2 minor criteria.⁵⁹

Workup of Suspected MPN

Initial evaluation of patients with suspected MPN should include a history and physical exam, palpation of spleen, evaluation of thrombotic/hemorrhagic events, cardiovascular risk factors, and documentation of transfusion/medication history. Laboratory evaluations should include complete blood count (CBC), microscopic examination of the peripheral smear, comprehensive metabolic panel with serum uric acid, serum LDH, liver function tests, serum EPO level, and serum iron studies. Human leukocyte antigen (HLA) typing should be performed for patients with MF for whom allogeneic HCT would be considered.

Fluorescence in situ hybridization (FISH) or a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) on peripheral blood

to detect *BCR-ABL1* transcripts and exclude the diagnosis of CML is especially recommended for patients with left-shifted leukocytosis and/or thrombocytosis with basophilia.⁵² Molecular testing for *JAK2* V617F mutations is recommended as part of initial workup for all patients.⁵² If *JAK2* V617F mutation testing is negative, molecular testing for *MPL* and *CALR* mutations should be performed for patients with MF and ET; molecular testing for the *JAK2* exon12 mutation should be done for those with suspected PV and negative for the *JAK2* V617F mutation.^{16,17} Alternatively, molecular testing using the multi-gene NGS panel that includes *JAK2*, *CALR*, and *MPL* can be used as part of initial workup for all patients. The application of an NGS-based 28-gene panel in patients with MPN identified significantly more mutated splicing genes (*SF3B1*, *SRSF2*, and *U2AF1*) in patients with PMF compared to those with ET, and no mutations in splicing genes were found in patients with PV.⁶⁰ NGS may also be useful to establish the clonality in selected circumstances (eg, triple-negative MPN with non-mutated *JAK2*, *MPL*, and *CALR*). It can also identify second, third, and fourth mutations that may hold prognostic relevance.

Bone marrow aspirate and biopsy with trichrome and reticulin stain and bone marrow cytogenetics (karyotype, with or without FISH; blood, if bone marrow is inaspirable) are necessary to accurately distinguish the bone marrow morphologic features between the disease subtypes (early or prefibrotic PMF, ET, and masked PV).^{52,54,57} Bone marrow histology shows hypercellularity and megakaryocytic proliferation. In the case of MF, bone marrow fibrosis is demonstrated on the reticulin stain and an additional trichrome stain is recommended to distinguish grade MF-1 from MF-2 or MF-3, as outlined in the 2017 WHO diagnostic criteria.^{52,61} Progression of PV or ET to MF can only be detected by performing a bone marrow biopsy; however, in patients with PV, bone marrow biopsy may not be required in patients with sustained absolute

erythrocytosis (hemoglobin levels >18.5 g/dL in men [hematocrit, 55.5%] or >16.5 g/dL in women [hematocrit, 49.5%]), *JAK2*V617F or *JAK2* exon12 mutations, and subnormal EPO level.⁵²

MPN are associated with an increased risk of major bleeding and thrombosis/thromboembolism compared to the general population, and these events contribute considerably to morbidity and mortality in patients with MPN.^{62,63} Acquired von Willebrand disease (VWD) is associated with a variety of hematologic disorders, being particularly frequent in lymphoproliferative (48%) and myeloproliferative disorders (15%). Among MPN, the frequency of acquired VWD is more common among patients with ET (11%–17%) but can also be seen in patients with PV.⁶⁴ Coagulation tests to evaluate for acquired VWD (plasma von Willebrand factor antigen measurement, von Willebrand ristocetin cofactor activity, von Willebrand multimer analysis, and Factor VIII level)⁶⁵ and/or other coagulopathies (prothrombin time, partial thromboplastin time, and fibrinogen activity) are recommended for patients undergoing high-risk surgical procedures and those with elevated platelet count or unexplained bleeding.

Assessment of Symptom Burden

MPN are characterized by a complicated symptom profile resulting in reductions in quality of life, functional status, and activities of daily living.³⁻⁵ Constitutional symptoms (fever, night sweats, and weight loss) are more frequently reported in patients with MF compared to those with PV or ET.^{3,5} In a landmark survey that evaluated the symptom burden experienced by patients with MPN, disease-related symptoms were reported ≥1 year before diagnosis in 49% of patients with MF, 61% of patients with PV, and 58% of patients with ET.⁴ In a recent online survey of 669 patients with MPN, fatigue was the most frequent symptom observed in 54% of patients with MF, 45% of patients with PV,

and 64% of patients with ET.⁵ Abdominal discomfort, night sweats, difficulty sleeping, shortness of breath, pruritus, bruising, loss of concentration, and dizziness were the other common symptoms and the incidences varied by disease type.

Various tools have been developed and validated in a large cohort of patients with MPN for the assessment of symptom burden.⁶⁶⁻⁷⁰

Myelofibrosis Symptom Assessment Form (MF-SAF) is a 20-item tool used for the assessment of MF-associated symptoms, including fatigue, symptoms associated with splenomegaly (early satiety, abdominal pain or discomfort, inactivity, and cough), constitutional symptoms (night sweats, itching, bone pain, fever, and weight loss), and quality of life.⁶⁶

MF-SAF was subsequently expanded to a 27-item tool, MPN Symptom Assessment Form (MPN-SAF), to include the assessment of additional symptoms that are relevant to ET and PV (insomnia, headaches, concentration, dizziness, vertigo, lightheadedness, numbness or tingling, depression, and sexual desire dysfunction).⁶⁸

MPN-SAF was further simplified to a concise and abbreviated tool, MPN-SAF Total Symptom Score (MPN-SAF TSS; MPN 10), which is used for the assessment of the 10 most relevant symptoms in patients with MPN (fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fever) in both clinical practice and clinical trial settings.⁶⁹

All 3 symptom assessment tools are coadministered with Brief Fatigue Inventory and the symptom severity is rated by patients on a scale of 1 to 10. Assessment of symptom burden at baseline and during the course of treatment with MPN-SAF TSS (MPN-10) is recommended for all patients.^{68,69}

Management of Myelofibrosis

The treatment approach is currently identical for PMF and post-PV or post-ET MF. Referral to specialized centers with expertise in the management of MPN is strongly recommended for all patients diagnosed with MF.

Risk Stratification

Primary Myelofibrosis

The International Prognostic Scoring System (IPSS), dynamic International Prognostic Scoring System (DIPSS), and DIPSS-Plus are the 3 most common prognostic scoring systems used for the risk stratification of patients with MF.⁷¹⁻⁷³

Other prognostic models incorporating cytogenetic information and mutational status such as mutation-enhanced international prognostic scoring system for (MIPSS70 and MIPSS70-plus) and genetically inspired prognostic scoring system (GIPSS) have been developed to further refine the risk stratification.^{74,75} Further validation is essential before these models can be widely adopted for risk stratification of patients with MF.

IPSS should be used for the risk stratification at time of diagnosis.⁷¹ DIPSS-Plus is preferred for the risk stratification during the course of treatment.⁷³ DIPSS can be used if karyotyping is not available.⁷²

IPSS

Age >65 years, presence of constitutional symptoms, hemoglobin level <10 g/dL, leukocyte count > 25 x 10⁹/L, and circulating blast cells 1% or greater at the time of diagnosis were identified as independent predictors of inferior survival.⁷¹ IPSS stratifies patients at the time of diagnosis into 4 different risk groups based on the presence of 0, 1, 2, and 3 or more adverse factors: low-risk, intermediate-1-risk (INT-1-risk),

intermediate-2-risk (INT-2-risk), and high-risk with the median survival of 135 months, 95 months, 48 months, and 27 months, respectively ($P < .001$).

DIPSS

In a subsequent analysis that evaluated the impact of each adverse factor on survival during follow-up after treatment, all variables retained statistical significance. However, development of anemia over time significantly affected survival (hazard ratio [HR] was approximately double than that of other adverse factors).⁷² Thus, a modified risk stratification system (DIPSS) was developed using the same prognostic variables as in IPSS (age >65 years, presence of constitutional symptoms, hemoglobin level <10 g/dL, leukocyte count >25 x 10⁹/L, and circulating blast cells ≥1% at the time of diagnosis), but two points were assigned for hemoglobin <10 g/dL. The DIPSS can be applied at any point during the disease course to stratify patients into 4 different risk groups: low-risk (0 adverse points), INT-1-risk (1 or 2 points), INT-2-risk (3 or 4 points), and high-risk (5 or 6 points) with the median survival rates of not reached, 14 years, 4 years, and 1.5 years, respectively.⁷²

DIPSS-Plus

In subsequent reports, the need for red blood cell (RBC) transfusion, platelet count, and unfavorable karyotype have been identified as additional IPSS- and DIPSS-independent prognostic factors for inferior OS and LFS in patients with PMF.⁷⁶⁻⁷⁹ The median survival of DIPSS low-risk patients with thrombocytopenia or unfavorable karyotype was 6.5 years compared to >15 years in the absence of these 2 additional risk factors.⁷³ Similarly, the median survival was <1.5 years for DIPSS high-risk patients with one or more of these additional prognostic factors compared to approximately 3 years for those patients without these prognostic factors.⁷³

DIPSS was modified into DIPSS-Plus by the incorporation of platelet count <100 x 10⁹/L, RBC transfusion need, and unfavorable karyotype [complex karyotype or one or two abnormalities that include trisomy 8, del 7/7q, i(17q), del5/5q, del12p, inv(3), or 11q23 rearrangement].⁷³ DIPSS-Plus also stratifies patients into 4 risk groups based on the aforementioned 8 risk factors: low-risk (no risk factors), INT-1-risk (one risk factor), INT-2-risk (2 or 3 risk factors), and high-risk (4 or more risk factors) with respective median survival rates of 15.4, 6.5, 2.9, and 1.3 years.

MIPSS70 and MIPSS70-plus

In a study of 805 patients with PMF (≤70 years), in a multivariate analysis, hemoglobin level <10 g/dL, leukocyte count >25 x 10⁹/L, platelet count <100 x 10⁹/L, circulating blast cells ≥2%, bone marrow fibrosis grade ≥2, constitutional symptoms, absence of *CALR* type-1 mutation, and presence of ≥2 HMR mutations (*ASXL1*, *EZH2*, *SRSF2*, and *IDH1/2*) were identified as independent predictors of inferior OS.⁷⁴ The MIPSS70 prognostic model (without the cytogenetic information) stratified patients into 3 risk categories (low-risk, intermediate-risk, and high-risk) with the median OS of 28 years, 7 years, and 2 years, respectively. The 5-year OS rates were 95%, 70%, and 29%, respectively. The MIPSS70-plus prognostic model, which included cytogenetic information, stratified patients into 4 risk categories (low-risk, intermediate-risk, high-risk, and very high-risk) with the 5-year OS rates of 91%, 66%, 42%, and 7%, respectively.

GIPSS

In an analysis of 641 patients with PMF for whom both cytogenetic information and mutational status were available, in a multivariate analysis, “very high-risk” (VHR) karyotype, unfavorable karyotype, absence of type 1/like *CALR* mutation, and the presence of *ASXL1*, *SRSF2*, or *U2AF1* Q157 mutations were identified as

inter-independent predictors of inferior survival.⁷⁵ GIPSS stratified patients into 4 risk categories (low-risk, INT-1 and INT-2, and high-risk) based exclusively on genetic factors described above. The median 5-year survival rates were 94%, 73%, 40%, and 14%, respectively. However, the authors point out that this prognostic model should not be considered as a finished product but rather a template for incorporating additional genetic information, as it becomes available.

Post-PV MF and Post-ET MF

The prognostic scoring systems described above have been studied and validated only in patients with PMF. Although these prognostic scoring systems have been clinically used for the risk stratification of patients with post-PV or post-ET MF, they are not effective for the risk stratification of patients with post-PV or post-ET MF.⁸⁰ Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) is a novel prognostic model that stratifies patients with post-PV or post-ET MF into 4 risk groups, with distinct survival outcomes (low, INT-1, INT-2, and high risk) based on the hemoglobin level (<11 g/dL), circulating blasts (≥3%), *CALR* mutation status, platelet count (<150 × 10⁹/L), and constitutional symptoms.⁸¹ The median survival was not reached at 9 years, 4 years, and 2 years, respectively. Further validation studies are necessary to confirm these findings.

Treatment Options

Interferons

Interferon alfa, peginterferon alfa-2a, and peginterferon alfa-2b have been evaluated in a small series of patients with MF.^{82,83}

In a retrospective study of 62 patients with early MF treated with peginterferon alfa-2a, improvement in constitutional symptoms and complete resolution of thrombocytosis and leukocytosis were

observed in 82%, 83%, and 69% of patients, respectively, and a reduction of splenomegaly was seen in 47% of patients.⁸²

In a prospective trial of 30 patients (21 patients with PMF, 7 patients with post-PV MF, and 2 patients with post-ET MF), treatment with interferon alfa-2b or peginterferon alfa-2a resulted in an overall response rate (ORR) of 73% (7% complete response [CR], 30% partial response [PR], 13% clinical improvement [CI], and 23% of patients had stable disease [SD]).⁸³ The corresponding response rates were 3%, 27%, 6%, and 13%, respectively, for patients with low-risk disease. Among patients with marked splenomegaly, spleen response (≤50% reduction in spleen size) was observed in 40% of patients (4 out of 10), and 60% of patients (6 out of 10) had either a slight decrease in spleen size or stable spleen size. Among the 25 patients with evaluable bone marrow biopsies, reduction in bone marrow cellularity and reductions of reticulin fibrosis were observed in 12 patients and 5 patients, respectively, after a median treatment duration of 6 years. The presence of HMR mutations or ≥3 mutations was associated with inferior response rates and the survival rates were better for patients without *ASXL1* mutation; the 5-year PFS and OS rates were 88% and 92%, respectively.

Ruxolitinib

Ruxolitinib is a potent and selective *JAK2* inhibitor approved for the treatment of intermediate-risk or high-risk MF, based on the results of phase III studies (COMFORT-I and COMFORT-II).^{84,85} The COMFORT studies did not include patients with low-risk or INT-1-risk MF, and the use of ruxolitinib in this patient population is based the evidence from retrospective analysis and non-randomized studies as discussed below.⁸⁶⁻⁸⁹

Low-Risk MF

The efficacy of ruxolitinib in low-risk MF has not been evaluated in prospective clinical trials. The results from a retrospective analysis suggest that ruxolitinib may be an appropriate treatment option for symptomatic patients with low-risk MF.⁸⁶ In this retrospective analysis of 108 patients (25 patients with low-risk MF and 83 patients with INT-1-risk MF) treated with ruxolitinib, patients with low-risk MF experienced a substantial improvement in splenomegaly and constitutional symptoms.⁸⁶ The proportion of patients with moderate to severe splenomegaly reduced from 64% at the time of diagnosis to 16% at the time of best response to ruxolitinib. The proportion of patients with moderate or severe fatigue decreased from 90% at the time of diagnosis to 37% at the time of best response to ruxolitinib.

Intermediate-1-risk MF

The safety and efficacy of ruxolitinib in patients with INT-1-risk MF has been demonstrated in a retrospective analysis⁸⁶ and nonrandomized studies.⁸⁷⁻⁸⁹

In the retrospective analysis (discussed above), among the 83 patients with INT-1-risk MF, the proportion of patients with moderate or severe splenomegaly decreased from 53% at the time of diagnosis to 10% at the time of best response to ruxolitinib, and the proportion of patients with moderate or severe fatigue decreased from 76% at the time of diagnosis to 42% at the time of best response to ruxolitinib.⁸⁶

The ROBUST trial is an open-label phase II trial that evaluated the efficacy of ruxolitinib in patients with INT-1-risk MF (48 patients; 14 patients with INT-1-risk MF along with 13 patients with INT-2-risk MF and 21 patients had high-risk MF).⁸⁷ The primary composite endpoint was the achievement of treatment success at 48 weeks after ruxolitinib therapy ($\geq 50\%$ reduction in palpable spleen length and/or a

$\geq 50\%$ decrease in MF-SAF). At 48 weeks, 47% of the overall population achieved a reduction in mean palpable spleen length and the effect was seen across all risk groups (52% of patients with INT-1-risk, 37% of patients with INT-2-risk, and 49% of patients with high-risk disease). A $\geq 50\%$ reduction in MF-SAF at 48 weeks was achieved in 20.8% of patients in the overall population and across all risk groups (INT-1-risk, 21%; INT-2-risk, 23%; high-risk, 19%). Improvements in MF-SAF were seen in 80%, 73%, and 72% of patients with INT-1-risk, INT-2-risk, and high-risk disease, respectively.

JUMP is an expanded-access phase III study designed to assess the safety and efficacy of ruxolitinib in patients with INT-2-risk or high-risk MF with or without splenomegaly or INT-1-risk MF with a palpable spleen (≥ 5 cm from the costal margin).⁸⁸ Among 163 evaluable patients with INT-1-risk MF, at 24 and 48 weeks 64% and 61% of patients achieved a $\geq 50\%$ reduction from baseline in palpable spleen length, respectively, and an additional 20% and 21% of patients had a 25% to $< 50\%$ reduction in palpable spleen length, respectively. The median time to a $\geq 50\%$ reduction in palpable spleen length was 5 weeks and the estimated probability of maintaining a response was 91% at 48 weeks and 88% at 60 weeks.

In another study that evaluated efficacy and safety of ruxolitinib in 70 patients with INT-1-risk MF, at 6 months the rates of spleen and symptom response were 55% and 80%, respectively. The majority of patients (83%) were still on therapy after a median follow-up of 27 months.⁸⁹

Intermediate-2-risk/High-risk MF

The results of COMFORT-I^{84,90,91} and COMFORT-II^{85,92,93} studies demonstrated that continuous ruxolitinib therapy was associated with

significant clinical benefits in patients with MF in terms of reduction in spleen size, amelioration of disease-related symptoms, and improvement in quality-of-life and OS compared to either placebo or best available therapy for patients with INT-2-risk or high-risk MF (PMF, post-PV MF, or post-ET MF).

The COMFORT-I trial randomized 259 patients with INT-2-risk or high-risk MF to twice-daily ruxolitinib (n = 155) or placebo (n = 154).⁸⁴ The starting dose of ruxolitinib was based on the baseline platelet count (15 mg twice daily for a platelet count of 100 x 10⁹/L to 200 x 10⁹/L and 20 mg twice daily for >200 x 10⁹/L), and patients with protocol-defined worsening splenomegaly were permitted to cross over from placebo to ruxolitinib. The primary endpoint (≥35% reduction in spleen volume as assessed by MRI at 24 weeks) was reached in 42% of patients in the ruxolitinib group as compared with 0.7% in the placebo group (*P* < .001). An improvement of ≥50% in the MF-SAF at 24 weeks was seen in 46% of patients treated with ruxolitinib as compared with 5% of patients who received placebo (*P* < .001). Long-term follow-up results confirmed the safety and durable efficacy of ruxolitinib for the treatment of patients with INT-2-risk or high-risk MF.^{90,91} The 5-year follow-up data showed that patients treated with ruxolitinib had prolonged median OS compared to placebo (not reached compared to 200 weeks for patients randomized to placebo; *P* = .025). Spleen response (≥35% reduction from baseline in spleen volume) was achieved in 59% of patients randomized to ruxolitinib and the median duration of spleen response was 168 weeks.⁹¹ At the time of this analysis, 111 patients from the placebo group had crossed over to ruxolitinib (median time to crossover was 40 weeks). The subgroup analyses showed that clinical benefit of ruxolitinib was seen across all patient subgroups including PMF, post-ET MF or post-PV MF, IPSS risk groups, and *JAK* mutation status (positive or negative), and there was also a nonsignificant trend

toward longer OS for patients with IPSS INT-2-risk and high-risk MF treated with ruxolitinib. However, this study was not designed or powered to detect treatment efficacies between treatment arms within each subgroup.^{91,94}

In the COMFORT-II study, 219 patients with INT-2-risk or high-risk MF were randomized to ruxolitinib (n = 146) or best available therapy (n = 73).⁸⁵ The primary endpoint was at least a 35% reduction in spleen volume as assessed with MRI or CT scan at 48 weeks. The starting dose of ruxolitinib was based on the baseline platelet count (15 mg twice daily if the platelet count was ≤200 x 10⁹/L and 20 mg twice daily if the platelet count was >200 x 10⁹/L). A total of 28% of the patients in the ruxolitinib arm had a ≤35% reduction in spleen volume at 48 weeks compared with 0% in the group receiving the best available therapy (*P* < .0001). The median duration of response among patients treated with ruxolitinib was not reached, with 80% of patients still having a response at a median follow-up of 12 months.⁸⁵ Patients receiving ruxolitinib had improved quality of life and role functioning as well as significant reductions in disease-related symptoms compared to those receiving best available therapy. Long-term follow-up results confirmed that ruxolitinib is associated with durable efficacy and survival benefit compared to best available therapy for patients with INT-2-risk or high-risk MF.^{92,93} At the time of 5-year final analysis, 53% of patients in the ruxolitinib arm achieved a ≥35% reduction in spleen volume at any time on treatment, and spleen volume reductions of ≥35% were sustained with long-term therapy (median duration, 3 years).⁹³ The median OS was not reached for patients in the ruxolitinib arm, and it was 4 years for those in the best available therapy arm.

The pooled analysis of COMFORT-I and COMFORT-II studies showed that patients with INT-2-risk or high-risk MF treated with ruxolitinib had prolonged OS, and the OS of patients with high-risk disease in the

ruxolitinib group was similar to that of patients with INT-2-risk MF in the control group.⁹⁵ Larger spleen size at baseline was associated with shortened survival, whereas any spleen volume reductions (>10% reduction in spleen size) and a palpable spleen length reduction of ≥25% correlated with longer survival.

Toxicity

Anemia and thrombocytopenia were the most common hematologic toxicities associated with ruxolitinib, consistent with its mechanism of action, and the incidences of grade 3/4 anemia or thrombocytopenia were higher during the first 8 to 12 weeks of treatment.^{84,85} In the COMFORT-I study, ecchymosis, dizziness, and headache were the most frequent nonhematologic toxicities associated with ruxolitinib, and diarrhea was the most frequent nonhematologic adverse event associated with ruxolitinib in the COMFORT-II study.^{84,85} In general, the incidences of nonhematologic toxicities decreased with long-term therapy.^{90,93}

Ruxolitinib is associated with a potentially increased risk of opportunistic infections.^{96,97} In particular, tuberculosis, progressive multifocal leukoencephalopathy, reactivation of hepatitis B virus, and herpes simplex virus have been reported in patients treated with ruxolitinib.^{91,98-102} Patients should be monitored for signs and symptoms of infections. Serious infections should be resolved prior to initiation of ruxolitinib. Ruxolitinib is contraindicated in patients with evidence of active or latent tuberculosis. Viral reactivations should be treated and monitored according to clinical guidelines.

Non-melanoma skin cancers have been reported in patients treated with ruxolitinib; periodic skin examinations are recommended.¹⁰³ Lymphoid neoplasms may be diagnosed concurrently with MPN or may develop during the natural history of MF, PV, or ET.¹⁰⁴⁻¹⁰⁷

Although one report indicated that *JAK* inhibitor therapy is associated with an increased risk of aggressive B-cell lymphomas in patients with MF, additional studies are required to validate these observations.¹⁰⁸

Impact of Mutational Status and Response to Ruxolitinib

In the COMFORT-II study, ruxolitinib was associated with clinical efficacy and survival improvement across different molecular subsets of patients with MF.¹⁰⁹ HMR mutations (*ASXL1*, *EZH2*, *SRSF2*, *IDH1*, or *IDH2*) were identified in 33%, 7%, 4%, 3%, <1%, and 0% of patients, respectively, and these frequencies were comparable in ruxolitinib and best available therapy arms. Responses in splenomegaly (>35% spleen volume reduction), symptomatic improvement, and the risk of ruxolitinib-associated anemia and thrombocytopenia were observed at similar frequencies across different mutation profiles. Ruxolitinib improved survival and reduced the risk of death in patients harboring HMR mutations (*ASXL1*, *EZH2*, *SRSF2*, *IDH1*, or *IDH2*) with a hazard ratio of 0.57.¹⁰⁹

The results of another analysis of 95 patients with MF treated with ruxolitinib in a single institution also showed that *ASXL1*, *EZH2*, and *IDH1/2* mutations are associated with poor outcomes and patients with ≥1 mutations in *ASXL1*, *EZH2*, or *IDH1/2* had shorter time to treatment discontinuation and OS.¹¹⁰ However, in contrast to the findings of the COMFORT-II study, patients with ≥1 mutations in *ASXL1*, *EZH2*, or *IDH1/2* were significantly less likely to have a spleen response. Patients with ≥3 mutations had the worst outcomes, suggesting that multigene profiling may be useful for treatment planning in patients with MF.

Allogeneic Hematopoietic Cell Transplant

Allogeneic hematopoietic cell transplant (HCT) is the only potentially curative treatment option resulting in long-term remissions for patients

with MF. However, the use of myeloablative conditioning is associated with higher rates of non-relapse mortality (NRM). The estimated OS rates and NRM rates at 3 to 5 years range from 30% to 61% and 24% to 43%, respectively.¹¹¹ In a retrospective registry analysis of 289 patients with MF, allogeneic HCT resulted in long-term OS in about a third of patients, but the probability of long-term survival and NRM was dependent on the source of stem cells.¹¹² The 5-year post-transplant OS rates were 37%, 40%, and 30%, respectively, for HLA-matched sibling donor transplant, other related donor transplant, and unrelated donor (URD) transplant, respectively. The corresponding 5-year disease-free survival rates were 33%, 22%, and 27%, respectively. The NRM rate at 5 years was higher for URD transplant (50% compared to 35% and 38% for HLA-matched sibling donor transplant and other related donor transplant, respectively).

The use of reduced-intensity conditioning (RIC) has lowered the rates of NRM but it is also associated with a higher risk of relapse compared to myeloablative conditioning.¹¹³⁻¹²⁰ In a prospective, multicenter study that evaluated the allogeneic HCT with RIC in 103 patients with MF, the cumulative incidence of NRM at 1 year was 16% and the cumulative incidence of relapse at 3 years was 22%.¹¹⁴ The estimated 5-year event-free survival and OS rates were 51% and 67%, respectively. The NRM was significantly lower for patients with a completely matched donor (12% vs. 38%; $P = .003$). Other large retrospective registry analyses have also reported similar outcomes.^{117,118} In the Center for International Blood and Marrow Transplant Research (CIBMTR) analysis that included 233 patients who underwent allogeneic HCT using RIC for PMF, the probabilities of OS and progression-free survival (PFS) at 5 years were 47% and 27%, respectively.¹¹⁷ The cumulative incidence of NRM and relapse/progression at 5 years were 24% and 48%, respectively. In

the European Bone Marrow Transplantation Registry (EBMTR) analysis that included 193 patients who underwent transplantation for post-PV or post-ET MF, the 3-year OS rate, incidence of relapse, and NRM were 55%, 32%, and 28%, respectively.¹¹⁸

Age (>55 years) and donor type (HLA-identical sibling donor transplant vs. HLA-well-matched URD transplant or partially/mismatched URD transplant) have been the most important prognostic factors of OS and NRM. Among patients who underwent allogeneic HCT with RIC for PMF, the 5-year survival rates following HLA-identical sibling donor transplant, HLA-well-matched URD transplant, and partially/mismatched URD transplant were 56%, 48%, and 34%, respectively ($P = .002$) and the relative risk of NRM was also the lowest for HLA-identical sibling donor transplant (1%) compared to 3% and 9% for HLA-well-matched URD transplant and partial/mismatched URD transplant, respectively.¹¹⁷ In patients who underwent allogeneic HCT with RIC for post-PV MF or post-ET MF, the overall 3-year cumulative incidence of NRM was significantly higher in patients >55 years (35% vs. 20% for younger patients; $P = .032$) and in those who underwent URD transplant (34% vs. 18% for those who had a related donor transplant; $P = .034$).¹¹⁸

DIPSS risk score has been shown to predict outcome after transplant.^{117,121} In the aforementioned CIBMTR analysis, there was a trend towards lower mortality rates in patients with low-risk/INT-1-risk disease and higher NRM in patients with INT-2-risk/high-risk disease.¹¹⁷ In another retrospective analysis of 170 patients with MF who received HCT, DIPSS risk score significantly correlated with mortality risk and NRM (hazard ratio for post-transplant mortality was 4.11 for high-risk disease compared to 3.15, 1.97, and 1, respectively, for INT-2-risk, INT-1-risk, and low-risk disease; the corresponding hazard ratios for NRM were 3.41, 3.19, 1.41, and 1, respectively).¹²¹

The association of DIPSS risk score with relapse was not significant, although patients with higher-risk disease experienced more relapses than those with lower-risk disease.

DIPSS risk scores prior to HCT have also been shown to correlate with OS following allogeneic HCT.^{117,122,123} However, in one retrospective analysis, the differences in OS between patients with INT-1-risk and INT-2-risk disease were not significantly different. In a multivariate analysis, only *JAK2* wild-type, age ≥ 57 years, and the presence of constitutional symptoms were independent predictors of OS. The 5-year OS rates were 90%, 74%, and 50% for the presence of 0, 1, and 2 risk factors.¹²² In another retrospective analysis that evaluated the impact of allogeneic HCT on survival in patients < 65 years of age at the time of diagnosis of PMF (n = 438; 190 patients received allogeneic HCT and 248 patients received conventional therapy), the relative risk of death after allogeneic HCT was 5.6 for patients with DIPSS low-risk disease, 1.6 for INT-1-risk disease, 0.55 for INT-2-risk disease, and 0.37 for high-risk disease.¹²³

These findings suggest that outcomes following allogeneic HCT are better for patients with low-risk or INT-1-risk MF.^{117,121} However, it is also associated with high transplant-related morbidity and mortality in this group of patients. Allogeneic HCT is associated with a clear benefit in patients with INT-2-risk/high-risk PMF.

Impact of Mutational Status

CALR mutation is associated with higher OS rates and lower rate of NRM following allogeneic HCT in patients with PMF as well as post-PV or post-ET MF.^{124,125} Identification of HMR mutations (*ASXL1*, *EZH2*, *SRSF2*, *TP53*, *IDH1*, or *IDH2* mutations) may be helpful in decision-making regarding allogeneic HCT in patients with PMF.^{27,35,36,125}

In a study of 133 patients who underwent allogeneic HCT for PMF (n = 97) or post-ET/post-PV MF (n = 36), the 4-year OS rate was 82% for patients with *CALR* mutations compared to 56% for patients without *CALR* mutation (*CALR* wild-type). The NRM rate was also significantly lower in patients with *CALR* mutations compared with those who were *CALR* wild-type (4-year NRM rates were 7% and 31%, respectively; $P = .024$).¹²⁴

In another study that evaluated the impact of molecular genetics on the outcome after allogeneic HCT in patients with MF (PMF, n = 110; post-PV or ET MF, n = 46; and MF in transformation, n = 13), in a multivariate analysis, *CALR* mutation was an independent factor for lower NRM, and improved PFS, and OS.¹²⁵ *ASXL1* and *IDH2* mutations were independent risk factors for lower PFS, whereas no impact was observed for triple-negative patients.

As discussed earlier, *CALR*(-)/*ASXL1*(+) is associated with a poor prognosis (independent of the DIPSS-plus risk score) in patients with PMF and this subset of patients with should be considered for allogeneic HCT earlier in the disease course.³⁹

Treatment Recommendations Based on Symptom Assessment and Risk Stratification

The selection of appropriate treatment should be based on the risk score and the presence of symptoms. Enrollment in clinical trial is recommended for all patients with the aim of reducing bone marrow fibrosis, improving cytopenias and symptom burden, restoring transfusion independence, and preventing/delaying progression to AML.

Low-risk or INT-1-risk MF

Asymptomatic patients with low-risk or INT-1-risk MF should be observed. Ruxolitinib⁸⁶⁻⁸⁸ or interferons (interferon alfa-2b, peginterferon

alfa-2a, or peginterferon alfa-2b)^{82,83} are included as options for symptomatic patients. Hydroxyurea has been shown to be an effective treatment option for the hyperproliferative manifestations of MF (thrombocytosis or leukocytosis). In a small study of 40 patients with symptomatic MF (constitutional symptoms, splenomegaly, thrombocytosis, leukocytosis, pruritus, and bone pain), treatment with hydroxyurea (500 mg/d, subsequently adjusted to the individual efficacy and tolerability) resulted in CI in 40% of patients.¹²⁶

Anemia induced by hydroxyurea was manageable with concomitant treatment. The panel has included hydroxyurea as an option for low-risk MF, if the use of cytoreductive therapy would be symptomatically beneficial in selected patients with high platelet counts.

Allogeneic HCT is included as an option for patients with INT-1-risk MF. Although the outcomes following allogeneic HCT are better for patients with low-risk or INT-1-risk MF, due to the high transplanted-related morbidity and mortality, treatment decisions regarding allogeneic HCT should be individualized for patients with INT-1-risk MF.^{117,121,123}

Allogeneic HCT should be considered for low-risk or INT-1-risk MF in patients with either refractory, transfusion-dependent anemia; circulating blast cells >2% in peripheral blood; or adverse cytogenetics.¹²³ Evaluation for allogeneic HCT is recommended for patients with low platelet counts or complex cytogenetics.

INT-2-risk or High-risk MF

Evaluation for allogeneic HCT is recommended for all patients with INT-2-risk and high-risk MF. The selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and availability of caregiver.

Allogeneic HCT is recommended for patients with INT-2-risk or high-risk MF if they are candidates for transplant.¹²¹ Patients may be taken immediately to allogeneic HCT or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to allogeneic HCT.

In patients who are not candidates for transplant, treatment options are based on the platelet count. Ruxolitinib^{84,85,90-92} or clinical trial are included as options for patients with a platelet count >50K. Patients with a platelet count ≤50K experience a greater symptom burden and might benefit from symptomatically guided treatment options.¹²⁷ However, at the present time, there are no effective treatment options for this group of patients since the majority of clinical trials evaluating treatment options for MF have excluded this group of patients. The use of ruxolitinib at a lower dose (5 mg twice daily) has been shown to be effective, resulting in reductions in spleen volume and improvement in total symptom score even in patients with low platelet counts at baseline (50–100 x 10⁹/L).¹²⁸ While ruxolitinib could be considered in symptomatic patients with platelet count ≤50K, it is not FDA approved for this indication. Pacritinib (another JAK2 inhibitor) has also demonstrated significant activity resulting in ≥35% spleen volume reductions and symptom improvement, even in patients with severe baseline cytopenias.¹²⁹ Pacritinib could be an appropriate treatment option for patients with low platelet counts; however, it is not yet FDA approved. Therefore, enrollment in an appropriate clinical trial should be considered for patients with a platelet count ≤50K.

Management of Treatment-Related Anemia and Thrombocytopenia

In the COMFORT-I and COMFORT-II studies, anemia and thrombocytopenia were managed with dose modifications and RBC transfusions.^{84,85} Patients enrolled in the COMFORT trials were required to have a baseline platelet count of ≥100 x 10⁹/L, and the initial starting

dose of ruxolitinib was dependent on the patient's baseline platelet counts.^{84,85} Preliminary results of the phase II study suggest that a lower initial dose of ruxolitinib (5 mg twice daily) with escalation to 10 mg BID may be appropriate in patients with baseline platelet counts of 50–100 x 10⁹/L.¹²⁸

The guidelines recommend that the initial dosing of ruxolitinib should be based on the patient's baseline platelet counts (as described in the full prescribing information). However, certain clinical situations may support initiation of ruxolitinib at a lower dose (5 mg twice daily) with subsequent dose modifications based on CBC, which must be performed before initiating ruxolitinib and monitored every 2 to 4 weeks until the dose is stabilized, and then as clinically indicated.^{128,130} See *Special Considerations for the Use of Ruxolitinib* in the algorithm for dose modifications for the management of hematologic toxicities.

Treatment Response Criteria

In 2006, the IWG-MRT first published the response criteria for MF, and the responses were categorized as CR, PR, CI, progressive disease (PD), SD, and relapse.¹³¹ In 2013, these response criteria were revised by IWG-MRT and European LeukemiaNet (ELN) to include MPN-SAF TSS as a quantifiable tool to assess changes in disease-related symptoms and stricter definitions of RBC transfusion dependency and independency.¹³² These response criteria were developed mainly for use in clinical trials.

In addition to CR, PR, and CI, 3 other response categories (anemia response, spleen response, and symptoms response) have been included in the revised 2013 IWG-MRT and ELN response criteria to quantify treatment-induced improvements in symptom burden, particularly anemia, splenomegaly, and constitutional symptoms.¹³² The revised response criteria recommend that symptoms should be

evaluated by the MPN-SAF TSS, and symptom response requires ≥50% reduction in the TSS.⁶⁹ The revised 2013 IWG-MRT and ELN response criteria also require that a ≥35% reduction in spleen volume should be confirmed by MRI or CT scan. In addition, a ≥35% reduction in spleen volume by MRI or CT scan constitutes a spleen response regardless of that reported by physical examination. Additional criteria are also included for PD, SD, and relapse.

Morphologic response in bone marrow is required for CR. The criteria for PR require morphologic response in the peripheral blood (but not necessarily in the bone marrow). Patients meeting criteria for CR with inadequate blood count recovery are also included in the PR category to capture those patients who have achieved CR with persistent drug-induced cytopenia despite a morphologically normal bone marrow. The revised response criteria also include response categories for cytogenetic and molecular response. However, these are not required for CR assignment.

Monitoring Response and Follow-up Therapy

The goal of treatment is to reduce symptom burden and minimize the risk of leukemic transformation. Changes in symptom status could be a sign of disease progression. Therefore, change in symptom status should prompt evaluation of treatment efficacy and/or disease status. Evaluation of treatment efficacy should include CBC to assess normalization of blood counts, monitoring symptom status using MPN-SAF TSS, and monitoring spleen size either by palpation or imaging.¹³²

The guidelines recommend monitoring response (anemia response, spleen response, and symptom response), signs, and symptoms of disease progression every 3 to 6 months during the course of treatment. Bone marrow aspirate and biopsy should be performed as clinically

indicated (if supported by increased symptoms and signs of progression). Additional molecular testing using multi-gene NGS panel to evaluate for high-molecular-risk mutations associated with disease progression should be considered for patients with INT-1-risk or INT-2-risk/high-risk disease.^{35,36}

Continuation of prior treatment is recommended for patients achieving response to initial treatment. In the COMFORT-I study, the majority of patients (91%) treated with ruxolitinib experienced significant improvements in individual MF-related symptoms ($\geq 50\%$ improvement in total symptom score as assessed by MF-SAF) and quality of life; most importantly, patients with a lesser degree of symptom improvement ($< 50\%$ improvement in total symptom score) also achieved improvements over placebo on these measures and other patient-reported outcomes.⁷⁰ The panel acknowledges that clinical benefit may not reach the threshold of the 2013 IWG-ELN Response Criteria (ie, symptom response requires $\geq 50\%$ reduction in the MPN-SAF TSS) in patients receiving treatment with ruxolitinib. Continuation of ruxolitinib is recommended based on the discretion of the clinician, since a symptom response of $< 50\%$ may be clinically meaningful and justify the continued use of ruxolitinib.

Ruxolitinib should be discontinued if there is no response or improvement of symptoms after 6 months. However, disease-related symptoms may return to pretreatment levels over a period of approximately one week following discontinuation or interruption of ruxolitinib.¹³³ Low platelet counts (at initiation or completion of therapy) and clonal evolution (acquisition of new mutations while on treatment with ruxolitinib) were associated with a significantly shorter survival after discontinuation of ruxolitinib.¹³⁴ In a study that evaluated the outcomes of ruxolitinib discontinuation in patients with MF, after a median follow-up of 32 months, the median survival was 14 months among 42

patients who had molecular data at baseline; during follow-up, clonal evolution was seen in 14 patients (33%; *ASXL1* mutation in 60% of patients).¹³⁴ RBC transfusion dependence at baseline was the only clinical variable associated with clonal evolution; survival after discontinuation of ruxolitinib was 6 months for patients with clonal evolution compared to 16 months for those without clonal evolution.

Gradually tapering the dose of ruxolitinib should be considered, when discontinuing or interrupting ruxolitinib for reasons other than thrombocytopenia or neutropenia. See *Special Considerations for the Use of Ruxolitinib* in the algorithm.

JAK2 V617F Allele Burden

Long-term ruxolitinib therapy is associated with reductions in *JAK2* V617F allele burden.^{93,135} In the COMFORT-I study, $> 50\%$ reductions in *JAK2* V617F allele burden were observed in 12% of patients (28 patients); 20 of these patients met the criteria for partial molecular response (PMR) and 6 patients had *JAK2* V617F allele burden values below quantifiable limit, meeting the criteria for complete molecular response (CMR).¹³⁵ The median times to PMR and CMR were 22 months and 28 months, respectively. *JAK2* V617F allele burden reductions also correlated with spleen volume reductions. Achievement of *JAK2* V617F negativity or *JAK2* V617F allele burden reduction after allogeneic HCT has also been associated with a decreased incidence of relapse.^{136,137}

However, at the present time, the utility of *JAK2* V617F allele burden reduction as a predictor of treatment efficacy is not well established. In the 2013 IWG-MRT and ELN response criteria, cytogenetic and molecular responses are not required for CR assignment.¹³² Therefore, measurement of the *JAK2* V617F allele burden is not currently

recommended for use in routine clinical practice to guide treatment decisions.

Management of MF-Associated Anemia

Anemia is considered a negative prognostic risk factor for survival in patients with MF.⁷¹ Symptomatic anemia is observed in more than 50% of patients at the time of diagnosis.¹³⁸ It is essential to rule out and treat (if necessary) the most common causes of anemia (eg, bleeding; hemolysis; iron deficiency; vitamin B12; and folic acid) before considering other treatment options.

Leukoreduced RBC transfusion support is recommended for symptomatic anemia. EPO-stimulating agents (ESAs), danazol, and immunomodulatory agents (lenalidomide, thalidomide, and pomalidomide) have also been evaluated for the management of MF-associated anemia.

The use of recombinant human EPO or darbepoetin alfa has resulted in anemia responses (transfusion independence with normal hemoglobin levels, sustained increase in hemoglobin levels [>2 g/dL] within 12 weeks, or $>50\%$ reduction in transfusion requirements within 12 weeks) in 45% to 60% of patients with MF.¹³⁹⁻¹⁴¹ Lower serum EPO levels (<125 mU/mL), smaller spleen size, and low RBC transfusion requirements have been associated with favorable responses.

In a study of 50 patients with MF and anemia, danazol therapy resulted in an anemia response in 30% of patients and responses are less frequent in patients with transfusion dependency (19% compared to 44% in patients without transfusion requirements).¹⁴² Prostate cancer screening and monitoring of liver function tests are recommended for patients receiving danazol for the management of MF-associated anemia.

Thalidomide (in escalating daily doses of 100–800 mg) has demonstrated very minimal efficacy, resulting in anemia response rates of 0% to 29%, and is also poorly tolerated.¹⁴³⁻¹⁴⁹ Lower dose of thalidomide (50 mg/d) when used in combination with prednisone is better tolerated, leading to improved anemia response rates (62%) compared to high-dose thalidomide monotherapy in the management of MF-associated symptomatic anemia (hemoglobin level <10 g/dL or symptomatic splenomegaly).¹⁵⁰ Lenalidomide, alone or in combination with prednisone, has also demonstrated modest efficacy in the management of MF-associated anemia, resulting in response rates of 19% to 32% with myelosuppression being the most common \geq grade 3 hematologic toxicity.¹⁵¹⁻¹⁵⁴ Lenalidomide is more likely to induce better response rates in patients with isolated 5q deletion.¹⁵⁵

In an analysis that reassessed the efficacy of thalidomide and lenalidomide in 125 patients with MF treated in 3 consecutive phase 2 trials, the combination of lenalidomide and prednisone was more effective and safer than single-agent thalidomide or lenalidomide.¹⁵⁶ After a median follow-up of 42 months, the ORR was 38% for the combination of lenalidomide and prednisone compared to 34% and 16%, respectively, for lenalidomide and thalidomide. There was also a trend for a higher efficacy in patients receiving lenalidomide-based therapy ($P = .06$), and in a multivariate analysis the lenalidomide-based regimen was the only factor independently associated with a higher response rate.

Pomalidomide has also been evaluated as a treatment option for MF-associated anemia.^{157,158} In one phase II study, pomalidomide (with or without prednisone) resulted in similar response rates (39%) in patients with MF and anemia and/or thrombocytopenia and/or neutropenia, with a median response duration of 13 months.¹⁵⁷ However, in another randomized study that evaluated pomalidomide in

patients with MF and RBC transfusion dependence, the RBC transfusion independence response rates were similar for patients treated with pomalidomide and placebo.¹⁵⁸

Enrollment in a clinical trial should be considered for all patients with MF-associated anemia. Additional treatment options for the management of MF-associated anemia are based on the serum EPO levels as described below.

Serum EPO <500 mU/mL

EPO or darbepoetin alfa are recommended for the treatment of anemia in patients with serum EPO levels <500 mU/mL.

In the COMFORT-II study, anemia was managed with packed RBC transfusions and only a small number of patients (13 out of 146 patients) received both ruxolitinib and an ESA. The concomitant use of an ESA with ruxolitinib was well tolerated and did not affect the efficacy of ruxolitinib.¹⁵⁹ Additional studies are warranted to evaluate the efficacy of ESAs for the management of anemia in patients receiving ruxolitinib. ESAs are not effective for the management of transfusion-dependent anemia.¹⁶⁰ Continuation of treatment with ESA is recommended in patients achieving anemia response; those with no response or loss of response should be managed with androgens or immunomodulatory agents as described below for patients with serum EPO \geq 500 mU/mL.

Serum EPO \geq 500 mU/mL

Immunomodulatory agents (lenalidomide or thalidomide) with or without prednisone or danazol are recommended for the treatment of anemia in patients with serum EPO levels >500 mU/mL. Continuation of prior treatment is recommended in patients achieving anemia response, and those with no response or loss of response should be managed with

another trial of treatment (danazol or immunomodulating agent) that has not been used before.

Disease Progression to Advanced Phase or Transformation to Acute Myeloid Leukemia

MF in accelerated phase (MF-AP) is characterized by the presence of \geq 10% (10%–19%) blasts in the peripheral blood or bone marrow, platelets $<50 \times 10^9/L$, and chromosome 17 aberrations.¹⁶¹ MF in blast phase (MF-BP) is defined by the presence of \geq 20% myeloid blasts in either the bone marrow or peripheral blood.⁵³

The incidence of transformation to AML is significantly higher for patients with MF than for those with PV and ET, although the risk is very low in patients who remain in chronic phase MF.^{161,162} Among patients who present with chronic phase MF, development of accelerated phase features during follow-up was associated with short median survival times.¹⁶¹

Treatment with hydroxyurea has been associated with increased risk of transformation to AML in some studies.^{163,164} These findings, however, were not confirmed in subsequent reports.¹⁶⁵⁻¹⁶⁷ In a large cohort analysis (n = 11,039; 162 patients with transformation to AML/myelodysplastic syndrome [MDS]) that evaluated treatment-related risk factors for transformation to AML/MDS in patients with MPN, the use of alkylating agents or a combination of \geq 2 cytoreductive—but not treatment with hydroxyurea alone—was significantly associated with an increased risk of transformation to AML.¹⁶⁵ The results of another large analysis (649 patients with PMF, post-PV MF, or post-ET MF) identified bone marrow blasts \geq 10% and high-risk karyotypes as independent prognostic factors for the transformation to AML.¹⁶⁷ Hydroxyurea, however, was not an independent risk factor for transformation to AML.

Mutations in several genes (*ASXL1*, *TET2*, *TP53*, *SRSF2*, and *IDH1* or *IDH2*) and other chromosomal abnormalities (eg, aberrations in chromosomes 1q and 9p) have been associated with transformation to AML.^{27,35,37,168} Molecular testing for AML-associated mutations is recommended as part of initial workup of patients with disease progression to advanced-phase MF or transformation to AML.

Treatment Options

In a retrospective analysis of 91 patients with MF that had transformed to AML, the median OS after transformation to AML was 3 months. Among patients who were treated with AML-type induction chemotherapy, reversal to chronic phase without an increase in the blast percentage occurred in 41% of patients.¹⁶⁹ However, it was also associated with a treatment-related mortality (TRM) rate of 33%. The median OS was 4 months, which was comparable to that observed in patients treated with supportive care or low-intensity chemotherapy (2 months and 3 months, respectively).

Hypomethylating agents (azacitidine or decitabine) have been evaluated in few small studies as a treatment option for MPN that has transformed to AML.¹⁷⁰⁻¹⁷² In a small series of 11 patients with MF-BP/AML, decitabine was associated with improved survival in patients who were not eligible for allogeneic HCT.¹⁷⁰ At a median follow-up of 9 months, 67% of the patients treated with decitabine were alive. In another series of 54 patients with MPN-BP/AML (21 patients with ET, 21 patients with PV, 7 patients with PMF, and 5 patients with unclassified MPN), first-line therapy with azacitidine resulted in an ORR of 52% (24% CR, 11% PR, 8% bone marrow CR or CR with incomplete recovery of cytopenias, and 9% hematologic improvement).¹⁷¹ The median duration of response and the median OS were 9 months and 11 months, respectively. In a retrospective analysis of 21 patients with MPN-BP/AML and 13 patients with MPN-AP treated with decitabine, the

ORRs were 62% (8 out of 13 patients) and 29% (6 out of 21 patients), respectively, for patients with MPN-AP and MPN-BP/AML.¹⁷² The median OS was significantly higher in patients with disease that responded to decitabine (12 months vs. 5 months, respectively, for patients with MPN-AP; 11 months vs. 4 months, respectively, for patients with MPN-BP/AML).

Allogeneic HCT remains the only curative option resulting in long-term disease control in selected transplant-eligible patients who achieve a CR to induction chemotherapy.¹⁷³⁻¹⁷⁶ In one retrospective analysis of 75 patients with MPN-BP/AML, patients who were treated with curative intent (induction chemotherapy with or without allogeneic HCT) had significantly improved survival compared with those treated with non-curative intent (non-intensive chemotherapy or supportive care).¹⁷⁵ The 2-year OS rates were 26% and 3%, respectively, and the median survival was 9 months and 2 months, respectively ($P < .0001$). Among patients treated with curative intent, the ORR to induction chemotherapy was 46% and reversal to chronic phase was observed in 31% of patients, with 17 patients undergoing allogeneic HCT. The OS rate was significantly higher for patients who underwent allogeneic HCT following induction chemotherapy (2-year OS rate was 47% compared with 15% for those who did not undergo allogeneic HCT; $P = .03$).¹⁷⁵ In another retrospective analysis of 46 patients who received allogeneic HCT for MF-BP/AML, the 3-year PFS and OS rates following transplant were 26% and 33%, respectively. The response status prior to transplant (CR vs. no CR) was a significant predictor of OS (69% for CR vs. 22% for no CR; $P = .008$) and PFS (55% and 19%, respectively; $P = .02$).¹⁷⁶ The cumulative incidence of TRM was 28% at 1 year and the absence of CR before allogeneic HCT was also associated with significantly increased TRM (35% vs. 0%, $P = .053$).

Treatment Recommendations Based on Eligibility for Transplant

The selection of patients for allogeneic HCT should be based on age, performance status, major comorbid conditions, psychosocial status, patient preference, and the availability of caregiver. Patients may be taken immediately to transplant or bridging therapy can be used to decrease marrow blasts to an acceptable level prior to transplant.

Disease control/reduction in blast counts with hypomethylating agents (azacitidine or decitabine) or intensive AML-type induction chemotherapy followed by allogeneic HCT is recommended for patients who are candidates for transplant.^{170,175,176} Enrollment in a clinical trial or treatment with hypomethylating agents (azacitidine or decitabine) or low-intensity AML-type induction chemotherapy is recommended for those who are not candidates for transplant. AML-type induction chemotherapy regimens are generally used for the management of disease progression to advanced phase or transformation to AML. However, these regimens typically result in poor responses.

The results of recent retrospective analyses suggest that prior exposure to ruxolitinib does not adversely affect outcomes after allogeneic HCT and that ruxolitinib should be continued near to the start of conditioning therapy.^{177,178} The guidelines recommend continuation of ruxolitinib for all patients for the improvement of splenomegaly and other disease-related symptoms.

Supportive Care

Supportive care for disease-related symptoms should be an integral part of clinical management during the course of treatment. This should include assessment and monitoring symptom status, counseling for the identification, and assessment and management of cardiovascular risk factors (eg, smoking, diet, exercise, thrombotic and hemorrhagic risk factors).

Transfusion support should include platelet transfusions for thrombocytopenic bleeding or a platelet count $<10,000 \text{ m}^3$ and RBC transfusions for symptomatic anemia.¹⁷⁹ The use of leukocyte-reduced blood products is recommended in transplant candidates to prevent HLA alloimmunization and reduce the risk of cytomegalovirus transmission. Antifibrinolytic agents should be considered for bleeding that is refractory to transfusions. Iron chelation could be considered for patients who have received >20 transfusions and/or ferritin $>2500 \text{ ng/mL}$ in patients with low-risk or INT-1-risk disease.¹⁷⁹ However, the role of iron chelation remains unclear. Cytoreductive therapy (eg, hydroxyurea) is recommended for thrombocytosis or leukocytosis.

Serious bacterial, fungal, and viral infections have been reported in patients receiving ruxolitinib. Patients should be monitored for signs and symptoms of infections. Serious infections should be resolved prior to initiation of ruxolitinib. Antibiotic prophylaxis and vaccinations for recurrent infections are recommended as outlined in the NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections. In splenectomized patients, antibiotic prophylaxis should be given per Infectious Diseases Society of America (IDSA) Guidelines. Growth factor support should be considered for recurrent infections with neutropenia. Cytoreductive therapy with hydroxyurea could be considered for the management of hyperproliferative manifestations of PMF (thrombocytosis or leukocytosis).¹²⁶

Prophylaxis for tumor lysis syndrome (ie, hydration and/or diuresis, management of hyperuricemia with allopurinol or rasburicase) should be considered for patients undergoing induction chemotherapy for advanced-stage MF or leukemic transformation. Rasburicase should be considered as initial treatment in patients with rapidly increasing blast counts, high uric acid, and evidence of impaired renal function.

Management of Polycythemia Vera and Essential Thrombocythemia

Referral to specialized centers with expertise in the management of MPN is strongly recommended for all patients diagnosed with PV or ET.

Risk Stratification

Retrospective studies have shown that leukocytosis at diagnosis is associated with higher risk of thrombosis and major hemorrhage in patients with PV and ET.¹⁸⁰⁻¹⁸⁴ Data from some studies suggest that the prognostic significance of leukocytosis for the risk of recurrent thrombosis may be significant only in patients <60 years of age,^{185,186} and other studies have reported that leukocytosis at diagnosis is not associated with the risk of subsequent thrombosis.¹⁸¹ Thrombocytosis (platelet count >1000 x 10⁹/L) has been associated with an immediate risk of major hemorrhage but not with the risk of thrombosis in patients with ET.¹⁸⁴ In fact, some studies have reported that elevated platelet counts at diagnosis (>1000 x 10⁹/L) are associated with significantly lower rate of thrombosis; this association was significant even in patients with *JAK2*-mutated ET.^{182,183} The potential benefit of initiation of cytoreductive therapy based on elevated blood counts (leukocytosis or thrombocytosis) at the time of diagnosis has not been evaluated in prospective studies.

Polycythemia Vera

Advanced age (ie, >60 years) and history of thrombosis are the most consistent risk factors associated with the risk of thrombosis.¹⁸⁷ In a cohort of 1638 patients with PV who were screened for inclusion in the ECLAP trial, age >65 years and a previous history of thrombosis were the two most important prognostic factors associated with an increasing risk of cardiovascular events resulting in the identification of 2 different

risk groups: low-risk (age <60 years and no prior history of thrombosis) and high-risk (age >60 years and/or prior history of thrombosis).

In another retrospective study of 1545 patients with PV, age ≥67 years, leukocyte count ≥15 x 10⁹/L, and venous thrombosis were identified as independent risk factors for LFS.¹⁸⁸ A prognostic model incorporating leukocytosis at the time of diagnosis in addition to age has been developed to stratify patients into 3 risk groups with different survival outcomes. However, this model has not been validated in prospective clinical trials.

Essential Thrombocythemia

In an analysis of 867 patients with ET, age ≥60 years or older, leukocyte count ≥11 x 10⁹/L, and prior thrombosis were significantly associated with inferior survival.¹⁸⁹ Based on these findings, IPSET was developed to stratify patients at the time of diagnosis into 3 risk categories: low-risk, intermediate-risk, and high-risk. The median survival was not reached for the low-risk group and the median survival was 24 years and 14 years, respectively, for the intermediate-risk and high-risk groups. In a subsequent analysis of 891 patients with ET, age >60 years, history of thrombosis, cardiovascular risk factors, and presence of *JAK2* V617F mutation retained their prognostic significance regarding thrombosis risk in multivariable analysis.¹⁹⁰ Thus, a modified prognostic model (IPSET-thrombosis) including cardiovascular risk factors and presence of *JAK2* V617F mutation status as additional risk factors was developed to stratify patients into the same 3 groups with significantly different thrombosis-free survival: 87% after 15-year follow-up for low-risk patients and 50% after 7-year follow-up for high-risk patients.¹⁹⁰ In the intermediate-risk group, the thrombosis-free survival rate for the first 10 years was closer to that of the low-risk group and then progressively reached the high-risk survival rate in the subsequent 5 years.

Further analysis of the IPSET-thrombosis showed that among the low-risk patients, the risk of thrombosis was significantly lower in patients with *JAK2*-negative/unmutated ET in the absence of cardiovascular risk factors (0.44%) compared to the risk of thrombosis in patients with *JAK2* unmutated ET in the presence of cardiovascular risk factors (1%).¹⁹¹ The risk of thrombosis in the presence of *JAK2* mutation without cardiovascular risk factors and in the presence of both *JAK2* mutation and cardiovascular risk factors were 2% and 3%, respectively. These findings led to the development of revised IPSET-thrombosis that stratifies patients into 4 different risk groups: very low risk (age ≤60 years, no prior history of thrombosis, and no *JAK2* mutation); low risk (age ≤60 years, no prior history of thrombosis, and *JAK2* mutation); intermediate risk (age >60 years, no prior history of thrombosis, and no *JAK2* mutation); and high risk (prior history of thrombosis and/or age >60 years with *JAK2* mutation). The revised IPSET-thrombosis has also been validated in an independent cohort of 585 patients.^{191,192}

CALR mutation status, however, did not have a significant impact on the IPSET-thrombosis prognostic score for predicting the risk of thrombosis.⁴⁶ While the incidences of thrombosis were slightly lower in patients with *CALR*-mutated ET than in those with *JAK2*-mutated ET, in multivariable analysis, *CALR* mutation status did not retain the association with the risk of thrombosis in low-risk and intermediate-risk groups. In part, this may be explained by the fact that *CALR* mutation status tended to cluster with other lower risk features. The significance of *CALR* mutations and the risk of thrombosis could not be evaluated in the high-risk group since there was a lower proportion of patients with the *CALR* mutation in this group.

Treatment Options

Antiplatelet Therapy

The safety and efficacy of low-dose aspirin for the prevention of thrombotic complications in PV was established in a multicenter trial in patients with no contraindication to aspirin therapy and no history of a thrombotic event (ECLAP study; 518 patients).¹⁹³ The use of aspirin resulted in a significant reduction (60%) of combined risk of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes ($P = .03$) and the incidence of major bleeding was not significantly increased in the aspirin group. The role of maintaining the hematocrit level <45% in patients receiving treatment was established in the CYTO-PV study.¹⁹⁴ In this randomized study of 365 patients with PV treated with phlebotomy and/or hydroxyurea, the hematocrit target of <45% resulted in a significantly lower rate of cardiovascular death and major thrombotic events (primary endpoint) than a hematocrit target of 45 to 50%.¹⁹⁴ After a median follow-up of 31 months, death from cardiovascular causes or major thrombotic events was recorded in 3% (5 of 182 patients) of patients with a hematocrit level of <45% compared to 10% (18 of 183 patients) of patients with a hematocrit level of 45% to 50% ($P = .007$).

The efficacy of low-dose aspirin for the prevention of thrombosis in patients with ET has not been evaluated in randomized clinical trials. The data supporting the use of aspirin in patients with ET is based on the extrapolation of results from the ECLAP study that evaluated the efficacy of aspirin in patients with PV and the results of retrospective analyses.^{195,196} Results from one retrospective analysis suggest that aspirin may be effective for the prevention of thrombosis in patients with low-risk *JAK2*-mutated ET and in those with cardiovascular risk factors.¹⁹⁵ Observation may be appropriate for all other patients with

low-risk ET. In this retrospective analysis of 300 patients with low-risk ET managed with aspirin (n = 198) or observation (n = 102), the incidences of venous thrombosis were higher for those with *JAK2* V617F-positive ET not receiving any antiplatelet therapy; patients with cardiovascular risk factors had increased rates of arterial thrombosis while on observation.¹⁹⁵

Cytoreductive Therapy

Hydroxyurea,^{164,194,197} interferon alfa,¹⁹⁸⁻²⁰⁰ and peginterferon alfa²⁰¹⁻²⁰⁴ have been shown to be effective for the prevention of thrombotic complications in patients with PV.

In a nonrandomized study of 51 patients with PV, the use of hydroxyurea along with phlebotomy as needed significantly reduced the risk of thrombosis compared to a historical control of patients treated with phlebotomy alone.¹⁹⁷ Long-term follow-up of this study (after a median follow-up of 9 years) showed that prolonged use of hydroxyurea was associated with leukemic transformations (6% compared to 2% for phlebotomy).²⁰⁵ However, an analysis from the ECLAP study identified older age and the use of other alkylating agents (eg, P32, busulphan, pipobroman) but not hydroxyurea alone as an independent risk factor for leukemic transformation.²⁰⁶ In the randomized trial that compared hydroxyurea and pipobroman as first-line therapy in 285 patients with PV <65 years, the cumulative incidence of leukemic transformation was significantly higher with pipobroman than with hydroxyurea.¹⁶⁴ At a median follow-up of 15 years the incidences of leukemic transformation were 17% and 34%, respectively, for hydroxyurea and pipobroman.

In a randomized, prospective, observational study that included 136 patients with *JAK2*-mutated PV, interferon alfa-2b resulted in greater molecular response rate (55% and 19%, respectively; $P < .01$) and 5-year PFS rate (66% and 47%, respectively; $P < .01$) than

hydroxyurea.²⁰⁰ In a phase II multicenter study of 40 patients with PV, peginterferon alfa-2a resulted in high rates of complete hematologic response (CHR; 95%) and CMR (24%) with limited toxicity.²⁰² At a median follow-up of 31 months, 36 patients with a response remained phlebotomy free. A more recent phase II trial that included 43 patients with PV reported a CHR rate of 77% and a CMR rate of 20% after a median follow-up of 83 months.²⁰⁴ The duration of response was longer among patients with CMR (70 months) than for those with CHR (65 months). The presence of *TET2*, *ASXL1*, *EZH2*, *DNMT3A*, and *IDH1/2* mutations was associated with failure to achieve CMR.²⁰³ Patients with both *JAK2* V617F and *TET2* mutations at initiation of treatment had a less significant reduction in *JAK2* V617F allele burden compared to those with *JAK2*-mutated/*TET2* wild-type disease.

Hydroxyurea,²⁰⁷⁻²⁰⁹ interferon alfa,^{198,200,210,211} peginterferon alfa,^{201,203,204,212} and possibly anagrelide^{208,209} have been shown to be effective for the prevention of venous thrombotic complications in patients with high-risk ET.

In a study of 114 patients with high-risk ET (>60 years and high risk of thrombosis) randomized to receive hydroxyurea (n = 56) or no myelosuppressive therapy (n = 58), the incidences of thrombotic episodes were significantly lower in patients treated with hydroxyurea (3.6% compared to 24%; $P = .003$).²⁰⁷ In another randomized study of 809 patients with high-risk ET, hydroxyurea plus low-dose aspirin was superior to anagrelide plus low-dose aspirin. After a median follow-up of 39 months, the long-term control of platelet counts was equivalent in both groups and anagrelide plus aspirin was better in the prevention of venous thrombosis ($P = .006$).²⁰⁸ However, the incidences of arterial thrombosis ($P = .004$), serious hemorrhage ($P = .008$), and transformation to MF ($P = .01$) were higher with anagrelide plus aspirin. In addition, treatment discontinuation rate was also significantly higher

with anagrelide plus aspirin. The diagnosis of ET in this trial was based on the Polycythemia Vera Study Group criteria. A more recent phase III randomized study showed that anagrelide was not inferior to hydroxyurea as first-line therapy for the prevention of thrombotic complications in patients with high-risk ET diagnosed according to the WHO criteria.²⁰⁹ In this study, 259 patients were randomized to either hydroxyurea (n = 122) or anagrelide (n = 137). After a total observation time of 730 patient-years, there was no significant difference between anagrelide and hydroxyurea in the incidences of arterial or venous thrombotic events, severe bleeding, or rates of discontinuation.

Interferon alfa-2b has been shown to be effective for patients with *JAK2*-mutated and *CALR*-mutated ET.^{200,211} In a randomized, prospective, observational study that included 123 patients with ET, the 5-year PFS rate was 76% for those with *JAK2*-mutated ET compared to 48% for those without *JAK2* mutation ($P < .05$).²⁰⁰ In another study of 31 patients, interferon alfa induced high rates of hematologic and molecular responses in *CALR*-mutated ET. However, the presence of additional mutations (*TET2*, *ASXL1*, *IDH2*, and *TP53*) was associated with poorer molecular response.²¹¹ In a phase II trial that included 40 patients with ET, peginterferon alfa-2a induced a CHR rate of 73% and a CMR rate of 9% after a median follow-up of 83 months.²⁰⁴ The presence of *TET2*, *ASXL1*, *EZH2*, *DNMT3A*, and *IDH1/2* mutations was associated with failure to achieve CMR.²⁰³ Patients with both *JAK2* V617F and *TET2* mutations at initiation of treatment had a less significant reduction in *JAK2* V617F allele burden compared to those with *JAK2*-mutated or *TET2* wild-type disease.

Ongoing randomized clinical trials are evaluating hydroxyurea versus peginterferon alfa-2a or ropeginterferon alfa-2b as initial treatment for high-risk PV and ET.^{213,214}

Ruxolitinib

The results of the phase III randomized trial (RESPONSE) confirmed that ruxolitinib is superior to best available therapy (hydroxyurea, interferon or pegylated interferon, pipobroman, anagrelide, lenalidomide, thalidomide, or observation with the use of aspirin) at controlling hematocrit and improving splenomegaly and symptoms in patients with PV.²¹⁵⁻²¹⁷

In this study, 222 phlebotomy-dependent patients with splenomegaly and an inadequate response to or intolerance of hydroxyurea were randomized to receive ruxolitinib (110 patients) or best available therapy (112 patients). The primary endpoint was hematocrit control without phlebotomy and at least a 35% reduction in spleen volume (as assessed by imaging) by 32 weeks. Patients randomized to best available therapy were eligible to cross over to ruxolitinib after 32 weeks if the primary endpoint was not met or if there were signs of disease progression. After 32 weeks, hematocrit control was achieved in 60% of patients treated with ruxolitinib compared to 20% of patients treated with best available therapy. A reduction in spleen volume ($\geq 35\%$), CHR, and at least a 50% reduction in symptom burden were achieved in 38%, 24%, and 49% of patients, respectively, in the ruxolitinib group and in 1%, 9%, and 5% of patients, respectively, in the best available therapy group. The incidences of grade 3/4 anemia and herpes zoster infection were higher among patients treated with ruxolitinib (occurring in 2% and 6% of patients, respectively, compared to 0% of patients treated with best available therapy). The 80-week follow-up data confirmed the long-term efficacy of ruxolitinib, and the probability of maintaining CHR for ≥ 80 weeks was 69%.²¹⁶ Ruxolitinib was also associated with a lower rate of thromboembolic events (1.8% and 4.1%, respectively, for patients originally randomized to ruxolitinib and for those receiving ruxolitinib after crossover compared to 8.2% for those receiving best available therapy).²¹⁶

Ruxolitinib has also been shown to be effective for the treatment of PV with an inadequate response to hydroxyurea in patients without splenomegaly.²¹⁸ The results of another phase III study showed that ruxolitinib was also effective and resulted in improvements in symptoms (although non-significant) compared to hydroxyurea in patients with well-controlled PV; however, other disease-associated symptoms were reported.²¹⁹

Treatment Recommendations Based on Risk Stratification

Treatment options should be individualized based on age and history of thrombosis for patients with PV,¹⁸⁷ and the revised IPSET-thrombosis is preferred for the risk stratification of patients with ET.^{191,192}

Polycythemia Vera

Low-risk (age <60 years and no prior history of thrombosis)

Aspirin (81–100 mg/d) and phlebotomy (to maintain hematocrit <45%) are recommended for all patients with low-risk PV.^{193,194} Cytoreductive therapy is not recommended as initial treatment. In the CYTO-PV study, the hematocrit target was the same for both men and women. No thrombotic event was observed in the 66 women with hematocrit of <45% compared to 9 events reported in the 72 women with a hematocrit target of 45% to 50%.¹⁹⁴ However, normal hematocrit levels vary in men (42%–54%) and women (38%–46%). While the target hematocrit level of <45% may be adequate for the majority of patients, there may be situations in which a lower hematocrit cutoff may be appropriate and it should be individualized (eg, 42% for female patients and/or for patients with progressive or residual vascular symptoms).

High-risk (age >60 years and/or prior history of thrombosis)

In addition to aspirin and phlebotomy, cytoreductive therapy is also used to reduce the risk of thrombotic complications for patients with high-risk PV. Cytoreductive therapy (hydroxyurea) with aspirin (81–100

mg/d) for vascular symptoms and phlebotomy (to maintain hematocrit <45%) is recommended as initial treatment. Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b could be considered for younger patients, in pregnant patients requiring cytoreductive therapy, or in those patients requiring cytoreductive therapy that defer hydroxyurea.

Essential Thrombocythemia

Very-low-risk (age ≤60 years without JAK2 mutation and no prior history of thrombosis) or Low-risk (age ≤60 years with JAK2 mutation and no prior history) or Intermediate-risk (age >60 years, no JAK2 mutation, and no prior history of thrombosis)

As discussed above, the efficacy and safety of low-dose aspirin in patients with ET has not been evaluated in randomized clinical trials. The results of a recent systematic review also suggest that the risks and benefit of antiplatelet therapy in patients with ET remains highly uncertain.²²⁰ Observation is appropriate for patients with very-low-risk or low-risk ET. Aspirin (81–100 mg/d) could be considered to reduce the risk of thrombotic complications for patients with very-low-risk, low-risk, or intermediate-risk ET. Aspirin should be used with caution in patients with acquired VWD who have an increased risk of bleeding.

A report from a more recent retrospective analysis suggests that the use of low-dose aspirin may not be beneficial in patients with low-risk *CALR*-mutated ET.¹⁹⁶ In an analysis that evaluated the benefit-to-risk ratio of low-dose aspirin in 433 patients with low-risk ET (271 patients with *CALR* mutation and 162 patients with a *JAK2* V617F mutation) who were on antiplatelet therapy or observation, low-dose aspirin did not affect the risk of thrombosis but was associated with a higher incidence of bleeding in patients with *CALR*-mutated ET.¹⁹⁶ These findings have to be confirmed in prospective clinical trials. Therefore, at present, the

panel feels that there is not enough evidence to recommend withholding aspirin for patients with *CALR*-mutated ET.

In carefully selected patients, twice-daily aspirin at a 100-mg dose has been found to be more effective than once-daily aspirin (100 mg), a finding that has yet to be confirmed in randomized controlled studies.^{221,222} The safety and efficacy of different aspirin dosing regimens in patients with ET is being evaluated in a phase II randomized trial.²²³ At the present time, the risk and benefits of higher dose aspirin must be weighed based on the presence of vasomotor symptoms and the risk of bleeding. It may be appropriate in carefully selected patients as clinically indicated.

High-risk (History of thrombosis at any age or >60 years with JAK2 mutation)

Cytoreductive therapy (hydroxyurea or anagrelide) with aspirin (81–100 mg/d) is recommended as initial treatment. Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b could be considered for younger patients, in pregnant patients requiring cytoreductive therapy, or in those patients requiring cytoreductive therapy that defer hydroxyurea.

Treatment Response Criteria

The IWG-MRT and ELN treatment response criteria for PV and ET were first published in 2009 and were revised in 2013.²²⁴ Responses are categorized as CR, PR, no response, and PD. The revised response criteria recommend that symptoms should be evaluated by the MPN-SAF TSS. The evaluation of CR or PR includes 4 categories: 1) resolution of disease-related signs and symptoms including palpable splenomegaly and large symptom improvement (≥ 10 point decrease in MPN-SAF TSS); 2) peripheral blood count response (platelet count $\leq 400 \times 10^9/L$, white blood cell [WBC] count $< 10 \times 10^9/L$, absence of

leukoerythroblastosis, and hematocrit $< 45\%$ without phlebotomies); 3) absence of signs of PD and absence of any hemorrhagic or thrombotic events; and 4) histologic response in bone marrow. Molecular response is not required for the assignment of CR or PR and the revised IWG-MRT and ELN treatment response criteria do not provide a definition of molecular response.

JAK2 V617F Allele Burden

Long-term ruxolitinib therapy has been shown to reduce *JAK2* V617F allele burden in patients with PV that is resistant to hydroxyurea.²²⁵ High *JAK2* V617F allele burden has also been reported as a risk factor for myelofibrotic transformation and higher incidences of thrombotic events in patients with PV and ET.²²⁶⁻²²⁸ These findings suggest that monitoring *JAK2* V617F allele burden could be useful to identify patients at higher risk of myelofibrotic transformation. However, the utility of *JAK2* V617F allele burden reduction as a predictor of clinical outcome is not well established. In addition, in patients with other mutations in addition to *JAK2* mutation, a remission of one mutated clone is not always accompanied by remission of other mutated clones.²²⁴ Therefore, measurement of the *JAK2* V617F allele burden is not currently recommended for use in routine clinical practice to guide treatment decisions.

Monitoring Response and Follow-up Therapy

The goal of therapy is to prevent thrombotic and hemorrhagic complications without increasing the risk of bleeding. Monitoring for new thrombosis or bleeding, management of cardiovascular risk factors, and monitoring of acquired VWD and/or disease-related major bleeding (in patients with ET) is recommended for all patients. After initiation of low-dose aspirin (and phlebotomy for patients with PV), the guidelines recommend monitoring symptom status using MPN-SAF TSS, signs/symptoms of disease progression, and evaluation for potential

indications for cytoreductive therapy every 3 to 6 months or more frequently if clinically indicated. Bone marrow aspirate and biopsy should be performed as clinically indicated (if supported by increased symptoms and signs of progression).

The development of new thrombosis or disease-related major bleeding, frequent or persistent need for phlebotomy, splenomegaly, thrombocytosis, leukocytosis, or disease-related symptoms are considered as potential indications for cytoreductive therapy. In one recent retrospective study, the need for ≥ 3 phlebotomies per year was associated with a significantly higher rate of thrombosis in patients with PV treated with hydroxyurea (21% at 3 years compared to 5% at 3 years for those receiving ≤ 2 phlebotomies per year; $P < .0001$).²²⁹ However, these findings could not be confirmed by other investigators.^{230,231} The development of cytopenia (one of the ELN-defined criteria for resistance or intolerance to hydroxyurea) at the lowest dose of hydroxyurea is an adverse prognostic factor associated with higher risk of death and transformation to AML.^{232,233} Patients with high-risk PV or ET treated with cytoreductive therapy as initial treatment should also be monitored for intolerance or resistance to hydroxyurea.²³⁴

The panel acknowledges that the IWG-MRT and ELN treatment response criteria were developed mainly for use in clinical trials and that clinical benefit may not reach the threshold of the IWG-MRT and ELN response criteria. Response criteria are not defined for patients treated with low-dose aspirin. Available evidence from retrospective studies that have evaluated these response criteria in patients with PV and ET treated with cytoreductive therapy suggests that achievement of CR as outlined in the response criteria did not correlate with a lower incidence of thrombosis or improvement in thrombosis-free survival.^{232,235-237} In selected patients with a severe thrombotic event, normalization of blood

counts might be an essential goal of treatment. While normalization of blood counts after initiation of treatment is usually done in clinical practice, it is not associated with long-term clinical benefit and there is no evidence-based data to recommend a target WBC or platelet count for patients receiving cytoreductive therapy. Response assessment should be done based on the improvement of disease-related symptoms at the discretion of the clinician, and target WBC or platelet counts should be individualized to prevent new thrombosis or bleeding in each patient depending on the presence of risk factors.

Continuation of prior treatment is recommended for asymptomatic patients (low-risk PV and very-low-risk, low-risk, or intermediate-risk ET) with no potential indications for cytoreductive therapy and for patients with high-risk PV or ET with adequate response to initial cytoreductive therapy. Initiation of cytoreductive therapy is recommended for symptomatic patients with potential indications for cytoreductive therapy.

Ruxolitinib is FDA approved for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea. Switching to ruxolitinib (for patients with PV) or alternate cytoreductive therapy (not used before) is recommended for patients with intolerance or with disease that is resistant to hydroxyurea or interferon. Busulfan has also been effective in the treatment of PV and ET that is refractory to hydroxyurea resulting in a CHR rate of 83% and a PMR rate of 33%.²³⁸ However, it is also associated with a significant rate of transformation to AML, and the sequential use of busulfan and hydroxyurea has also been reported to significantly increase the risk of second malignancies.^{206,239} Therefore, the panel does not recommend the use of busulfan as a treatment option.

Special Considerations in the Management of PV and ET

Management of Thrombosis

The use of clinically appropriate anticoagulant therapy (eg, low-molecular-weight heparin [LMWH], direct oral anticoagulant, warfarin) is recommended for patients with active thrombosis.²⁴⁰⁻²⁴² The initial use of anticoagulant therapy for the prevention and treatment of thrombosis should be based on the current American College of Chest Physicians Guidelines.²⁴⁰ There are no evidence-based data to guide the selection or appropriate duration of anticoagulation with or without antiplatelet therapy in patients with PV or ET. The duration of anticoagulant therapy is dependent on the severity of the thrombotic event, degree of disease control, and assessment of likelihood of recurrence after cessation of anticoagulant therapy.²⁴¹ Plateletpheresis may be indicated in patients with ET presenting with acute life-threatening thrombosis or severe bleeding.

Management of Bleeding

It is essential to rule out other potential causes and treat any coexisting causes as necessary. Aspirin should be withheld until bleeding is under control and the use of appropriate cytoreductive therapy should be considered to normalize platelet counts. Coagulation tests to evaluate for acquired VWD (von Willebrand factor activity level) and/or other coagulopathies are recommended for patients undergoing high-risk surgical procedures and those with elevated platelet count and/or splenomegaly or unexplained bleeding. In unanticipated gastrointestinal bleeding, particularly in the setting of splenomegaly, portal hypertension, and gastric varices, special consultation (for endoscopic evaluation) with a hepatologist or a gastrointestinal specialist is recommended.

Surgery

The thrombotic and bleeding risk of the surgical procedure should be strongly considered prior to elective surgery since patients with PV and ET are at higher risk for bleeding despite optimal management. In a retrospective analysis that evaluated the post-surgery outcomes in patients with PV (n = 105) and ET (n = 150), although the majority of patients (74%) were treated with cytoreductive therapy and phlebotomy prior to surgery and antithrombotic prophylaxis, a significant proportion of surgeries was complicated by vascular occlusion (8%) or major hemorrhage (7%). Arterial thrombotic events were more frequent in patients with ET (5% vs. 2%; $P = .08$) and venous thrombotic events were more frequent in PV (8% vs. 1%; $P = .002$).²⁴³

Multidisciplinary management with careful review of bleeding and thrombosis history is recommended prior to surgery for all patients. Emergency surgery should be performed as necessary with close postoperative surveillance for the symptoms of arterial or venous thrombosis and bleeding. Thrombosis and bleeding should be well controlled without causing prohibitive cytopenias prior to performing elective surgery (particularly for orthopedic surgeries or any surgical procedures associated with prolonged immobilization) with the use of appropriate antiplatelet therapy, anticoagulant prophylaxis, and cytoreductive therapy. In patients with PV, hematocrit should be controlled for 3 months before elective surgery with the use of additional phlebotomy if necessary to maintain hematocrit <45% prior to performing elective surgery. Prophylaxis with aspirin may be considered following vascular surgery. Extended prophylaxis with LMWH should be considered, if surgery is associated with a high risk for venous thromboembolism.

Pregnancy

Pregnancy is considered a high-risk clinical situation in patients with PV and ET.²⁴⁴ The presence of *JAK2* V617F mutation is an adverse prognostic factor for pregnancy outcome, and pregnancy complications are associated with a higher risk of subsequent thrombotic events in patients with ET.²⁴⁵⁻²⁴⁸ The use of aspirin has been reported to be effective in reducing pregnancy complications, especially in patients with *JAK2*-mutated ET.^{249,250} In a study that investigated 129 pregnancies in 78 patients with ET, among patients with *JAK2*-mutated ET, complications occurred in 36% of patients receiving aspirin compared to 68% of patients not receiving aspirin. In another study of 63 pregnancies among 36 women with ET, the rate of pregnancy loss was 21% among patients receiving aspirin during the first trimester compared to 75% among those not receiving aspirin ($P = .002$).²⁵⁰ The results of a recent UK prospective cohort study (58 women with a diagnosis of MPN; 47 had a diagnosis of ET) suggest that maternal MPN is associated with higher incidences of maternal complications, preterm delivery, and small-for-gestational-age infants compared to the general population.²⁵¹ The majority of women (88%) received aspirin and 38% of women additionally received a prophylactic dose of LMWH. Preeclampsia was the most common antenatal complication reported in 9% of women, and 22% of neonates were below the 10th percentile for growth. Aggressive intervention for the control of hematocrit, the use of aspirin, and LMWH were associated with significantly better pregnancy outcome in patients with PV.²⁵²

Evaluation by a high-risk obstetrician should be considered prior to conception. In low-risk pregnancy (no prior ET-related complications, absence of hereditary thrombophilic factors, age <35 years, and platelet count <1000 x 10⁹/L), low-dose aspirin (50–100 mg/d) is recommended throughout pregnancy and for 6 weeks postpartum. Aspirin could be stopped and substituted by LMWH about 2 weeks before labor is

expected. In high-risk pregnancy (previous microcirculatory disturbances, presence of 2 or more hereditary thrombophilic factors, severe complications in a previous pregnancy, or age >35 years and platelet count >1000 x 10⁹/L), the use of prophylactic LMWH (subcutaneously) with low-dose aspirin should be considered throughout pregnancy and for 6 weeks postpartum.

Low-dose aspirin should be stopped 1 to 2 weeks prior to delivery and LMWH should be stopped 12 hours to 24 hours before labor is expected.²⁴⁴ In patients taking LMWH, consultation with a high-risk obstetrician and obstetric anesthesiologist is recommended to determine the optimal timing of discontinuation in preparation for an epidural prior to delivery. In patients without prior bleeding or thrombotic complications, the use of LMWH instead of low-dose aspirin should be considered in the last 2 weeks of pregnancy and continued until 6 weeks postpartum. Interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b should be considered, if cytoreductive therapy is necessary.^{246,253,254} Hydroxyurea is excreted in breastmilk and should be avoided in women who are breast-feeding. Patients on hydroxyurea prior to pregnancy should be switched to interferons.

Summary

MPN are characterized by a significant symptom burden and a propensity for disease transformation to blast phase and then AML. The goal of treatment is to reduce symptom burden and the risk of developing thrombotic and hemorrhagic complications. Regular monitoring of disease-related symptoms, assessment of need for cytoreductive therapy, and appropriate evaluation to rule out disease progression should be an integral part of management of patients with MPN.

References

1. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. *Leuk Lymphoma* 2014;55:595-600. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23768070>.
2. Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. *Br J Haematol* 2016;174:382-396. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27061824>.
3. Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls. *Am J Hematol* 2015;90:864-870. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26113113>.
4. Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey. *BMC Cancer* 2016;16:167. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26922064>.
5. Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. *Ann Hematol* 2017;96:1653-1665. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28780729>.
6. Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. *Blood* 2014;123:3803-3810. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24553173>.
7. Price GL, Davis KL, Karve S, et al. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN). *PLoS One* 2014;9:e90299. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24618579>.
8. Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. *Blood* 2008;112:1628-1637. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18566326>.
9. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. *Blood* 2014;124:2507-2513; quiz 2615. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25037629>.
10. Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. *Am J Hematol* 2016;91:50-58. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26492355>.
11. Stein BL, Gotlib J, Arcasoy M, et al. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. *J Natl Compr Canc Netw* 2015;13:424-434. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25870379>.
12. U.S. National Library of Medicine Key MEDLINE® Indicators Available at: http://www.nlm.nih.gov/bsd/bsd_key.html.
13. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet* 2005;365:1054-1061. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15781101>.
14. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med* 2005;352:1779-1790. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15858187>.
15. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia,



NCCN Guidelines Version 2.2019

Myeloproliferative Neoplasms

and myeloid metaplasia with myelofibrosis. *Cancer Cell* 2005;7:387-397. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15837627>.

16. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. *N Engl J Med* 2007;356:459-468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17267906>.

17. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. *Blood* 2008;111:1686-1689. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17984312>.

18. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. *Blood* 2006;108:3472-3476. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16868251>.

19. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. *PLoS Med* 2006;3:e270. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16834459>.

20. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. *Blood* 2008;112:141-149. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18451306>.

21. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med* 2013;369:2379-2390. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24325356>.

22. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *N Engl J Med* 2013;369:2391-2405. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24325359>.

23. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. *Leukemia* 2014;28:1568-1570. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24569778>.

24. Tefferi A, Lasho TL, Tischer A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. *Blood* 2014;124:2465-2466. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25301336>.

25. Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. *Leukemia* 2016;30:431-438. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26449662>.

26. Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. *Hematology Am Soc Hematol Educ Program* 2014;2014:287-296. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25696868>.

27. Rampal R, Ahn J, Abdel-Wahab O, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. *Proc Natl Acad Sci U S A* 2014;111:E5401-5410. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25516983>.

28. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. *Blood* 2014;124:1062-1069. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24986690>.

29. Guglielmelli P, Rotunno G, Fanelli T, et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. *Blood Cancer J* 2015;5:e360. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26473532>.

30. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al. Anaemia characterises patients with myelofibrosis harbouring MPL mutation. *Br J*

Haematol 2007;137:244-247. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/17408465>.

31. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. *Leukemia* 2014;28:1472-1477. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/24402162>.

32. Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. *Blood* 2016;127:325-332. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/26423830>.

33. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. *Blood* 2011;118:5227-5234. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21921040>.

34. Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. *Leukemia* 2012;26:475-480. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/21912393>.

35. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. *Leukemia* 2013;27:1861-1869. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/23619563>.

36. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. *Leukemia* 2014;28:1804-1810. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/24549259>.

37. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. *Blood* 2014;123:2220-2228. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/24478400>.

38. Tefferi A, Finke CM, Lasho TL, et al. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. *Leukemia* 2018;32:2274-2278. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/29535431>.

39. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. *Leukemia* 2014;28:1494-1500. Available at:
<http://www.ncbi.nlm.nih.gov/pubmed/24496303>.

40. Rotunno G, Pacilli A, Artusi V, et al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. *Am J Hematol* 2016;91:681-686. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/27037840>.

41. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. *Blood* 2011;117:2813-2816. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/21224469>.

42. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. *Blood* 2014;123:1552-1555. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/24371211>.

43. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. *Blood* 2014;123:1544-1551. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/24366362>.

44. Elala YC, Lasho TL, Gangat N, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. *Am J Hematol* 2016;91:503-506. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/26890983>.

45. Alvarez-Larran A, Senin A, Fernandez-Rodriguez C, et al. Impact of genotype on leukaemic transformation in polycythaemia vera and

essential thrombocythaemia. *Br J Haematol* 2017;178:764-771.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28542718>.

46. Finazzi G, Carobbio A, Guglielmelli P, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. *Blood* 2014;124:2611-2612. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25323688>.

47. Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. *Blood Adv* 2016;1:21-30. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29296692>.

48. Senin A, Fernandez-Rodriguez C, Bellosillo B, et al. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. *Ann Hematol* 2018;97:443-451. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29181548>.

49. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood* 2002;100:2292-2302. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12239137>.

50. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood* 2009;114:937-951. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19357394>.

51. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. *Blood Cancer J* 2015;5:e337. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26832847>.

52. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues (revised 4th edition). International Agency for Research on Cancer; Lyon, France; 2017.

53. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). *Leuk Res* 2007;31:737-740. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17210175>.

54. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. *J Clin Oncol* 2011;29:3179-3184. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21747083>.

55. Guglielmelli P, Pacilli A, Rotunno G, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. *Blood* 2017;129:3227-3236. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28351937>.

56. Jeryczynski G, Thiele J, Gisslinger B, et al. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. *Am J Hematol* 2017;92:885-891. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28543356>.

57. Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. *Am J Hematol* 2014;89:52-54. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23996471>.

58. Alvarez-Larran A, Angona A, Ancochea A, et al. Masked polycythemia vera: presenting features, response to treatment and clinical outcomes. *Eur J Haematol* 2016;96:83-89. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25810304>.

59. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. *Leukemia* 2008;22:437-438. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17728787>.
60. Delic S, Rose D, Kern W, et al. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythemia, primary myelofibrosis and polycythemia vera. *Br J Haematol* 2016;175:419-426. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27447873>.
61. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. *Haematologica* 2005;90:1128-1132. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16079113>.
62. McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. *Semin Thromb Hemost* 2013;39:101-111. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23264112>.
63. Kaifia A, Kirschner M, Wolf D, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. *J Hematol Oncol* 2016;9:18. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26944254>.
64. Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. *Thromb Haemost* 2000;84:345-349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10959711>.
65. Lippi G, Franchini M, Salvagno GL, et al. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma. *J Thromb Thrombolysis* 2008;26:150-153. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17786534>.
66. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. *Leuk Res* 2009;33:1199-1203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19250674>.
67. Mesa RA, Kantarjian H, Tefferi A, et al. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. *Cancer* 2011;117:4869-4877. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21480207>.
68. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. *Blood* 2011;118:401-408. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21536863>.
69. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. *J Clin Oncol* 2012;30:4098-4103. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23071245>.
70. Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 2013;31:1285-1292. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23423753>.
71. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. *Blood* 2009;113:2895-2901. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18988864>.



NCCN Guidelines Version 2.2019

Myeloproliferative Neoplasms

72. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood* 2010;115:1703-1708. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20008785>.

73. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol* 2011;29:392-397. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21149668>.

74. Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. *J Clin Oncol* 2018;36:310-318. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29226763>.

75. Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. *Leukemia* 2018;32:1631-1642. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29654267>.

76. Patnaik MM, Caramazza D, Gangat N, et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. *Eur J Haematol* 2010;84:105-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19895568>.

77. Tefferi A, Siragusa S, Hussein K, et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. *Am J Hematol* 2010;85:14-17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20029953>.

78. Hussein K, Pardanani AD, Van Dyke DL, et al. International Prognostic Scoring System-independent cytogenetic risk categorization

in primary myelofibrosis. *Blood* 2010;115:496-499. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19901264>.

79. Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. *Leukemia* 2011;25:82-88. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20944670>.

80. Masarova L, Bose P, Daver N, et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. *Leuk Res* 2017;59:110-116. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28601551>.

81. Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. *Leukemia* 2017;31:2726-2731. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28561069>.

82. Ianotto JC, Boyer-Perrard F, Gyan E, et al. Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. *Br J Haematol* 2013;162:783-791. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23848933>.

83. Silver RT, Barel AC, Lascu E, et al. The effect of initial molecular profile on response to recombinant interferon-alpha (rIFNalpha) treatment in early myelofibrosis. *Cancer* 2017;123:2680-2687. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28518222>.

84. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *N Engl J Med* 2012;366:799-807. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22375971>.

85. Harrison C, Kiladjan JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *N Engl J Med*

2012;366:787-798. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22375970>.

86. Davis KL, Cote I, Kaye JA, et al. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib. *Adv Hematol* 2015;2015:848473. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26635878>.

87. Mead AJ, Milojkovic D, Knapper S, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. *Br J Haematol* 2015;170:29-39. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25824940>.

88. Al-Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. *Haematologica* 2016;101:1065-1073. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27247324>.

89. Palandri F, Tiribelli M, Benevolo G, et al. Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. *Hematol Oncol* 2018;36:285-290. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28512865>.

90. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. *Haematologica* 2015;100:479-488. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25616577>.

91. Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. *J Hematol Oncol* 2017;10:55. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28228106>.

92. Cervantes F, Vannucchi AM, Kiladjan JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study

comparing ruxolitinib with best available therapy for myelofibrosis. *Blood* 2013;122:4047-4053. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24174625>.

93. Harrison CN, Vannucchi AM, Kiladjan JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. *Leukemia* 2016;30:1701-1707. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27211272>.

94. Verstovsek S, Mesa RA, Gotlib J, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. *Br J Haematol* 2013;161:508-516. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23480528>.

95. Vannucchi AM, Kantarjian HM, Kiladjan JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. *Haematologica* 2015;100:1139-1145. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26069290>.

96. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? *Blood* 2013;122:3843-3844. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24288410>.

97. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. *Chest* 2013;143:1478-1479. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23648912>.

98. Shamil E, Cunningham D, Wong BL, Jani P. Ruxolitinib associated tuberculosis presenting as a neck lump. *Case Rep Infect Dis* 2015;2015:284168. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26788384>.

99. Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. *N Engl J Med*

2013;369:197-198. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23841743>.

100. Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. *Leukemia* 2014;28:225-227. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23929216>.

101. Shen CH, Hwang CE, Chen YY, Chen CC. Hepatitis B virus reactivation associated with ruxolitinib. *Ann Hematol* 2014;93:1075-1076. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24173089>.

102. Tong LX, Jackson J, Kerstetter J, Worswick SD. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. *J Am Acad Dermatol* 2014;70:e59-60. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/24528917>.

103. Blechman AB, Cabell CE, Weinberger CH, et al. Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib. *J Drugs Dermatol* 2017;16:508-511. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28628689>.

104. Palandri F, Derenzini E, Ottaviani E, et al. Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience. *Leuk Lymphoma* 2009;50:481-484. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/19241208>.

105. Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. *Cancer Epidemiol Biomarkers Prev* 2009;18:2068-2073. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/19531676>.

106. Rumi E, Passamonti F, Elena C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. *Haematologica* 2011;96:454-458. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21109692>.

107. Masarova L, Newberry KJ, Pierce SA, et al. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. *Leuk Res* 2015;39:822-827. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26012362>.

108. Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. *Blood* 2018;132:694-706. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29907599>.

109. Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. *Blood* 2014;123:2157-2160. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24458439>.

110. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. *Blood* 2015;126:790-797. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26124496>.

111. Deeg HJ, Bredeson C, Farnia S, et al. Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. *Biol Blood Marrow Transplant* 2015;21:1883-1887. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26371371>.

112. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. *Biol Blood Marrow Transplant* 2010;16:358-367. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19879949>.

113. Snyder DS, Palmer J, Stein AS, et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. *Biol Blood Marrow Transplant* 2006;12:1161-1168.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17085309>.

114. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood* 2009;114:5264-5270. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19812383>.

115. Patriarca F, Bacigalupo A, Sperotto A, et al. Outcome of allogeneic stem cell transplantation following reduced-intensity conditioning regimen in patients with idiopathic myelofibrosis: the G.I.T.M.O. Experience. *Mediterr J Hematol Infect Dis* 2010;2:e2010010. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21415963>.

116. Snyder DS, Palmer J, Gaal K, et al. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. *Biol Blood Marrow Transplant* 2010;16:281-286. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19786111>.

117. Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant* 2014;20:89-97. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24161923>.

118. Lussana F, Rambaldi A, Finazzi MC, et al. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica* 2014;99:916-921. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24389309>.

119. Rondelli D, Goldberg JD, Isola L, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell

transplantation in patients with myelofibrosis. *Blood* 2014;124:1183-1191. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24963042>.

120. Robin M, Porcher R, Wolschke C, et al. Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis. *Biol Blood Marrow Transplant* 2016;22:1206-1211. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26970380>.

121. Scott BL, Gooley TA, Sorrow ML, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. *Blood* 2012;119:2657-2664. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22234678>.

122. Alchalby H, Yunus DR, Zabelina T, et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. *Br J Haematol* 2012;157:75-85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22280409>.

123. Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. *Blood* 2015;125:3347-3350; quiz 3364. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25784679>.

124. Panagiota V, Thol F, Markus B, et al. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. *Leukemia* 2014;28:1552-1555. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24504025>.

125. Kroger N, Panagiota V, Badbaran A, et al. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant* 2017;23:1095-1101. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28389256>.

126. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. *Ann Hematol*

2010;89:1233-1237. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/20567824>.

127. Scotch AH, Kosiorek H, Scherber R, et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. *Leuk Res* 2017;63:34-40. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/29096334>.

128. Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. *J Hematol Oncol* 2013;6:81. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/24283202>.

129. Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. *Lancet Haematol* 2017;4:e225-e236. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28336242>.

130. Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. *J Hematol Oncol* 2013;6:79. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/24283870>.

131. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). *Blood* 2006;108:1497-1503. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16675707>.

132. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood* 2013;122:1395-1398. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23838352>.

133. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. *Mayo Clin Proc*

2011;86:1188-1191. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/22034658>.

134. Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. *Blood* 2017;130:1125-1131. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28674026>.

135. Deininger M, Radich J, Burn TC, et al. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. *Blood* 2015;126:1551-1554. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/26228487>.

136. Alchalby H, Badbaran A, Zabelina T, et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. *Blood* 2010;116:3572-3581. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20489052>.

137. Lange T, Edelmann A, Siebolts U, et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. *Haematologica* 2013;98:722-728. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23300178>.

138. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. *Mayo Clin Proc* 2012;87:25-33. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/22212965>.

139. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. *Br J Haematol* 2004;127:399-403. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/15521916>.

140. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid

metaplasia. *Br J Haematol* 2006;134:184-186. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16740139>.

141. Tsiara SN, Chaidos A, Bourantas LK, et al. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. *Acta Haematol* 2007;117:156-161. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17159338>.

142. Cervantes F, Isola IM, Alvarez-Larran A, et al. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. *Ann Hematol* 2015;94:1791-1796. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26122869>.

143. Barosi G, Elliott M, Canepa L, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. *Leuk Lymphoma* 2002;43:2301-2307. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12613516>.

144. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. *Br J Haematol* 2002;117:288-296. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11972510>.

145. Merup M, Kutti J, Birgergard G, et al. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. *Med Oncol* 2002;19:79-86. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12180484>.

146. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. *J Clin Oncol* 2004;22:424-431. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14752066>.

147. Strupp C, Germing U, Scherer A, et al. Thalidomide for the treatment of idiopathic myelofibrosis. *Eur J Haematol* 2004;72:52-57. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14962263>.

148. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. *Cancer* 2006;106:1974-1984. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16583431>.

149. Abgrall JF, Guibaud I, Bastie JN, et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. *Haematologica* 2006;91:1027-1032. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16885042>.

150. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. *Blood* 2003;101:2534-2541. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12517815>.

151. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. *Blood* 2006;108:1158-1164. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16609064>.

152. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. *J Clin Oncol* 2009;27:4760-4766. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19720904>.

153. Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. *Blood* 2010;116:4436-4438. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20651074>.

154. Chihara D, Masarova L, Newberry KJ, et al. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. *Leuk Res* 2016;48:1-5. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27416326>.

155. Santana-Davila R, Tefferi A, Holtan SG, et al. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. *Leuk Res* 2008;32:1927-1930. Available at:

156. Jabbour E, Thomas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. *Blood* 2011;118:899-902. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21622644>.

157. Schlenk RF, Stegelmann F, Reiter A, et al. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. *Leukemia* 2017;31:889-895. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27774990>.

158. Tefferi A, Al-Ali HK, Barosi G, et al. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. *Leukemia* 2017;31:896-902. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/27773929>.

159. McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. *Exp Hematol Oncol* 2015;4:26. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26380150>.

160. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. *Eur J Haematol* 2009;83:154-155. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/19366369>.

161. Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. *J Clin Oncol* 2009;27:5587-5593. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/19786661>.

162. Abdulkarim K, Girodon F, Johansson P, et al. AML transformation in 56 patients with Ph-MPD in two well defined populations. *Eur J*

Haematol 2009;82:106-111. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/19134023>.

163. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. *Am J Hematol* 2003;74:26-31. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/12949887>.

164. Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. *J Clin Oncol* 2011;29:3907-3913. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21911721>.

165. Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. *J Clin Oncol* 2011;29:2410-2415. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21537037>.

166. Noor SJ, Tan W, Wilding GE, et al. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. *Leuk Res* 2011;35:608-613. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/20727590>.

167. Quintas-Cardama A, Kantarjian H, Pierce S, et al. Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk* 2013;13:315-318 e312. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23391717>.

168. Klampfl T, Harutyunyan A, Berg T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. *Blood* 2011;118:167-176. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21531982>.

169. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience

with 91 cases. Blood 2005;105:973-977. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15388582>.

170. Mascarenhas J, Navada S, Malone A, et al. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res 2010;34:1246-1249. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20627294>.

171. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010;116:3735-3742. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20664061>.

172. Badar T, Kantarjian HM, Ravandi F, et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res 2015;39:950-956. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26183878>.

173. Ciurea SO, de Lima M, Giralt S, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 2010;16:555-559. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20005966>.

174. Cherington C, Slack JL, Leis J, et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res 2012;36:1147-1151. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22578777>.

175. Kennedy JA, Atenafu EG, Messner HA, et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood 2013;121:2725-2733. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23361905>.

176. Alchalby H, Zabelina T, Stubig T, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of

the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014;20:279-281. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24201159>.

177. Shanavas M, Popat U, Michaelis LC, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant 2016;22:432-440. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26493563>.

178. Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, et al. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol 2018;101:305-317. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29791053>.

179. Cervantes F. How I treat myelofibrosis. Blood 2014;124:2635-2642. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25232060>.

180. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446-2452. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17105814>.

181. Gangat N, Wolanskyj AP, Schwager SM, et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009;115:5740-5745. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19806641>.

182. Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008;112:3135-3137. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18587010>.

183. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an

international study of 891 patients. *Blood* 2011;117:5857-5859. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21490340>.

184. Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. *Blood* 2012;120:1409-1411. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22709688>.

185. De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. *Haematologica* 2008;93:372-380. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18268279>.

186. De Stefano V, Za T, Rossi E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. *Am J Hematol* 2010;85:97-100. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20052743>.

187. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. *J Clin Oncol* 2005;23:2224-2232. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15710945>.

188. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. *Leukemia* 2013;27:1874-1881. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23739289>.

189. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. *Blood* 2012;120:1197-1201. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22740446>.

190. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health

Organization-essential thrombocythemia (IPSET-thrombosis). *Blood* 2012;120:5128-5133; quiz 5252. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23033268>.

191. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. *Blood Cancer J* 2015;5:e369. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26617062>.

192. Haider M, Gangat N, Lasho T, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. *Am J Hematol* 2016;91:390-394. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26799697>.

193. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med* 2004;350:114-124. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14711910>.

194. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. *N Engl J Med* 2013;368:22-33. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23216616>.

195. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. *Blood* 2010;116:1205-1210; quiz 1387. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20508163>.

196. Alvarez-Larran A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. *Haematologica* 2016;101:926-931. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27175028>.

197. Kaplan ME, Mack K, Goldberg JD, et al. Long-term management of polycythemia vera with hydroxyurea: a progress report. *Semin Hematol* 1986;23:167-171. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/3749925>.

198. Radin AI, Kim HT, Grant BW, et al. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group. *Cancer* 2003;98:100-109. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/12833462>.

199. Stauffer Larsen T, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. *Leuk Res* 2013;37:1041-1045. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23827351>.

200. Huang BT, Zeng QC, Zhao WH, et al. Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. *Leuk Res* 2014;38:1177-1183. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/25069759>.

201. Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. *Cancer* 2006;106:2397-2405. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/16639737>.

202. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. *Blood* 2008;112:3065-3072. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/18650451>.

203. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. *Blood* 2013;122:893-901. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23782935>.

204. Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2

trial. *Lancet Haematol* 2017;4:e165-e175. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/28291640>.

205. Fruchtmann SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. *Semin Hematol* 1997;34:17-23. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/9025158>.

206. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. *Blood* 2005;105:2664-2670. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15585653>.

207. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. *N Engl J Med* 1995;332:1132-1136. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/7700286>.

208. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. *N Engl J Med* 2005;353:33-45. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/16000354>.

209. Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. *Blood* 2013;121:1720-1728. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23315161>.

210. Saba R, Jabbour E, Giles F, et al. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. *Cancer* 2005;103:2551-2557. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/15861412>.

211. Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-alpha therapy in essential thrombocythemia patients with CALR mutations. *Blood* 2015;126:2585-2591. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26486786>.

212. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. *Haematologica* 2005;90:1333-1338. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16219569>.

213. Mascarenhas JO, Prchal JT, Rambaldi A, et al. Interim analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 global phase III trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia [abstract]. *Blood* 2016;128:Abstract 479. Available at: <http://www.bloodjournal.org/content/128/22/479.abstract>.

214. Gisslinger H, Klade C, Georgiev P, et al. Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients [abstract]. *Blood* 2016;128:Abstract 475. Available at: <http://www.bloodjournal.org/content/128/22/475.abstract>.

215. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. *N Engl J Med* 2015;372:426-435. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25629741>.

216. Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. *Haematologica* 2016;101:821-829. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27102499>.

217. Kiladjian JJ, Guglielmelli P, Griesshammer M, et al. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. *Ann Hematol* 2018;97:617-627. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29396713>.

218. Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b

study. *Lancet Oncol* 2017;18:88-99. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27916398>.

219. Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). *Br J Haematol* 2017;176:76-85. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27858987>.

220. Chu DK, Hillis CM, Leong DP, et al. Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review. *Ann Intern Med* 2017;167:170-180. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28632284>.

221. Dillinger JG, Sideris G, Henry P, et al. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. *Thromb Res* 2012;129:91-94. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22014557>.

222. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. *Blood* 2012;119:3595-3603. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22234683>.

223. De Stefano V, Rocca B, Tosetto A, et al. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. *Blood Cancer J* 2018;8:49. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29880847>.

224. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. *Blood* 2013;121:4778-4781. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23591792>.

225. Vannucchi AM, Verstovsek S, Guglielmelli P, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera

enrolled in the RESPONSE study. *Ann Hematol* 2017;96:1113-1120. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28456851>.

226. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. *Leukemia* 2010;24:1574-1579. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20631743>.

227. Alvarez-Larran A, Bellosillo B, Pereira A, et al. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. *Am J Hematol* 2014;89:517-523. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24458835>.

228. Borowczyk M, Wojtaszewska M, Lewandowski K, et al. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. *Thromb Res* 2015;135:272-280. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25559461>.

229. Alvarez-Larran A, Perez-Encinas M, Ferrer-Marin F, et al. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. *Haematologica* 2017;102:103-109. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27686377>.

230. Barbui T, Carobbio A, Ghirardi A, et al. No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from ECLAP and CYTO-PV clinical trials. *Haematologica* 2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28255021>.

231. Enblom-Larsson A, Girodon F, Bak M, et al. A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythemia vera. *Br J Haematol* 2017;177:800-805. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28474342>.

232. Hernandez-Boluda JC, Alvarez-Larran A, Gomez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythemia. *Br J Haematol* 2011;152:81-88. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21083657>.

233. Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythemia vera. *Br J Haematol* 2016;172:786-793. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26898196>.

234. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *J Clin Oncol* 2011;29:761-770. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21205761>.

235. Carobbio A, Finazzi G, Antonioli E, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. *Blood* 2010;116:1051-1055. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20479281>.

236. Alvarez-Larran A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. *Blood* 2012;119:1363-1369. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22160617>.

237. Hernandez-Boluda JC, Pereira A, Cervantes F, et al. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. *Ann Hematol* 2013;92:771-775. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23354997>.

238. Alvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC, et al. Busulfan in patients with polycythemia vera or essential

thrombocytopenia refractory or intolerant to hydroxyurea. *Ann Hematol* 2014;93:2037-2043. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24981691>.

239. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. *Br J Haematol* 2000;110:577-583. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/10997967>.

240. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141:7S-47S. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22315257>.

241. Kreher S, Ochsenreither S, Trappe RU, et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). *Ann Hematol* 2014;93:1953-1963. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25307456>.

242. Hernandez-Boluda JC, Arellano-Rodrigo E, Cervantes F, et al. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. *Ann Hematol* 2015;94:911-918. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25680896>.

243. Ruggeri M, Rodeghiero F, Tassetto A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. *Blood* 2008;111:666-671. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17909074>.

244. Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. *Blood Rev*

2008;22:235-245. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18617299>.

245. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. *Blood* 2007;110:485-489. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17426257>.

246. Melillo L, Tieghi A, Candoni A, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. *Am J Hematol* 2009;84:636-640. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19705431>.

247. Randi ML, Bertozzi I, Rumi E, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. *Am J Hematol* 2014;89:306-309. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24265194>.

248. Rumi E, Bertozzi I, Casetti IC, et al. Impact of mutational status on pregnancy outcome in patients with essential thrombocythemia. *Haematologica* 2015;100:e443-445. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26250575>.

249. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. *Eur J Haematol* 2009;82:350-353. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19243425>.

250. Passamonti F, Rumi E, Randi ML, et al. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. *J Thromb Haemost* 2010;8:411-413. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19912517>.

251. Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. *Br J Haematol* 2016;175:31-36. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27612319>.



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 2.2019 Myeloproliferative Neoplasms

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

252. Robinson S, Bewley S, Hunt BJ, et al. The management and outcome of 18 pregnancies in women with polycythemia vera. *Haematologica* 2005;90:1477-1483. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16266894>.

253. Beauverd Y, Radia D, Cargo C, et al. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. *Haematologica* 2016;101:e182-184. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26819057>.

254. Yazdani Brojeni P, Matok I, Garcia Bournissen F, Koren G. A systematic review of the fetal safety of interferon alpha. *Reprod Toxicol* 2012;33:265-268. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22200624>.